0001493152-19-007021.txt : 20190514 0001493152-19-007021.hdr.sgml : 20190514 20190514130850 ACCESSION NUMBER: 0001493152-19-007021 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20190331 FILED AS OF DATE: 20190514 DATE AS OF CHANGE: 20190514 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Processa Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001533743 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 451539785 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-184948 FILM NUMBER: 19821740 BUSINESS ADDRESS: STREET 1: 7380 COCA COLA DRIVE STREET 2: SUITE 106 CITY: HANOVER STATE: MD ZIP: 21076 BUSINESS PHONE: 443-776-3133 MAIL ADDRESS: STREET 1: 7380 COCA COLA DRIVE STREET 2: SUITE 106 CITY: HANOVER STATE: MD ZIP: 21076 FORMER COMPANY: FORMER CONFORMED NAME: Heatwurx, Inc. DATE OF NAME CHANGE: 20111028 10-Q 1 form10-q.htm

United States
Securities and Exchange Commission
Washington, D.C. 20549

FORM 10-Q

(Mark One)

[X]

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2019

[ ]

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____ to ____

Commission File Number 333-184948

Processa Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

45-1539785

(State or other jurisdiction

of incorporation or organization)

(IRS Employer

Identification No.)

7380 Coca Cola Drive, Suite 106,

Hanover, Maryland 21076

(443) 776-3133

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES [X] NO [ ]

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YES [X] NO [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

	Large accelerated filer [ ]	Accelerated filer [ ]
	Non-accelerated filer [ ]	Smaller reporting company [X]
		Emerging growth company [X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES [ ] NO [X]

The registrant has 38,674,265 shares of common stock outstanding as of April 30, 2019.

Securities registered pursuant to Section 12(b) of the Exchange Act: None.

PROCESSA PHARMACEUTICALS, INC.

TABLE OF CONTENTS

PART 1: FINANCIAL INFORMATION		3
	ITEM 1: FINANCIAL STATEMENTS	3
	ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	15
	ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	22
	ITEM 4. CONTROLS AND PROCEDURES	23
PART II. OTHER INFORMATION		23
	ITEM 1. LEGAL PROCEEDINGS	23
	ITEM 1A. RISK FACTORS	23
	ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	23
	ITEM 3. DEFAULTS UPON SENIOR SECURITIES	24
	ITEM 4. MINE SAFETY DISCLOSURES	24
	ITEM 5. OTHER INFORMATION	24
	ITEM 6. EXHIBITS	24

PART 1: FINANCIAL INFORMATION

ITEM 1: FINANCIAL STATEMENTS

Processa Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

	March 31, 2019			December 31, 2018
ASSETS
Current Assets
Cash and cash equivalents	$	1,248,532		$	1,740,961
Due from related party		47,165			21,583
Prepaid expenses and other		247,200			257,832
Total Current Assets		1,542,897			2,020,376
Property and equipment, net		15,264			17,375
Operating lease right-of-use assets, net		275,251			-
Intangible assets, net		10,238,950			10,437,782
Security deposit		5,535			5,535
Total Assets	$	12,077,897		$	12,481,068

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities
Senior convertible notes	$	230,000		$	230,000
Current maturities of operating lease liability		58,504			-
Accrued interest		24,943			20,343
Accounts payable		283,057			292,102
Accrued expenses		128,220			103,259
Total Current Liabilities		724,724			645,704
Non-current Liabilities
Noncurrent operating lease liability		225,381			-
Net deferred tax liability		2,004,047			2,134,346
Total Liabilities		2,954,152			2,780,050

Commitments and Contingencies		-			-

Stockholders’ Equity
Preferred stock, par value $0.0001, 10,000,000 shares authorized; no shares issued and outstanding		-			-
Common stock, par value $0.0001, 350,000,000 shares authorized; 38,674,265 issued and outstanding at both March 31, 2019 and December 31, 2018		3,867			3,867
Additional paid-in capital		19,179,844			19,121,285
Stock subscription receivable		(1,685,000	)		(1,800,000	)
Accumulated deficit		(8,374,966	)		(7,624,134	)
Total Stockholders’ Equity		9,123,745			9,701,018
Total Liabilities and Stockholders’ Equity	$	12,077,897		$	12,481,068

The accompanying notes are an integral part of these condensed consolidated financial statements.

Processa Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

Three Months Ended March 31, 2019 and 2018

(Unaudited)

	Three Months Ended March 31,
	2019			2018
Operating Expenses:
Research and development	$	484,750		$	821,388
General and administrative		397,766			470,228

Operating Loss		(882,516	)		(1,291,616	)

Other Income (Expense):
Interest expense		(4,600	)		(87,740	)
Interest income		5,985			1,024

Net Operating Loss Before Income Tax Benefit		(881,131	)		(1,378,332	)
Income Tax Benefit		130,299			281,534

Net Loss	$	(750,832	)	$	(1,096,798	)

Net Loss Per Common Share - Basic and Diluted	$	(0.02	)	$	(0.03	)

Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Basic and Diluted		38,674,265			35,272,626

The accompanying notes are an integral part of these condensed consolidated financial statements.

Processa Pharmaceuticals, Inc.

Condensed Consolidated Statement of Changes in Stockholders’ Equity

Three Months Ended March 31, 2019 and 2018

(Unaudited)

									Additional
	Common Stock				Preferred Stock				Paid-In		Subscription			Accumulated
	Shares		Amount		Shares		Amount		Capital		Receivable			Deficit			Total
Balance at January 1, 2019		38,674,265	$	3,867		-	$	-	$	19,121,285	$	(1,800,000	)	$	(7,624,134	)	$	9,701,018
Stock based compensation		-		-		-		-		58,559		-			-			58,559
Payments made directly by investor for clinical trial costs		-		-		-		-		-		115,000			-			115,000
Net loss		-		-		-		-		-		-			(750,832	)		(750,832	)
Balance, March 31, 2019		38,674,265	$	3,867		-	$	-	$	19,179,844	$	(1,685,000	)	$	(8,374,966	)	$	9,123,745

									Additional
	Common Stock				Preferred Stock				Paid-In		Accumulated
	Shares		Amount		Shares		Amount		Capital		Deficit			Total
Balance at January 1, 2018		35,272,626	$	3,527		-	$	-	$	4,228,723	$	(3,859,086	)	$	373,164
Recognize the fair value of the license acquired from CoNCERT in exchange for 2,090,301 common shares of Processa held by Promet		-		-		-		-		8,000,000		-			8,000,000
Net loss		-		-		-		-		-		(1,096,798	)		(1,096,798	)
Balance, March 31, 2018		35,272,626	$	3,527		-	$	-	$	12,228,723	$	(4,955,884	)	$	7,276,366

The accompanying notes are an integral part of these condensed consolidated financial statements.

Processa Pharmaceuticals, Inc.

Condensed Consolidated Statements of Cash Flows

Three Months Ended March 31, 2019 and 2018

(Unaudited)

	2019			2018
Cash Flows From Operating Activities
Net loss	$	(750,832	)	$	(1,096,798	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		2,111			2,112
Amortization of right-of-use assets		17,947			-
Amortization of debt issuance costs		-			36,140
Amortization of intangible asset		198,832			25,435
Deferred income tax benefit		(130,299	)		(281,534	)
Stock-based compensation		58,559			-
Payments made directly to our Contract Research Organization by an investor in partial satisfaction of their stock subscription receivable		115,000			-
Net changes in operating assets and liabilities:
Prepaid expenses		10,632			1,257
Current portion of operating lease liability		(19,276	)		-
Accrued interest		4,600			51,600
Accounts payable		(9,045	)		54,194
Due (from) to related parties		(25,582	)		36,025
Accrued expenses		34,924			102,561
Net cash used in operating activities		(492,429	)		(1,069,008	)

Cash Flows From Investing Activities
Purchase of intangible asset		-			(1,782	)
Net cash provided by (used in) investing activities		-			(1,782	)

Net Decrease in Cash		(492,429	)		(1,070,790	)
Cash and Cash Equivalents – Beginning of Period		1,740,961			2,847,429
Cash and Cash Equivalents – End of Period	$	1,248,532		$	1,776,639

Processa Pharmaceuticals, Inc.

Condensed Consolidated Statements of Cash Flows (continued)

Three Months Ended March 31, 2019 and 2018

(Unaudited)

	2019			2018
Non-Cash Investing and Financing Activities:
Right-of-use asset obtained in exchange for operating lease liability	$	(293,198	)	$	-
Reduction in deferred lease liability		(9,963	)		-
Operating lease liability		303,161			-
Recognize the exclusive license intangible asset acquired from CoNCERT		-			(11,037,147	)
Recognize deferred tax liability for basis difference of Intangible asset		-			3,037,147
Recognize additional paid-in-capital for consideration paid from the transfer of 2,090,301 common shares of Processa released by Promet to CoNCERT for Processa		-			8,000,000
Net	$	-		$	-

The accompanying notes are an integral part of these condensed consolidated financial statements.

Processa Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note 1 – Organization and Summary of Significant Accounting Policies

Business Activities and Organization

Processa Pharmaceuticals, Inc. is an emerging clinical stage biopharmaceutical company focused on the development of drug products that are intended to provide treatment for and improve the survival and/or quality of life of patients who have a high unmet medical need condition or who have no alternative treatment. Within this group of pharmaceutical products, we currently are developing one product for multiple indications (i.e., the use of a drug to treat a particular disease) and searching for additional products for our portfolio.

Our lead product, PCS-499 is an oral tablet that is an analog of an active metabolite of an already approved FDA drug. The advantage of PCS-499 is that it potentially may work in many conditions because it has multiple pharmacological targets it affects that are important in the treatment of these conditions. Based on its pharmacological activity, we have identified multiple unmet medical need conditions where the use of PCS-499 may result in clinical efficacy. The lead indication currently under development for PCS-499 is Necrobiosis Lipoidica (NL). On June 22, 2018, the FDA granted orphan-drug designation to PCS-499 for the treatment of NL. On September 28, 2018, the FDA cleared our IND for PCS-499 in NL such that we could move forward with the Phase 2a safety-dose tolerability trial. We dosed our first NL patient in this Phase 2a clinical trial on January 29, 2019. As of May 1, 2019, we have enrolled nine patients in the trial with one of these patients discontinuing in the trial because of the inconvenience associated with a clinical trial. No adverse effects were noted in this patient. All eight of the other patients are receiving 1.8 gm of PCS-499 daily with no dose limiting side effects. One of these patients has been dosed for three months while two others will soon reach three months of treatment on PCS-499. As expected, we have not seen any significant change in the NL lesion in the one patient who has been treated for three months. Our expectation is that changes in the NL lesion will take at least six months to see any major effect. We anticipate all 12 patients planned for this trial will be enrolled on or before June 2019. In addition, we expect to request a meeting with the FDA before the end of 2019 to further discuss the development of PCS-499, including the next clinical trial.

We continue to evaluate other unmet need conditions for PCS-499, as well as other potential assets and are developing strategies, including the regulatory pathway and commercialization plans for product(s) for these unmet medical conditions.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions of the Securities and Exchange Commission (“SEC”) on Form 10-Q and Rule 10-01 of Regulation S-X.

Accordingly, they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the Company’s financial position and of the results of operations and cash flows for the periods presented. These consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the SEC (as amended). The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year.

Certain amounts have been reclassified in our March 31, 2018 statement of operations to confirm to the current year presentation.

Going Concern and Management’s Plans

Our condensed consolidated financial statements have been prepared using U.S. GAAP and are based on the assumption that we will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. We face certain risks and uncertainties that are present in many emerging growth companies regarding product development and commercialization, limited working capital, recurring losses and negative cash flow from operations, future profitability, ability to obtain future capital, protection of patents, technologies and property rights, competition, rapid technological change, navigating the domestic and major foreign markets’ regulatory and clinical environment, recruiting and retaining key personnel, dependence on third party manufacturing organizations, third party collaboration and licensing agreements, lack of sales and marketing activities. We currently have no customers or pharmaceutical products to sell or distribute. These risks and other factors raise substantial doubt about our ability to continue as a going concern.

We have relied exclusively on private placements with a small group of accredited investors to finance our business and operations. We do not have any prospective arrangements or credit facilities as a source of future funds. We have not had any revenue since our inception. We are looking at ways to add a revenue stream to offset some of our expenses but do not currently have any revenue under contract or any immediate sales prospects. During the three months ended March 31, 2019, we had an accumulated deficit of $8.4 million, incurred a net loss for the three months of $750,832 and used $492,429 in net cash from operating activities from continuing operations. At March 31, 2019, we had cash and cash equivalents totaling $1.2 million and a Clinical Trial Funding commitment from an investor (PoC Capital) of $1.7 million. During the three months ended March 31, 2019, PoC Capital paid $115,000 of costs on our behalf related to our Phase 2a trial for NL directly to our CRO. Subsequent to March 31, 2019, PoC Capital has paid an additional $216,965 directly to our CRO.

Based on our current plan and our available resources (including the Clinical Trial Funding commitment from PoC Capital), we will need to raise additional capital before the end of the second quarter of 2019 in order to fund our future operations. While we believe our current resources are adequate to complete our current Phase 2a trial for NL, we do not currently have resources to conduct other future trials without raising additional capital. As noted above, the timing and extent of our spending will depend on the costs associated with, and the results of our Phase 2a trial for NL. Our anticipated spending and our cash flow needs could change significantly as the trial progresses. There may be costs we incur during our trial that we do not currently anticipate in order to complete the trial, requiring us to need additional capital sooner than currently expected.

Additional funding may not be available to us on acceptable terms, or at all. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or future clinical trials, or research and development programs. We may seek to raise any necessary additional capital through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. To the extent that we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.

Uncertainty concerning our ability to continue as a going concern may hinder our ability to obtain future financing. Continued operations and our ability to continue as a going concern are dependent on our ability to obtain additional funding in the future and thereafter, and no assurances can be given that such funding will be available at all, in a sufficient amount, or on reasonable terms. Without additional funds from debt or equity financing, sales of assets, sales or out-licenses of intellectual property or technologies, or other transactions providing funds, we will rapidly exhaust our resources and be unable to continue operations. Absent additional funding, we believe that our cash and cash equivalents will not be sufficient to fund our operations for a period of one year or more after the date that these consolidated financial statements are available to be issued based on the timing and amount of our projected net loss from continuing operations and cash to be used in operating activities during that period of time.

As a result, substantial doubt exists about our ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are available to be issued. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be different should we be unable to continue as a going concern based on the outcome of these uncertainties described above.

Use of Estimates

In preparing our condensed consolidated financial statements and related disclosures in conformity with GAAP and pursuant to the rules and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates are used for, but not limited to: stock-based compensation, determining the fair value of acquired assets and assumed liabilities, intangible assets, and income taxes. These estimates and assumptions are continuously evaluated and are based on management’s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable, actual results could differ materially from those estimates and could impact future results of operations and cash flows.

Intangible Assets

Intangible assets acquired individually or with a group of other assets from others (other than in a business combination) are recognized at cost, including transaction costs, and allocated to the individual assets acquired based on relative fair values and no goodwill is recognized. Cost is measured based on cash consideration paid. If consideration given is in the form of non-cash assets, liabilities incurred, or equity interests issued, measurement of cost is based on either the fair value of the consideration given or the fair value of the assets (or net assets) acquired, whichever is more clearly evident and more reliably measurable. Costs of internally developing, maintaining or restoring intangible assets that are not specifically identifiable, have indeterminate lives or are inherent in a continuing business are expensed as incurred.

Intangible assets purchased from others for use in research and development activities and that have alternative future uses (in research and development projects or otherwise) are capitalized in accordance with ASC Topic 350, Intangibles – Goodwill and Other. Those that have no alternative future uses (in research and development projects or otherwise) and therefore no separate economic value are considered research and development costs and are expensed as incurred. Amortization of intangibles used in research and development activities is a research and development cost.

Intangibles with a finite useful life are amortized using the straight-line method unless the pattern in which the economic benefits of the intangible assets are consumed or used up are reliably determinable. The useful life is the best estimate of the period over which the asset is expected to contribute directly or indirectly to our future cash flows. The useful life is based on the duration of the expected use of the asset by us and the legal, regulatory or contractual provisions that constrain the useful life and future cash flows of the asset, including regulatory acceptance and approval, obsolescence, demand, competition and other economic factors. We evaluate the remaining useful life of intangible assets each reporting period to determine whether any revision to the remaining useful life is required. If the remaining useful life is changed, the remaining carrying amount of the intangible asset will be amortized prospectively over the revised remaining useful life. If an income approach is used to measure the fair value of an intangible asset, we consider the period of expected cash flows used to measure the fair value of the intangible asset, adjusted as appropriate for company-specific factors discussed above, to determine the useful life for amortization purposes.

If no regulatory, contractual, competitive, economic or other factors limit the useful life of the intangible to us, the useful life is considered indefinite. Intangibles with an indefinite useful life are not amortized until its useful life is determined to be no longer indefinite. If the useful life is determined to be finite, the intangible is tested for impairment and the carrying amount is amortized over the remaining useful life in accordance with intangibles subject to amortization. Indefinite-lived intangibles are tested for impairment annually and more frequently if events or circumstances indicate that it is more-likely-than-not that the asset is impaired.

Impairment of Long-Lived Assets and Intangibles Other Than Goodwill

We account for the impairment of long-lived assets in accordance with ASC 360, Property, Plant and Equipment and ASC 350, Intangibles – Goodwill and Other, which require that long-lived assets and certain identifiable intangibles be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to its expected future undiscounted net cash flows generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amounts of the assets exceed the fair value of the assets based on the present value of the expected future cash flows associated with the use of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. Based on management’s evaluation, there was no impairment loss recorded during the three months ended March 31, 2019.

Stock-based Compensation

Stock-based compensation expense is based on the grant-date fair value estimated in accordance with the provisions of ASC 718, Compensation-Stock Compensation. We expense stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. We estimate the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. Stock-based compensation costs are recorded as general and administrative or research and development costs in the statements of operations based upon the underlying individual’s role.

Net Loss Per Share

Basic loss per share is computed by dividing our net loss available to common shareholders by the weighted average number of shares of common stock outstanding during the year. Diluted loss per share is computed by dividing our net loss available to common shareholders by the diluted weighted average number of shares of common stock during the period. Since we experienced a net loss for both periods presented, basic and diluted net loss per share are the same. As such, diluted loss per share for the three months ended March 31, 2019 and 2018 excludes the impact of potentially dilutive common shares related to the conversion of our Senior Notes and outstanding stock options and warrants since those shares would have an anti-dilutive effect on loss per share.

Research and Development

Research and development costs are expensed as incurred and consisted of direct and overhead-related expenses.

Recently Adopted Accounting Pronouncements

On January 1, 2019, we adopted Accounting Standards Codification (ASC) 842, Leases. ASC 842 was issued to increase transparency and comparability among entities by recognizing right-of-use assets and lease liabilities on the balance sheet and disclosing key information about our lease agreements. We elected practical expedients upon transition that allows us to not reassess the lease classification of our leases, whether initial direct costs qualify for capitalization for our leases or whether any expired contracts are or contain leases. Additionally, we elected the optional transition method that allows for a cumulative effect adjustment in the period of adoption and we did not restate prior periods. The adoption of the new guidance on leasing resulted in the recognition of a right-of-use asset of $293,198 and lease obligations of $303,161. The difference between the right-of-use asset and the lease obligations is due to deferred rent liability related to our facility operating lease at December 31, 2018.

The adoption of the new guidance did not have a material impact on the condensed consolidated statement of operations. For further details regarding the adoption of this standard, see Note 7, “Operating Leases.”

Note 2 – Intangible Assets

Intangible assets at March 31, 2019 and December 31, 2018 consisted of the following:

	March 31, 2019			December 31, 2018
Gross intangible assets	$	11,059,429		$	11,059,429
Less: accumulated amortization		(820,479	)		(621,647	)
Total intangible assets, net	$	10,238,950		$	10,437,782

Amortization expense was $198,832 and $25,435 for the three months ended March 31, 2019 and 2018, respectively, and is included within research and development expense in the accompanying condensed consolidated statements of operations. Our estimated amortization expense for the next two years will be approximately $795,000 per year and for annual periods thereafter approximately $788,000 per year.

The capitalized costs for the license rights to PCS-499 included the $8 million purchase price, $1,782 in transaction costs and $3,037,147 associated with the initial recognition of an offsetting deferred tax liability related to the acquired temporary difference for an asset purchased that is not a business combination and has a tax basis of $1,782 in accordance with ASC 740-10-25-51 Income Taxes. In accordance with ASC Topic 730, Research and Development, we capitalized the costs of acquiring the exclusive license rights to PCS-499, as the exclusive license rights represent intangible assets to be used in research and development activities that management believes has future alternative uses.

Note 3 – Income Taxes

We account for income taxes in accordance with ASC Topic 740, Income Taxes. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the tax basis of assets and liabilities for financial reporting purposes and amounts recognized for income tax purposes. As of March 31, 2019, and December 31, 2018, we recorded a valuation allowance equal to the full recorded amount of our net deferred tax assets related to deferred start-up costs and other minor temporary differences since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed quarterly and is maintained until sufficient positive evidence exists to support its reversal.

A deferred tax liability was recorded on March 19, 2018 when Processa received CoNCERT’s license and “Know-How” in exchange for Processa stock that had been issued in the Internal Revenue Code Section 351 Transaction. The Section 351 Transaction treats the acquisition of the license and Know-How for stock as a tax-free exchange. As a result, under ASC 740-10-25-51 Income Taxes, Processa recorded a deferred tax liability of $3,037,147 for the acquired temporary difference between intangible assets (see Note 2) for the financial reporting basis of $11,038,929 and the tax basis of $1,782. The deferred tax liability will be reduced for the effect of non-deductibility of the amortization of the intangible asset and may be offset by the deferred tax assets resulting from net operating tax losses.

Under ACS 740-270 Income Taxes – Interim Reporting, we are required to project our annual federal and state effective income tax rate and apply it to the year to date ordinary operating tax basis loss before income taxes. Based on the projection, we expect to recognize the tax benefit from our projected ordinary tax loss, which can be used to offset the deferred tax liabilities related to the intangible assets and resulted in the recognition of a deferred tax benefit shown in the condensed consolidated statements of operations for three months ended March 31, 2019 and 2018. No current income tax expense is expected for the foreseeable future as we expect to generate taxable net operating losses.

Note 4 - Stock-based Compensation

We did not grant any stock options to employees or non-employees during the three months ended March 31, 2019 or 2018. At March 31, 2019, we had outstanding options to purchase 384,400 shares of our common stock of which options for the purchase of 9,000 shares of our common stock were vested. We recorded $58,559 of stock-based compensation expense for the three months ended March 31, 2019 as general and administrative expense. No expense was recorded during the three months ended March 31, 2018 since we had not stock options outstanding at March 31, 2018.

Note 5 – Senior Convertible Notes

At March 31, 2019 and December 31, 2018, we had $230,000 of Senior Convertible Notes outstanding held by Canadian individuals that cannot be converted until the Alberta Securities Commission permits the issuance of our common stock units (consisting of shares of our common stock and stock purchase warrants) to these Canadian holders. If the Alberta Securities Commission does not allow us to convert this debt into common stock units, we will be required to repay the principal and related accrued interest of approximately $255,000.

Note 6 – Net Loss per Share of Common Stock

Basic net loss per share is computed by dividing net loss by the weighted average common shares outstanding. Diluted net loss per share is computed by dividing net loss by the weighted average common shares outstanding, which includes potentially dilutive effect of stock options, warrants and senior convertible notes. Since we experienced a loss for both periods presented, including any dilutive common shares outstanding would have an anti-dilutive impact on diluted net loss per share, and as shown below were excluded from the computation. The treasury-stock method is used to determine the dilutive effect of our stock options and warrants grants, and the if-converted method is used to determine the dilutive effect of the Senior Notes.

The computation of net loss per share for the three months ended March 31, 2019 and 2018 was as follows:

	For the three months ended March 31,
	2019			2018
Basic and diluted net loss per share:
Net loss	$	(750,832	)	$	(1,096,798	)
Weighted-average number of common shares-basic and diluted		38,674,265			35,272,626

Basic and diluted net loss per share	$	(0.02	)	$	(0.03	)

The following potentially dilutive securities were excluded from the computation of diluted net income per share as their effect would have been anti-dilutive for the periods presented.

	2019		2018
Stock options and purchase warrants		3,917,763		-
Senior convertible notes		124,789		1,305,577

Note 7 - Operating Leases

We lease our office space under an operating lease agreement. This lease does not have significant rent escalation, concessions, leasehold improvement incentives, or other build-out clauses. Further, the lease does not contain contingent rent provisions. We also lease office equipment under an operating lease. Our office space lease includes both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area or other maintenance costs), which are accounted for as a single lease component as we have elected the practical expedient to group lease and non-lease components for all leases. Our leases do not provide an implicit rate and, as such, we have used our incremental borrowing rate of 8% in determining the present value of the lease payments based on the information available at the lease commencement date.

Lease costs included in our statement of operations totaled $24,563 and $27,981 for the three months ended March 31, 2019 and 2018, respectively. The weighted average remaining lease terms and discount rate for our operating leases were as follows at March 31, 2019:

Weighted average remaining lease term (years) for our facility and equipment leases			3.35
Weighted average discount rate for our facility and equipment leases			8.00	%

Maturities of our lease liabilities for all operating leases were as follows as of March 31, 2019:

2019	$	73,508
2020		92,603
2021		90,495
2022		69,741
Total lease payments		326,347
Less: Interest		(42,462	)
Present value of lease liabilities		283,885
Less: current maturities		(58,504	)
Non-current lease liability	$	225,381

Note 8 – Related Party Transactions

A shareholder, CorLyst, LLC, reimburses us for shared costs related to payroll, health care insurance and rent based on actual costs incurred, which are recognized as a reduction of our general and administrative operating expenses being reimbursed in our condensed consolidated statement of operations. We did not receive reimbursements during the three months ended March 31, 2019 and 2018. Amounts due from CorLyst at March 31, 2019 and December 31, 2018 were $47,165 and $21,583, respectively.

Note 9 – Commitments and Contingencies

Purchase Obligations

We enter into contracts in the normal course of business with contract research organizations and subcontractors to further develop our products. The contracts are cancellable, with varying provisions regarding termination. If a contract with a specific vendor were to be terminated, we would only be obligated for products or services that we received as of the effective date of the termination and any applicable cancellation fees. We had purchase obligations of approximately $23,000 at March 31, 2019.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operation

Forward Looking Statements

This Quarterly Report on Form 10-Q contains “forward-looking statements” that reflect, when made, the Company’s expectations or beliefs concerning future events that involve risks and uncertainties. Forward-looking statements frequently are identified by the words “believe,” “anticipate,” “expect,” “estimate,” “intend,” “project,” “will be,” “will continue,” “will likely result,” or other similar words and phrases. Similarly, statements herein that describe the Company’s objectives, plans or goals also are forward-looking statements. Actual results could differ materially from those projected, implied or anticipated by the Company’s forward-looking statements. Some of the factors that could cause actual results to differ include: our limited operating history, limited cash and history of losses; our ability to achieve profitability; our ability to obtain adequate financing to fund our business operations in the future; our ability to secure required FDA or other governmental approvals for our product candidates and the breadth of the indication sought; the impact of competitive or alternative products, technologies and pricing; whether we are successful in developing and commercializing our technology, including through licensing; the adequacy of protections afforded to us and/or our licensor by the anticipated patents that we own or license and the cost to us of maintaining, enforcing and defending those patents; our and our licensor’s ability to protect non-patented intellectual property rights; our exposure to and ability to defend third-party claims and challenges to our and our licensor’s anticipated patents and other intellectual property rights; and our ability to continue as a going concern. For a discussion of these and all other known risks and uncertainties that could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, as amended, which is available on the SEC’s website at www.sec.gov. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update this Quarterly Report on Form 10-Q to reflect events or circumstances after the date hereof.

For purposes of this Management’s Discussion and Analysis of Financial Condition and Results of Operations, references to the “Company,” “we,” “us” or “our” refer to the operations of Processa Pharmaceuticals, Inc. and its direct and indirect subsidiaries for the periods described herein.

Overview

We are an emerging pharmaceutical company focused on the clinical development of drug products that are intended to improve the survival and/or quality of life for patients who have a high unmet medical need. Within this group of pharmaceutical products, we currently are developing one product for multiple indications (i.e., the use of a drug to treat a particular disease) and searching for additional products for our portfolio.

On October 4, 2017, we acquired all the net assets of Promet Therapeutics, LLC (“Promet”), a private Delaware limited liability company, including the rights to the CoNCERT Agreement in exchange for 31,745,242 shares of our common stock. Immediately following the transaction, the former equity holders of Promet owned approximately 84% and held approximately 6% of the shares for the benefit of CoNCERT in relation to the CoNCERT contribution of the license to Processa as part of the Section 351 transaction, and our stockholders immediately prior to the transaction owned approximately 10% of our common stock. We traded on the OTC Pink Marketplace until December 8, 2018 when we listed our common stock on the OTCQB.

We accounted for the net asset acquisition transaction as a “reverse acquisition” merger under the acquisition method for GAAP, where Promet was considered the accounting acquirer; and for tax purposes, as a tax-free contribution under Internal Revenue Code Section 351. Accordingly, Promet’s historical results of operations replaced our historical results of operations for all periods prior to the merger. Unless otherwise stated, all comparisons in this Management’s Discussion and Analysis to periods prior to the merger are to the results of Promet for such period on a stand-alone basis. Prior to the acquisition, we had nominal net liabilities and operations. It was considered a non-operating public shell corporation.

We have a limited operating history as we were formed on March 29, 2011. Since that date, our operations have focused on acquiring the rights to PCS-499, organizing and staffing our company, business planning, raising capital, establishing our intellectual property portfolio and conducting clinical trials. We do not have any drug candidates approved for sale and have not yet generated any revenue from drug sales. We have funded our operations through the private sale of equity and equity-linked securities to accredited investors. Since inception, we have incurred operating losses. As of March 31, 2019, we had an accumulated deficit of $8.4 million. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase significantly in connection with our ongoing activities, as we:

	●	continue to invest in the development of PCS-499 for the treatment of NL;
	●	manufacture our drug candidate;
	●	hire additional research and development and general and administrative personnel;
	●	maintain, expand and protect our intellectual property portfolio;
	●	evaluate opportunities for the development of additional drug candidates; and
	●	incur additional costs associated with operating as a public company.

Going Concern and Management’s Plan

Our condensed consolidated financial statements are prepared using U.S. GAAP and are based on the assumption that we will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. We face certain risks and uncertainties that are present in many emerging growth companies regarding product development and commercialization, limited working capital, recurring losses and negative cash flow from operations, future profitability, ability to obtain future capital, protection of patents, technologies and property rights, competition, rapid technological change, navigating the domestic and major foreign markets’ regulatory and clinical environment, recruiting and retaining key personnel, dependence on third party manufacturing organizations, third party collaboration and licensing agreements, lack of sales and marketing activities and no customers or pharmaceutical products to sell or distribute. These risks and other factors raised substantial doubt about our ability to continue as a going concern as of the date of the filing of this quarterly report on Form 10-Q.

We have relied exclusively on private placements with a small group of accredited investors to finance our business and operations. We do not have any credit facilities as a source of future funds. We have not had any revenue since our inception and we do not currently have any revenue under contract or any immediate sales prospects. For the three months ended March 31, 2019, we incurred a net loss from continuing operations of $750,832 and used $492,429 in net cash from operating activities. We expect our operating costs to be substantial as we incur costs related to the clinical trials for our product candidates and that we will operate at a loss for the foreseeable future.

We are looking at ways to add an additional revenue stream to offset some of our expenses. We are planning on raising additional funds in the first half of 2019. In addition, we are seeking alternative options to add additional cash. However, no assurance can be given that we will be successful in securing adequate funds that may be required. If we are unable to raise additional capital on acceptable terms, or at all, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates, restrict our operations or obtain funds by entering into agreements on unattractive terms, which would likely have a material adverse effect on our business, stock price, and our relationships with third parties with whom we have business relationships, at least until additional funding is obtained.

As a result, substantial doubt existed about our ability to continue as a going concern as of the date of the filing of this quarterly report on Form 10-Q for the quarter ended March 31, 2019. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be different should the Company be unable to continue as a going concern based on the outcome of these uncertainties described above.

Status of our Phase 2a Clinical Trial in Necrobiosis Lipoidica

Phase 2a Study and Orphan Drug Designation. On June 22, 2018, the FDA granted orphan-drug designation to our leading clinical compound PCS-499 for the treatment of NL. On September 28, 2018, the FDA cleared our IND for PCS-499 in NL such that we could move forward with the Phase 2a safety-dose tolerability trial. We dosed our first NL patient in this Phase 2 clinical trial on January 29, 2019. As of May 1, 2019, we have enrolled nine patients in the trial with one of these patients discontinuing in the trial because of the inconvenience associated with a clinical trial. No adverse effects were noted in this patient. All eight of the other patients are receiving 1.8 gm of PCS-499 daily with no dose limiting side effects. One of these patients has been dosed for three months while two others will soon reach three months of treatment on PCS-499. As expected, we have not seen any significant change in the NL lesion in the one patient who has been treated for three months. Our expectation is that changes in the NL lesion will take at least six months to see any major effect. We anticipate all 12 patients planned for this trial will be enrolled on or before June 2019. In addition, we expect to request a meeting with the FDA before the end of 2019 to further discuss the development of PCS-499, including the next clinical trial.

Results of Operations

Comparison of the three months ended March 31, 2019 and 2018

The following table summarizes our net loss during the periods indicated:

	Three Months Ended
	March 31,
	2019			2018			Change
Operating Expenses
Research and development costs	$	484,750		$	821,388		$	(336,638	)
General and administrative expenses		397,766			470,228			(72,462	)
Total operating expenses		882,516			1,291,616			(409,100	)
Other Income (Expense)
Interest expense		(4,600	)		(87,740	)		83,140
Interest income		5,985			1,024			4,961
Total other income (expense)		1,385			(86,716	)		88,101
Net Operating Loss Before Income Tax Benefit		881,131			1,378,332			(497,201	)
Income Tax Benefit		(130,299	)		(281,534	)		151,235
Net Loss	$	750,832		$	1,096,798		$	(345,966	)

Revenues.

We do not currently have any revenue under contract or any immediate sales prospects.

Research and Development Expenses.

Our research and development costs are expensed as incurred. Research and development expenses include (i) licensing of compounds for product testing and development, (ii) program and testing related expenses, (iii) amortization of the exclusive license intangible asset used in research and development activities, and (iv) internal research and development staff related payroll, taxes and employee benefits, external consulting and professional fees related to the product testing and our development activities. Non-refundable advance payments for goods and services to be used in future research and development activities are recorded as prepaid expenses and expensed when the research and development activities are performed.

During the three months ended March 31, 2019 and 2018, we incurred total research and development expenses of $484,750 and $821,388, respectively, for the continued development and testing of our lead product, PCS-499. Costs for the three months ended March 31, 2019 and 2018 were as follows:

	Three months ended March 31,
	2019		2018
Amortization of intangible assets	$	198,832	$	25,435
Research and development salaries and benefits		158,855		165,512
Preclinical, clinical trial and other costs		127,063		630,441
Total	$	484,750	$	821,388

Overall, during the three months ended March 31, 2019, our research and development costs decreased by $336,638 as detailed below.

As a result of exercising the CoNCERT license and option agreement for PCS-499 in March 2018, and the purchase of a software license, we recognized $198,832 and $25,435 of amortization expense during the three months ended March 31, 2019 and 2018, respectively. Our research and development salaries and benefits decreased by $6,657 for the three months ended March 31, 2019 when compared to the same period in 2018 related to one of our research and development team members having a reduced level of involvement. A majority of the reduction related to lower research and development expenses for preclinical, clinical trial and other costs of $503,378 during the three months ended March 31, 2019 when compared to the same period in 2018. During the three months ended March 31, 2019, our focus was on enrolling patients in our trial, along with other trial costs, including providing doses of PCS-499 to participants in our Phase 2a clinical trial in NL. In contrast, during the same period in 2018, we experienced significantly higher costs related to a Phase 1 trial for PCS-499 and costs related to having to establishing a new site to contract manufacture the tablets of PCS-499 needed for our clinical trial since the original CoNCERT tablet manufacturing site could no longer be used.

We anticipate our research and development costs to increase in the future as we continue our Phase 2a clinical trial activities for NL in 2019. In the second quarter of 2019, we expect to incur additional costs to manufacture additional clinical material since we do not have enough product to complete our Phase 2a clinical trial. We incurred $83,562 of costs related to our Phase 2a trial during the three months ended March 31, 2019 and expect to spend an additional $395,000 during the remainder of 2019 and $711,000 through 2021 to complete our current trial. We believe, based on our estimates, the cost of our current Phase 2a trial to be approximately $1.6 to $1.8 million and anticipate our Clinical Trial Funding commitment of $1.8 million executed in June 2018 will be sufficient to fund the costs of this trial. The funding necessary to bring a drug candidate to market is, however, subject to numerous uncertainties. Once a drug candidate is identified, the further development of that drug candidate can be halted or abandoned at any time due to a number of factors. These factors include, but are not limited to, funding constraints, safety or a change in market demand. For each of our drug candidate programs, we periodically assess the scientific progress and merits of the programs to determine if continued research and development is economically viable. Certain of our programs may be terminated due to the lack of scientific progress and lack of prospects for ultimate commercialization.

During the year ended December 31, 2018, we made payments to our CRO related to our Phase 2a trial of approximately $239,000. We have accounted for these payments as either a prepaid expense or a research and development expense depending on whether the related service has been provided. During the three months ended March 31, 2019, PoC Capital made payments directly to our CRO totaling $115,000 for amounts being currently invoiced, thereby reducing the subscription receivable to $1,685,000. Subsequent to March 31, 2019, PoC Capital has made additional payments totaling $216,965 directly to our CRO. We expect PoC Capital to repay us, as well as continue to make payments to our CRO for outstanding and future invoices related to our Phase 2a trial. We will continue to reduce the subscription receivable in the period the investor makes payment to our CRO or us.

Our clinical trial accruals are based on estimates of patient enrollment and related costs at clinical investigator sites, as well as estimates for the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on our behalf.

We estimate preclinical and clinical trial expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on our behalf. In accruing service fees, we estimate the time-period over which services will be performed and the level of patient enrollment and activity expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the related series are recorded as prepaid expenses until the services are rendered.

General and Administrative Expenses.

Our general and administrative expenses for the three months ended March 31, 2019 decreased by $72,462 to $397,766 from $470,228 for the three months ended March 31, 2018. The decrease related primarily to a cybersecurity fraud loss of approximately $144,000, for which we did not have insurance coverage, during the three months ended March 31, 2018. We also saw reductions in professional fees for legal, accounting, advisory and consulting costs as we establish in-house capabilities as well as decreases in rent, repairs and maintenance, of approximately $47,000. We experienced increased payroll, and related costs of approximately $98,000 (including stock-based compensation of $58,559) as we build our finance team in the later part of 2018, including hiring a Chief Financial Officer and a Director of Finance and Accounting in the latter half of 2018 to support our growth and public company reporting and compliance requirements. The overall decrease in our general and administrative expenses during the three months ended March 31, 2019 was also offset by increases of approximately $20,000 in administrative costs such as insurance, office expenses, continuing education, and travel. Reimbursements from CorLyst of $25,964 for rent and other costs during the three months ended March 31, 2019 were comparable for the same period in 2018.

We expect the general and administrative expenses to continue to increase as we add staff to support our growing research and development activities and the administration required to operate as a public company.

Interest Expense.

Interest expense was $4,600 and $87,740 for the three months ended March 31, 2019 and 2018, respectively, related to our $2.58 million of 8% Senior Notes sold in 2017. In May 2018, $2.35 million of these Senior Convertible Notes were converted into shares of our common stock and stock purchase warrants. Included in interest expense is the amortization of debt issuance costs totaling $0 and $36,140 for the three months ended March 31, 2019 and 2018, respectively.

Interest Income.

Interest income was $5,985 and $1,024 for the three months ended March 31, 2019 and 2018, respectively. Interest income represents interest earned on money market funds and certificates of deposit.

Income Tax Benefit.

An income tax benefit of $130,299 was recognized for the three months ended March 31, 2019 as a result of our recording and amortizing the deferred tax liability created in connection with our acquisition of CoNCERT’s license and “Know-How” in exchange for Processa stock that had been issued in the Internal Revenue Code Section 351 transaction on March 19, 2018. The Section 351 transaction treated the acquisition of the Know-How for stock as a tax-free exchange. As a result, under ASC 740-10-25-51 Income Taxes, Processa recorded a deferred tax liability of $3,037,147 for the acquired temporary difference between the financial reporting basis of $11,038,929 and the tax basis of $1,782. The deferred tax liability will be reduced for the effect of the non-deductibility of the amortization of the intangible asset and may be offset by the deferred tax assets resulting from net operating tax losses. This offset results in the recognition of a deferred tax benefit shown in the consolidated statements of operations.

Financial Condition

At March 31, 2019, we had $1,248,532 in cash and a $1.7 million commitment for PoC Capital to fund our Phase 2a clinical trial for NL. Net cash used in our operating activities during the three months ended March 31, 2019 totaled $492,429 compared to $1,069,008 for the three months ended March 31, 2018.

Our total assets decreased by approximately $400,000 to $12.1 million at March 31, 2019 compared to $12.5 million at December 31, 2018. This decrease is a result of the operating costs we have incurred during the three months ended March 31, 2019, offset by the recording of right of use assets in conjunction with the adoption of ASC 842, and the tax effects resulting from the temporary difference between the book and tax basis of the intangible asset and transaction costs.

At March 31, 2019, our total liabilities, not including the impact of deferred income taxes, increased $304,401 to $950,105 when compared to $645,704 at December 31, 2018. This increase is due primarily to changes in accrued expenses as we continue the development of PCS-499 and conduct our Phase 2a clinical trial, as well as the recognition of operating lease liabilities in accordance with the adoption of ASC 842.

We continue to have $230,000 of Senior Convertible Notes outstanding that are held by Canadian individuals that, even though all the conditions for automatic conversion have been met, cannot be converted until the Alberta Securities Commission permits the issuance of our common stock units (consisting of shares of our common stock and stock purchase warrants) to these Canadian holders. If the Alberta Securities Commission does not allow us to convert this debt into common stock units, we will be required to repay the principal and related accrued interest of approximately $255,000.

In connection with exercising the option agreement with CoNCERT, we recognized a $3,037,147 deferred income tax liability since the intangible assets purchased had only a nominal tax basis. Our deferred tax liability has been and is expected to be reduced each period by an amount up to the income tax effect of our net loss.

Liquidity and Capital Resources

To date, we have funded our business and operations primarily through the private placement of equity securities and senior secured convertible notes. At March 31, 2019, we had $1.2 million in cash and cash equivalents compared to $1.7 million at December 31, 2018. We also received a Clinical Trial Funding commitment of $1.8 million to fund clinical trial expenses, of which $1.7 million has not been used as of March 31, 2019. We believe the clinical trial committed funds will be sufficient to fund our current Phase 2a clinical trial of PCS-499 in patients with NL. We do not have any credit facilities as a source of future funds, and there can be no assurance that we will be able to raise sufficient additional capital on acceptable terms, or at all. As a result, substantial doubt exists about our ability to continue as a going concern within one year after the date that this Form 10-Q is filed with the SEC.

Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, and the extent to which we may enter into additional agreements with third parties to participate in their development and commercialization, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical trials. Our future capital requirements will depend on many factors, including:

	●	the timing and extent of spending on our research and development efforts, including with respect to PCS-499 and our other product candidates;

	●	the scope, rate of progress, results and cost of our clinical trials, preclinical testing and other related activities;

	●	the time and costs involved in obtaining regulatory and marketing approvals in multiple jurisdictions for our product candidates that successfully complete clinical trials;

	●	the cost of preparing, filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;

	●	the emergence of competing technologies or other adverse market developments;

	●	the introduction of new product candidates and the number and characteristics of product candidates that we pursue; and

	●	the potential acquisition and in-licensing of other technologies, products or assets.

Based on our current plan and our available resources (including the remaining Clinical Trial Funding commitment of $1.7 million from PoC Capital), we will need to raise additional capital before the end of the second quarter of 2019 in order to fund our future operations. While we believe our current resources are adequate to complete our upcoming Phase 2a trial, we do not currently have resources to conduct other future trials without raising additional capital. As noted above, the timing and extent of our spending will depend on the cost associated with, and the results of our Phase 2a trial. Our anticipated spending and our cash flow needs could change significantly as the trial progresses. There may be costs we incur during our trial that we do not currently anticipate in order to complete our current trial, requiring us to need additional capital sooner than currently expected.

Additional funding may not be available to us on acceptable terms, or at all. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of or suspend our current or future clinical trials, or research and development programs. We may seek to raise any necessary additional capital through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. To the extent that we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.

Cash Flows

The following table sets forth our sources and uses of cash and cash equivalents for the three months ended March 31, 2019 and 2018:

	Three months ended
	March 31,
	2019			2018
Net cash provided by (used in):
Operating activities	$	(492,429	)	$	(1,069,008	)
Investing activities		-			(1,782	)
Financing activities		-			-
Net increase in cash and cash equivalents	$	(492,429	)	$	(1,070,790	)

Net cash used in operating activities

We used net cash in our operating activities of $492,429 and $1,069,008 during the three months ended March 31, 2019 and 2018, respectively. The decrease in cash used in operating activities during the first quarter of 2019 compared to the comparable period in 2018 was related to a decreased amount of direct cash costs incurred. Our net loss for the three months ended March 31, 2019 was $345,966 less than the comparable period in 2018. This was due primarily to our focus on PCS-499 leading to an overall reduction in our research and development expenses and that PoC Capital made direct payments to our CRO of $115,000 related to our Phase 2a trial. We also incurred a full quarter of amortization expense or $198,832 (versus $25,425 for the comparable period in 2018) and $58,559 of stock-based compensation during the three months ended March 31, 2019. During the three months ended March 31, 2018, we incurred a one-time cybersecurity fraud loss of approximately $144,000 in January 2018, which was recognized in general and administrative expenses.

Since we are in the process of developing our products, we anticipate our research and development efforts and on-going general and administrative costs will continue to generate negative cash flows from operating activities for the foreseeable future and that these amounts will increase in the future. We do not currently sell or distribute pharmaceutical products or have any sales or marketing capabilities.

Net cash used in investing activities

We had no cash sources or uses for investing activities during the three months ended March 31, 2019. Net cash used during the three months ended March 31, 2018 was $1,782 related to the transaction costs incurred to acquire the exclusive license of PCS-499 in 2018.

Net cash provided by (used in) financing activities

There were no financing activities for the three months ended March 31, 2019 and 2018. We expect that we will continue to seek additional capital through a combination of private and public equity offerings, debt financings, and strategic collaborations to fund future operations. However, no assurance can be given that we will be successful in raising adequate funds needed. Absent additional financing, substantial doubt exists about our ability to continue as a going concern, as noted under Going Concern above.

Contractual Obligations and Commitments

There have been no significant changes to the contractual obligations reported in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018.

Off Balance Sheet Arrangements

At March 31, 2019, we did not have any off-balance sheet arrangements.

Critical Accounting Policies and Use of Estimates

Our discussion and analysis of our financial condition and results of operations are based upon our Unaudited Condensed Consolidated Financial Statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities.

We believe that the estimates, assumptions and judgments involved in the accounting policies described in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section of our most recent Annual Report on Form 10-K have the greatest potential impact on our financial statements, so we consider these to be our critical accounting policies. Actual results could differ from the estimates we use in applying our critical accounting policies. We are not currently aware of any reasonably likely events or circumstances that would result in materially different amounts being reported.

There have been no changes in our critical accounting policies from our most recent Annual Report on Form 10-K.

Recently Issued Accounting Pronouncements

See Note 1 in the accompanying Notes to the Unaudited Condensed Consolidated Financial Statements for recently adopted accounting standards.

Emerging Growth Company

We are an “emerging growth company” as that term is defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (i.e., those that have not had a registration statement declared effective under the Securities Act, or do not have a class of securities registered under the Exchange Act) are required to comply with such new or revised financial accounting standards. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. We may still take advantage of all of the other provisions of the JOBS Act, which include, but are not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, the reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and the exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Item 3 is not applicable to us as a smaller reporting company and has been omitted.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Report. Based upon that evaluation, the CEO and CFO concluded that our disclosure controls and procedures as of the end of the period covered by this Report were not effective in providing reasonable assurance in the reliability of our report as of the end of the period covered by this report.

In our 2018 Annual Report on Form 10-K, we identified the following material weaknesses in our internal control over financial reporting, which are common in many small companies with limited staff including: (i) certain entity level controls; (ii) inadequate segregation of duties throughout the entire year; and (iii) insufficient documentation of certain policies and procedures for transaction processing, accounting and financial reporting with respect to the requirements and application of both GAAP and SEC guidelines, their related controls and the operation thereof. These material weaknesses continue to be present at March 31, 2019.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting during our quarter ended March 31, 2019, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. We are continuing to take remediation actions to rectify our control deficiencies (including material weaknesses) through the adoption and implementation of written policies and procedures for transaction processing, accounting and financial reporting, as well as strengthening our supervisory review processes.

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

We are currently not a party to any material legal proceedings.

Item 1A. Risk Factors

There are no material changes to the Company’s risk factors as described in Item 1A of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

(a) Recent Sale of Unregistered Securities

We did not have any sales of unregistered securities during the three months ended March 31, 2019.

(b) Use of Proceeds from Public Offering of Common Stock

None.

(c) Issuer Purchases of Equity Securities

We did not repurchase any shares of our common stock during the three months ended March 31, 2019.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

SEC Ref. No.		Title of Document
31.1*		Rule 153-14(a) Certification by Principal Executive Officer
31.2*		Rule 153-14(a) Certification by Principal Financial Officer
32.1*++		Section 1350 Certification of Principal Executive Officer and Principal Financial Officer
99.1		XBRL Files

* Filed herewith.

++ This certification is being furnished solely to accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350 and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	PROCESSA PHARMACEUTICALS, INC.

	By:	/s/ David Young
		David Young
		Chief Executive Officer (Principal Executive Officer) Dated: May 14, 2019

	By:	/s/ James Stanker
		James Stanker Chief Financial Officer (Principal Financial and Accounting Officer) Dated: May 14, 2019

EX-31.1 2 ex31-1.htm

Exhibit 31.1

CERTIFICATIONS

I, David Young, Chief Executive Officer of PROCESSA PHARMACEUTICALS, INC. certify that:

1. I have reviewed this quarterly report on Form 10-Q of PROCESSA PHARMACEUTICALS, INC. for the three months ended March 31, 2019;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules13a-15(f) and 15d-15 (f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	Date:	May 14, 2019

	By:	/s/ David Young
		David Young
		Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 ex31-2.htm

Exhibit 31.2

CERTIFICATIONS

I, James Stanker, Chief Financial Officer of PROCESSA PHARMACEUTICALS, INC. certify that:

1. I have reviewed this quarterly report on Form 10-Q of PROCESSA PHARMACEUTICALS, INC. for the three months ended March 31, 2019;

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	Date:	May 14, 2019

	By:	/s/ James Stanker
		James Stanker
		Chief Financial Officer (Principal Financial and Accounting Officer)

EX-32.1 4 ex32-1.htm

Exhibit 32.1

Written Statement of the Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. §1350

Solely for the purposes of complying with 18 U.S.C. §1350, I, the undersigned Chief Executive Officer of Processa Pharmaceuticals, Inc. (the “Company”), hereby certify, to the best of my knowledge, that the quarterly report on Form 10-Q of the Company for the quarter ended March 31, 2019 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

This certification is being furnished solely to accompany this Report pursuant to 18 U.S.C. 1350 and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

	Date:	May 14, 2019

	By:	/s/ David Young
		David Young
		Chief Executive Officer (Principal Executive Officer)

Solely for the purposes of complying with 18 U.S.C. §1350, I, the undersigned Chief Financial Officer of Processa Pharmaceuticals, Inc. (the “Company”), hereby certify, to the best of my knowledge, that the quarterly report on Form 10-Q of the Company for the quarter ended March 31, 2019 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	Date:	May 14, 2019

	By:	/s/ James Stanker
		James Stanker
		Chief Financial Officer (Principal Financial and Accounting Officer)

EX-101.INS 5 pcsa-20190331.xml XBRL INSTANCE FILE 0001533743 2019-01-01 2019-03-31 0001533743 2019-03-31 0001533743 2018-12-31 0001533743 2018-01-01 2018-03-31 0001533743 us-gaap:CommonStockMember 2017-12-31 0001533743 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001533743 us-gaap:RetainedEarningsMember 2017-12-31 0001533743 us-gaap:CommonStockMember 2018-12-31 0001533743 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001533743 us-gaap:RetainedEarningsMember 2018-12-31 0001533743 us-gaap:PreferredStockMember 2017-12-31 0001533743 us-gaap:PreferredStockMember 2018-12-31 0001533743 PCSA:CorlystMember 2019-03-31 0001533743 PCSA:CorlystMember 2018-12-31 0001533743 PCSA:SeniorConvertibleNotesMember 2019-01-01 2019-03-31 0001533743 PCSA:SubscriptionReceivableMember 2018-12-31 0001533743 PCSA:StockPurchaseWarrantsMember 2019-01-01 2019-03-31 0001533743 PCSA:StockPurchaseWarrantsMember 2018-01-01 2018-03-31 0001533743 PCSA:SeniorConvertibleNotesMember 2018-01-01 2018-03-31 0001533743 2019-04-30 0001533743 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001533743 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001533743 us-gaap:CommonStockMember 2019-03-31 0001533743 us-gaap:CommonStockMember 2018-03-31 0001533743 us-gaap:PreferredStockMember 2019-01-01 2019-03-31 0001533743 us-gaap:PreferredStockMember 2018-01-01 2018-03-31 0001533743 us-gaap:PreferredStockMember 2019-03-31 0001533743 us-gaap:PreferredStockMember 2018-03-31 0001533743 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001533743 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001533743 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001533743 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001533743 PCSA:SubscriptionReceivableMember 2019-01-01 2019-03-31 0001533743 PCSA:SubscriptionReceivableMember 2019-03-31 0001533743 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001533743 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001533743 us-gaap:RetainedEarningsMember 2019-03-31 0001533743 us-gaap:RetainedEarningsMember 2018-03-31 0001533743 2017-12-31 0001533743 2018-03-31 0001533743 PCSA:ContractResearchOrganizationMember 2019-01-01 2019-03-31 0001533743 2019-01-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure Processa Pharmaceuticals, Inc. 0001533743 10-Q 2019-03-31 --12-31 Non-accelerated Filer Q1 2019

0.0001

350000000

38674265

10000000

24943

20343

47165

21583

47165

21583

-750832

-1096798

-750832

-1096798

1248532

1740961

2847429

1776639

230000

2090301

PCSA

23000

3037147

11059429

10238950

10437782

Note 2 – Intangible Assets   Intangible assets at March 31, 2019 and December 31, 2018 consisted of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">March 31, 2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">December 31, 2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 57%; line-height: 107%">Gross intangible assets</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 18%; text-align: right; line-height: 107%">11,059,429</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 19%; text-align: right; line-height: 107%">11,059,429</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Less: accumulated amortization</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(820,479</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(621,647</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total intangible assets, net</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">10,238,950</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">10,437,782</td> <td style="line-height: 107%"> </td></tr> </table>   Amortization expense was $198,832 and $25,435 for the three months ended March 31, 2019 and 2018, respectively, and is included within research and development expense in the accompanying condensed consolidated statements of operations. Our estimated amortization expense for the next two years will be approximately $795,000 per year and for annual periods thereafter approximately $788,000 per year.   The capitalized costs for the license rights to PCS-499 included the $8 million purchase price, $1,782 in transaction costs and $3,037,147 associated with the initial recognition of an offsetting deferred tax liability related to the acquired temporary difference for an asset purchased that is not a business combination and has a tax basis of $1,782 in accordance with ASC 740-10-25-51 Income Taxes. In accordance with ASC Topic 730, Research and Development, we capitalized the costs of acquiring the exclusive license rights to PCS-499, as the exclusive license rights represent intangible assets to be used in research and development activities that management believes has future alternative uses.

Note 3 – Income Taxes   We account for income taxes in accordance with ASC Topic 740, Income Taxes. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the tax basis of assets and liabilities for financial reporting purposes and amounts recognized for income tax purposes. As of March 31, 2019, and December 31, 2018, we recorded a valuation allowance equal to the full recorded amount of our net deferred tax assets related to deferred start-up costs and other minor temporary differences since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed quarterly and is maintained until sufficient positive evidence exists to support its reversal.   A deferred tax liability was recorded on March 19, 2018 when Processa received CoNCERT’s license and “Know-How” in exchange for Processa stock that had been issued in the Internal Revenue Code Section 351 Transaction. The Section 351 Transaction treats the acquisition of the license and Know-How for stock as a tax-free exchange. As a result, under ASC 740-10-25-51 Income Taxes, Processa recorded a deferred tax liability of $3,037,147 for the acquired temporary difference between intangible assets (see Note 2) for the financial reporting basis of $11,038,929 and the tax basis of $1,782. The deferred tax liability will be reduced for the effect of non-deductibility of the amortization of the intangible asset and may be offset by the deferred tax assets resulting from net operating tax losses.   Under ACS 740-270 Income Taxes – Interim Reporting, we are required to project our annual federal and state effective income tax rate and apply it to the year to date ordinary operating tax basis loss before income taxes. Based on the projection, we expect to recognize the tax benefit from our projected ordinary tax loss, which can be used to offset the deferred tax liabilities related to the intangible assets and resulted in the recognition of a deferred tax benefit shown in the condensed consolidated statements of operations for three months ended March 31, 2019 and 2018. No current income tax expense is expected for the foreseeable future as we expect to generate taxable net operating losses.

Note 6 – Net Loss per Share of Common Stock   Basic net loss per share is computed by dividing net loss by the weighted average common shares outstanding. Diluted net loss per share is computed by dividing net loss by the weighted average common shares outstanding, which includes potentially dilutive effect of stock options, warrants and senior convertible notes. Since we experienced a loss for both periods presented, including any dilutive common shares outstanding would have an anti-dilutive impact on diluted net loss per share, and as shown below were excluded from the computation. The treasury-stock method is used to determine the dilutive effect of our stock options and warrants grants, and the if-converted method is used to determine the dilutive effect of the Senior Notes.   The computation of net loss per share for the three months ended March 31, 2019 and 2018 was as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid"> For the three months ended March 31,</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Basic and diluted net loss per share:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 72%; padding-left: 10pt; line-height: 107%">Net loss</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">(750,832</td> <td style="width: 1%; line-height: 107%">)</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">(1,096,798</td> <td style="width: 1%; line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Weighted-average number of common shares-basic and diluted</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">38,674,265</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">35,272,626</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 20pt; line-height: 107%">Basic and diluted net loss per share</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(0.02</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(0.03</td> <td style="line-height: 107%">)</td></tr> </table>   The following potentially dilutive securities were excluded from the computation of diluted net income per share as their effect would have been anti-dilutive for the periods presented.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 72%; line-height: 107%">Stock options and purchase warrants</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 11%; text-align: right; line-height: 107%">3,917,763</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 11%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Senior convertible notes</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">124,789</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,305,577</td> <td style="line-height: 107%"> </td></tr> </table>

Note 8 – Related Party Transactions   A shareholder, CorLyst, LLC, reimburses us for shared costs related to payroll, health care insurance and rent based on actual costs incurred, which are recognized as a reduction of our general and administrative operating expenses being reimbursed in our condensed consolidated statement of operations. We did not receive reimbursements during the three months ended March 31, 2019 and 2018. Amounts due from CorLyst at March 31, 2019 and December 31, 2018 were $47,165 and $21,583, respectively.

Note 9 – Commitments and Contingencies   Purchase Obligations   We enter into contracts in the normal course of business with contract research organizations and subcontractors to further develop our products. The contracts are cancellable, with varying provisions regarding termination. If a contract with a specific vendor were to be terminated, we would only be obligated for products or services that we received as of the effective date of the termination and any applicable cancellation fees. We had purchase obligations of approximately $23,000 at March 31, 2019.

Use of Estimates   In preparing our condensed consolidated financial statements and related disclosures in conformity with GAAP and pursuant to the rules and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates are used for, but not limited to: stock-based compensation, determining the fair value of acquired assets and assumed liabilities, intangible assets, and income taxes. These estimates and assumptions are continuously evaluated and are based on management’s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable, actual results could differ materially from those estimates and could impact future results of operations and cash flows.

Intangible Assets   Intangible assets acquired individually or with a group of other assets from others (other than in a business combination) are recognized at cost, including transaction costs, and allocated to the individual assets acquired based on relative fair values and no goodwill is recognized. Cost is measured based on cash consideration paid. If consideration given is in the form of non-cash assets, liabilities incurred, or equity interests issued, measurement of cost is based on either the fair value of the consideration given or the fair value of the assets (or net assets) acquired, whichever is more clearly evident and more reliably measurable. Costs of internally developing, maintaining or restoring intangible assets that are not specifically identifiable, have indeterminate lives or are inherent in a continuing business are expensed as incurred.   Intangible assets purchased from others for use in research and development activities and that have alternative future uses (in research and development projects or otherwise) are capitalized in accordance with ASC Topic 350, Intangibles – Goodwill and Other. Those that have no alternative future uses (in research and development projects or otherwise) and therefore no separate economic value are considered research and development costs and are expensed as incurred. Amortization of intangibles used in research and development activities is a research and development cost.   Intangibles with a finite useful life are amortized using the straight-line method unless the pattern in which the economic benefits of the intangible assets are consumed or used up are reliably determinable. The useful life is the best estimate of the period over which the asset is expected to contribute directly or indirectly to our future cash flows. The useful life is based on the duration of the expected use of the asset by us and the legal, regulatory or contractual provisions that constrain the useful life and future cash flows of the asset, including regulatory acceptance and approval, obsolescence, demand, competition and other economic factors. We evaluate the remaining useful life of intangible assets each reporting period to determine whether any revision to the remaining useful life is required. If the remaining useful life is changed, the remaining carrying amount of the intangible asset will be amortized prospectively over the revised remaining useful life. If an income approach is used to measure the fair value of an intangible asset, we consider the period of expected cash flows used to measure the fair value of the intangible asset, adjusted as appropriate for company-specific factors discussed above, to determine the useful life for amortization purposes.   If no regulatory, contractual, competitive, economic or other factors limit the useful life of the intangible to us, the useful life is considered indefinite. Intangibles with an indefinite useful life are not amortized until its useful life is determined to be no longer indefinite. If the useful life is determined to be finite, the intangible is tested for impairment and the carrying amount is amortized over the remaining useful life in accordance with intangibles subject to amortization. Indefinite-lived intangibles are tested for impairment annually and more frequently if events or circumstances indicate that it is more-likely-than-not that the asset is impaired.

Impairment of Long-Lived Assets and Intangibles Other Than Goodwill   We account for the impairment of long-lived assets in accordance with ASC 360, Property, Plant and Equipment and ASC 350, Intangibles – Goodwill and Other, which require that long-lived assets and certain identifiable intangibles be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to its expected future undiscounted net cash flows generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amounts of the assets exceed the fair value of the assets based on the present value of the expected future cash flows associated with the use of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. Based on management’s evaluation, there was no impairment loss recorded during the three months ended March 31, 2019.

Net Loss Per Share   Basic loss per share is computed by dividing our net loss available to common shareholders by the weighted average number of shares of common stock outstanding during the year. Diluted loss per share is computed by dividing our net loss available to common shareholders by the diluted weighted average number of shares of common stock during the period. Since we experienced a net loss for both periods presented, basic and diluted net loss per share are the same. As such, diluted loss per share for the three months ended March 31, 2019 and 2018 excludes the impact of potentially dilutive common shares related to the conversion of our Senior Notes and outstanding stock options and warrants since those shares would have an anti-dilutive effect on loss per share.

Recently Adopted Accounting Pronouncements   On January 1, 2019, we adopted Accounting Standards Codification (ASC) 842, Leases. ASC 842 was issued to increase transparency and comparability among entities by recognizing right-of-use assets and lease liabilities on the balance sheet and disclosing key information about our lease agreements. We elected practical expedients upon transition that allows us to not reassess the lease classification of our leases, whether initial direct costs qualify for capitalization for our leases or whether any expired contracts are or contain leases. Additionally, we elected the optional transition method that allows for a cumulative effect adjustment in the period of adoption and we did not restate prior periods. The adoption of the new guidance on leasing resulted in the recognition of a right-of-use asset of $293,198 and lease obligations of $303,161. The difference between the right-of-use asset and the lease obligations is due to deferred rent liability related to our facility operating lease at December 31, 2018.   The adoption of the new guidance did not have a material impact on the condensed consolidated statement of operations. For further details regarding the adoption of this standard, see Note 7, “Operating Leases.”

Intangible assets at March 31, 2019 and December 31, 2018 consisted of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">March 31, 2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">December 31, 2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 56%; line-height: 107%">Gross intangible assets</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 18%; text-align: right; line-height: 107%">11,059,429</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 20%; text-align: right; line-height: 107%">11,059,429</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Less: accumulated amortization</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(820,479</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(621,647</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total intangible assets, net</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">10,238,950</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">10,437,782</td> <td style="line-height: 107%"> </td></tr> </table>

The computation of net loss per share for the three months ended March 31, 2019 and 2018 was as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid"> For the three months ended March 31,</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Basic and diluted net loss per share:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 72%; padding-left: 10pt; line-height: 107%">Net loss</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">(750,832</td> <td style="width: 1%; line-height: 107%">)</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">(1,096,798</td> <td style="width: 1%; line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Weighted-average number of common shares-basic and diluted</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">38,674,265</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">35,272,626</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 20pt; line-height: 107%">Basic and diluted net loss per share</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(0.02</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(0.03</td> <td style="line-height: 107%">)</td></tr> </table>

1782

P2Y

1542897

2020376

15264

17375

12077897

12481068

10238950

10437782

2954152

2780050

2004047

2134346

724724

645704

128220

103259

283057

292102

19179844

19121285

3867

-8374966

-7624134

12077897

12481068

397766

470228

484750

821388

-882516

-1291616

5985

1024

4600

87740

-881131

-1378332

-130299

-281534

-0.02

-0.03

38674265

35272626

38674265

35272626

9123745

9701018

3527

4228723

-3859086

3867

19121285

-7624134

-1800000

3867

3527

19179844

12228723

-1685000

-8374966

-4955884

373164

7276366

36140

-130299

-281534

198832

25435

2111

2112

-492429

-1069008

34924

102561

-9045

54194

4600

51600

-10632

-1257

-1782

124789

3917763

1305577

The following potentially dilutive securities were excluded from the computation of diluted net income per share as their effect would have been anti-dilutive for the periods presented.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 72%; line-height: 107%">Stock options and purchase warrants</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 11%; text-align: right; line-height: 107%">3,917,763</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 11%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Senior convertible notes</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">124,789</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,305,577</td> <td style="line-height: 107%"> </td></tr> </table>

-492429

-1070790

-11037147 3037147 8000000 true true true 38674265

58559

1700000

795000

788000

384400

58559

Stock-based Compensation   Stock-based compensation expense is based on the grant-date fair value estimated in accordance with the provisions of ASC 718, Compensation-Stock Compensation. We expense stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. We estimate the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. Stock-based compensation costs are recorded as general and administrative or research and development costs in the statements of operations based upon the underlying individual’s role.

-25582

36025

1782

Basis of Presentation   The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions of the Securities and Exchange Commission (“SEC”) on Form 10-Q and Rule 10-01 of Regulation S-X.   Accordingly, they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the Company’s financial position and of the results of operations and cash flows for the periods presented. These consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the SEC (as amended). The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year.   Certain amounts have been reclassified in our March 31, 2018 statement of operations to confirm to the current year presentation.

8000000

Research and Development   Research and development costs are expensed as incurred and consisted of direct and overhead-related expenses.

8000000

820479

621647

1685000

1800000

false

275251

293198

58504

225381

247200

257832

5535

115000 115000 216965 115000 -19276

293198

-9963 303161

Note 1 – Organization and Summary of Significant Accounting Policies   Business Activities and Organization   Processa Pharmaceuticals, Inc. is an emerging clinical stage biopharmaceutical company focused on the development of drug products that are intended to provide treatment for and improve the survival and/or quality of life of patients who have a high unmet medical need condition or who have no alternative treatment. Within this group of pharmaceutical products, we currently are developing one product for multiple indications (i.e., the use of a drug to treat a particular disease) and searching for additional products for our portfolio.   Our lead product, PCS-499 is an oral tablet that is an analog of an active metabolite of an already approved FDA drug. The advantage of PCS-499 is that it potentially may work in many conditions because it has multiple pharmacological targets it affects that are important in the treatment of these conditions. Based on its pharmacological activity, we have identified multiple unmet medical need conditions where the use of PCS-499 may result in clinical efficacy. The lead indication currently under development for PCS-499 is Necrobiosis Lipoidica (NL). On June 22, 2018, the FDA granted orphan-drug designation to PCS-499 for the treatment of NL. On September 28, 2018, the FDA cleared our IND for PCS-499 in NL such that we could move forward with the Phase 2a safety-dose tolerability trial. We dosed our first NL patient in this Phase 2a clinical trial on January 29, 2019. As of May 1, 2019, we have enrolled nine patients in the trial with one of these patients discontinuing in the trial because of the inconvenience associated with a clinical trial. No adverse effects were noted in this patient. All eight of the other patients are receiving 1.8 gm of PCS-499 daily with no dose limiting side effects. One of these patients has been dosed for three months while two others will soon reach three months of treatment on PCS-499. As expected, we have not seen any significant change in the NL lesion in the one patient who has been treated for three months. Our expectation is that changes in the NL lesion will take at least six months to see any major effect. We anticipate all 12 patients planned for this trial will be enrolled on or before June 2019. In addition, we expect to request a meeting with the FDA before the end of 2019 to further discuss the development of PCS-499, including the next clinical trial.   We continue to evaluate other unmet need conditions for PCS-499, as well as other potential assets and are developing strategies, including the regulatory pathway and commercialization plans for product(s) for these unmet medical conditions.   Basis of Presentation   The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions of the Securities and Exchange Commission (“SEC”) on Form 10-Q and Rule 10-01 of Regulation S-X.   Accordingly, they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the Company’s financial position and of the results of operations and cash flows for the periods presented. These consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the SEC (as amended). The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year.   Certain amounts have been reclassified in our March 31, 2018 statement of operations to confirm to the current year presentation.   Going Concern and Management’s Plans   Our condensed consolidated financial statements have been prepared using U.S. GAAP and are based on the assumption that we will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. We face certain risks and uncertainties that are present in many emerging growth companies regarding product development and commercialization, limited working capital, recurring losses and negative cash flow from operations, future profitability, ability to obtain future capital, protection of patents, technologies and property rights, competition, rapid technological change, navigating the domestic and major foreign markets’ regulatory and clinical environment, recruiting and retaining key personnel, dependence on third party manufacturing organizations, third party collaboration and licensing agreements, lack of sales and marketing activities. We currently have no customers or pharmaceutical products to sell or distribute. These risks and other factors raise substantial doubt about our ability to continue as a going concern.   We have relied exclusively on private placements with a small group of accredited investors to finance our business and operations. We do not have any prospective arrangements or credit facilities as a source of future funds. We have not had any revenue since our inception. We are looking at ways to add a revenue stream to offset some of our expenses but do not currently have any revenue under contract or any immediate sales prospects. During the three months ended March 31, 2019, we had an accumulated deficit of $8.4 million, incurred a net loss for the three months of $750,832 and used $492,429 in net cash from operating activities from continuing operations. At March 31, 2019, we had cash and cash equivalents totaling $1.2 million and a Clinical Trial Funding commitment from an investor (PoC Capital) of $1.7 million. During the three months ended March 31, 2019, PoC Capital paid $115,000 of costs on our behalf related to our Phase 2a trial for NL directly to our CRO. Subsequent to March 31, 2019, PoC Capital has paid an additional $216,965 directly to our CRO.   Based on our current plan and our available resources (including the Clinical Trial Funding commitment from PoC Capital), we will need to raise additional capital before the end of the second quarter of 2019 in order to fund our future operations. While we believe our current resources are adequate to complete our current Phase 2a trial for NL, we do not currently have resources to conduct other future trials without raising additional capital. As noted above, the timing and extent of our spending will depend on the costs associated with, and the results of our Phase 2a trial for NL. Our anticipated spending and our cash flow needs could change significantly as the trial progresses. There may be costs we incur during our trial that we do not currently anticipate in order to complete the trial, requiring us to need additional capital sooner than currently expected.   Additional funding may not be available to us on acceptable terms, or at all. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or future clinical trials, or research and development programs. We may seek to raise any necessary additional capital through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. To the extent that we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.   Uncertainty concerning our ability to continue as a going concern may hinder our ability to obtain future financing. Continued operations and our ability to continue as a going concern are dependent on our ability to obtain additional funding in the future and thereafter, and no assurances can be given that such funding will be available at all, in a sufficient amount, or on reasonable terms. Without additional funds from debt or equity financing, sales of assets, sales or out-licenses of intellectual property or technologies, or other transactions providing funds, we will rapidly exhaust our resources and be unable to continue operations. Absent additional funding, we believe that our cash and cash equivalents will not be sufficient to fund our operations for a period of one year or more after the date that these consolidated financial statements are available to be issued based on the timing and amount of our projected net loss from continuing operations and cash to be used in operating activities during that period of time.    As a result, substantial doubt exists about our ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are available to be issued. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be different should we be unable to continue as a going concern based on the outcome of these uncertainties described above.   Use of Estimates   In preparing our condensed consolidated financial statements and related disclosures in conformity with GAAP and pursuant to the rules and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates are used for, but not limited to: stock-based compensation, determining the fair value of acquired assets and assumed liabilities, intangible assets, and income taxes. These estimates and assumptions are continuously evaluated and are based on management’s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable, actual results could differ materially from those estimates and could impact future results of operations and cash flows.   Intangible Assets   Intangible assets acquired individually or with a group of other assets from others (other than in a business combination) are recognized at cost, including transaction costs, and allocated to the individual assets acquired based on relative fair values and no goodwill is recognized. Cost is measured based on cash consideration paid. If consideration given is in the form of non-cash assets, liabilities incurred, or equity interests issued, measurement of cost is based on either the fair value of the consideration given or the fair value of the assets (or net assets) acquired, whichever is more clearly evident and more reliably measurable. Costs of internally developing, maintaining or restoring intangible assets that are not specifically identifiable, have indeterminate lives or are inherent in a continuing business are expensed as incurred.   Intangible assets purchased from others for use in research and development activities and that have alternative future uses (in research and development projects or otherwise) are capitalized in accordance with ASC Topic 350, Intangibles – Goodwill and Other. Those that have no alternative future uses (in research and development projects or otherwise) and therefore no separate economic value are considered research and development costs and are expensed as incurred. Amortization of intangibles used in research and development activities is a research and development cost.   Intangibles with a finite useful life are amortized using the straight-line method unless the pattern in which the economic benefits of the intangible assets are consumed or used up are reliably determinable. The useful life is the best estimate of the period over which the asset is expected to contribute directly or indirectly to our future cash flows. The useful life is based on the duration of the expected use of the asset by us and the legal, regulatory or contractual provisions that constrain the useful life and future cash flows of the asset, including regulatory acceptance and approval, obsolescence, demand, competition and other economic factors. We evaluate the remaining useful life of intangible assets each reporting period to determine whether any revision to the remaining useful life is required. If the remaining useful life is changed, the remaining carrying amount of the intangible asset will be amortized prospectively over the revised remaining useful life. If an income approach is used to measure the fair value of an intangible asset, we consider the period of expected cash flows used to measure the fair value of the intangible asset, adjusted as appropriate for company-specific factors discussed above, to determine the useful life for amortization purposes.   If no regulatory, contractual, competitive, economic or other factors limit the useful life of the intangible to us, the useful life is considered indefinite. Intangibles with an indefinite useful life are not amortized until its useful life is determined to be no longer indefinite. If the useful life is determined to be finite, the intangible is tested for impairment and the carrying amount is amortized over the remaining useful life in accordance with intangibles subject to amortization. Indefinite-lived intangibles are tested for impairment annually and more frequently if events or circumstances indicate that it is more-likely-than-not that the asset is impaired.    Impairment of Long-Lived Assets and Intangibles Other Than Goodwill   We account for the impairment of long-lived assets in accordance with ASC 360, Property, Plant and Equipment and ASC 350, Intangibles – Goodwill and Other, which require that long-lived assets and certain identifiable intangibles be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to its expected future undiscounted net cash flows generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amounts of the assets exceed the fair value of the assets based on the present value of the expected future cash flows associated with the use of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. Based on management’s evaluation, there was no impairment loss recorded during the three months ended March 31, 2019.   Stock-based Compensation   Stock-based compensation expense is based on the grant-date fair value estimated in accordance with the provisions of ASC 718, Compensation-Stock Compensation. We expense stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. We estimate the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. Stock-based compensation costs are recorded as general and administrative or research and development costs in the statements of operations based upon the underlying individual’s role.   Net Loss Per Share   Basic loss per share is computed by dividing our net loss available to common shareholders by the weighted average number of shares of common stock outstanding during the year. Diluted loss per share is computed by dividing our net loss available to common shareholders by the diluted weighted average number of shares of common stock during the period. Since we experienced a net loss for both periods presented, basic and diluted net loss per share are the same. As such, diluted loss per share for the three months ended March 31, 2019 and 2018 excludes the impact of potentially dilutive common shares related to the conversion of our Senior Notes and outstanding stock options and warrants since those shares would have an anti-dilutive effect on loss per share.   Research and Development   Research and development costs are expensed as incurred and consisted of direct and overhead-related expenses.   Recently Adopted Accounting Pronouncements   On January 1, 2019, we adopted Accounting Standards Codification (ASC) 842, Leases. ASC 842 was issued to increase transparency and comparability among entities by recognizing right-of-use assets and lease liabilities on the balance sheet and disclosing key information about our lease agreements. We elected practical expedients upon transition that allows us to not reassess the lease classification of our leases, whether initial direct costs qualify for capitalization for our leases or whether any expired contracts are or contain leases. Additionally, we elected the optional transition method that allows for a cumulative effect adjustment in the period of adoption and we did not restate prior periods. The adoption of the new guidance on leasing resulted in the recognition of a right-of-use asset of $293,198 and lease obligations of $303,161. The difference between the right-of-use asset and the lease obligations is due to deferred rent liability related to our facility operating lease at December 31, 2018.   The adoption of the new guidance did not have a material impact on the condensed consolidated statement of operations. For further details regarding the adoption of this standard, see Note 7, “Operating Leases.”

Note 5 – Senior Convertible Notes   At March 31, 2019 and December 31, 2018, we had $230,000 of Senior Convertible Notes outstanding held by Canadian individuals that cannot be converted until the Alberta Securities Commission permits the issuance of our common stock units (consisting of shares of our common stock and stock purchase warrants) to these Canadian holders. If the Alberta Securities Commission does not allow us to convert this debt into common stock units, we will be required to repay the principal and related accrued interest of approximately $255,000.

Note 7 - Operating Leases   We lease our office space under an operating lease agreement. This lease does not have significant rent escalation, concessions, leasehold improvement incentives, or other build-out clauses. Further, the lease does not contain contingent rent provisions. We also lease office equipment under an operating lease. Our office space lease includes both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area or other maintenance costs), which are accounted for as a single lease component as we have elected the practical expedient to group lease and non-lease components for all leases. Our leases do not provide an implicit rate and, as such, we have used our incremental borrowing rate of 8% in determining the present value of the lease payments based on the information available at the lease commencement date.    Lease costs included in our statement of operations totaled $24,563 and $27,981 for the three months ended March 31, 2019 and 2018, respectively. The weighted average remaining lease terms and discount rate for our operating leases were as follows at March 31, 2019:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 87%; line-height: 107%">Weighted average remaining lease term (years) for our facility and equipment leases</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 9%; text-align: right; line-height: 107%">3.35</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Weighted average discount rate for our facility and equipment leases</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">8.00</td> <td style="line-height: 107%">%</td></tr> </table>   Maturities of our lease liabilities for all operating leases were as follows as of March 31, 2019:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%; line-height: 107%">2019</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 17%; text-align: right; line-height: 107%">73,508</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">2020</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">92,603</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">2021</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">90,495</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">2022</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">69,741</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Total lease payments</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">326,347</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt; line-height: 107%">Less: Interest</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(42,462</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Present value of lease liabilities</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">283,885</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Less: current maturities</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(58,504</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Non-current lease liability</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">225,381</td> <td style="line-height: 107%"> </td></tr> </table>

Business Activities and Organization   Processa Pharmaceuticals, Inc. is an emerging clinical stage biopharmaceutical company focused on the development of drug products that are intended to provide treatment for and improve the survival and/or quality of life of patients who have a high unmet medical need condition or who have no alternative treatment. Within this group of pharmaceutical products, we currently are developing one product for multiple indications (i.e., the use of a drug to treat a particular disease) and searching for additional products for our portfolio.   Our lead product, PCS-499 is an oral tablet that is an analog of an active metabolite of an already approved FDA drug. The advantage of PCS-499 is that it potentially may work in many conditions because it has multiple pharmacological targets it affects that are important in the treatment of these conditions. Based on its pharmacological activity, we have identified multiple unmet medical need conditions where the use of PCS-499 may result in clinical efficacy. The lead indication currently under development for PCS-499 is Necrobiosis Lipoidica (NL). On June 22, 2018, the FDA granted orphan-drug designation to PCS-499 for the treatment of NL. On September 28, 2018, the FDA cleared our IND for PCS-499 in NL such that we could move forward with the Phase 2a safety-dose tolerability trial. We dosed our first NL patient in this Phase 2a clinical trial on January 29, 2019. As of May 1, 2019, we have enrolled nine patients in the trial with one of these patients discontinuing in the trial because of the inconvenience associated with a clinical trial. No adverse effects were noted in this patient. All eight of the other patients are receiving 1.8 gm of PCS-499 daily with no dose limiting side effects. One of these patients has been dosed for three months while two others will soon reach three months of treatment on PCS-499. As expected, we have not seen any significant change in the NL lesion in the one patient who has been treated for three months. Our expectation is that changes in the NL lesion will take at least six months to see any major effect. We anticipate all 12 patients planned for this trial will be enrolled on or before June 2019. In addition, we expect to request a meeting with the FDA before the end of 2019 to further discuss the development of PCS-499, including the next clinical trial.   We continue to evaluate other unmet need conditions for PCS-499, as well as other potential assets and are developing strategies, including the regulatory pathway and commercialization plans for product(s) for these unmet medical conditions. Going Concern and Management’s Plans   Our condensed consolidated financial statements have been prepared using U.S. GAAP and are based on the assumption that we will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. We face certain risks and uncertainties that are present in many emerging growth companies regarding product development and commercialization, limited working capital, recurring losses and negative cash flow from operations, future profitability, ability to obtain future capital, protection of patents, technologies and property rights, competition, rapid technological change, navigating the domestic and major foreign markets’ regulatory and clinical environment, recruiting and retaining key personnel, dependence on third party manufacturing organizations, third party collaboration and licensing agreements, lack of sales and marketing activities. We currently have no customers or pharmaceutical products to sell or distribute. These risks and other factors raise substantial doubt about our ability to continue as a going concern.   We have relied exclusively on private placements with a small group of accredited investors to finance our business and operations. We do not have any prospective arrangements or credit facilities as a source of future funds. We have not had any revenue since our inception. We are looking at ways to add a revenue stream to offset some of our expenses but do not currently have any revenue under contract or any immediate sales prospects. During the three months ended March 31, 2019, we had an accumulated deficit of $8.4 million, incurred a net loss for the three months of $750,832 and used $492,429 in net cash from operating activities from continuing operations. At March 31, 2019, we had cash and cash equivalents totaling $1.2 million and a Clinical Trial Funding commitment from an investor (PoC Capital) of $1.7 million. During the three months ended March 31, 2019, PoC Capital paid $115,000 of costs on our behalf related to our Phase 2a trial for NL directly to our CRO. Subsequent to March 31, 2019, PoC Capital has paid an additional $216,965 directly to our CRO.   Based on our current plan and our available resources (including the Clinical Trial Funding commitment from PoC Capital), we will need to raise additional capital before the end of the second quarter of 2019 in order to fund our future operations. While we believe our current resources are adequate to complete our current Phase 2a trial for NL, we do not currently have resources to conduct other future trials without raising additional capital. As noted above, the timing and extent of our spending will depend on the costs associated with, and the results of our Phase 2a trial for NL. Our anticipated spending and our cash flow needs could change significantly as the trial progresses. There may be costs we incur during our trial that we do not currently anticipate in order to complete the trial, requiring us to need additional capital sooner than currently expected.   Additional funding may not be available to us on acceptable terms, or at all. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or future clinical trials, or research and development programs. We may seek to raise any necessary additional capital through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. To the extent that we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.   Uncertainty concerning our ability to continue as a going concern may hinder our ability to obtain future financing. Continued operations and our ability to continue as a going concern are dependent on our ability to obtain additional funding in the future and thereafter, and no assurances can be given that such funding will be available at all, in a sufficient amount, or on reasonable terms. Without additional funds from debt or equity financing, sales of assets, sales or out-licenses of intellectual property or technologies, or other transactions providing funds, we will rapidly exhaust our resources and be unable to continue operations. Absent additional funding, we believe that our cash and cash equivalents will not be sufficient to fund our operations for a period of one year or more after the date that these consolidated financial statements are available to be issued based on the timing and amount of our projected net loss from continuing operations and cash to be used in operating activities during that period of time.    As a result, substantial doubt exists about our ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are available to be issued. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be different should we be unable to continue as a going concern based on the outcome of these uncertainties described above. The weighted average remaining lease terms and discount rate for our operating leases were as follows at March 31, 2019:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 87%; line-height: 107%">Weighted average remaining lease term (years) for our facility and equipment leases</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">3.35</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Weighted average discount rate for our facility and equipment leases</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">8.00</td> <td style="line-height: 107%">%</td></tr> </table>

Maturities of our lease liabilities for all operating leases were as follows as of March 31, 2019:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%; line-height: 107%">2019</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 18%; text-align: right; line-height: 107%">73,508</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">2020</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">92,603</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">2021</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">90,495</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">2022</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">69,741</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Total lease payments</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">326,347</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 20pt; line-height: 107%">Less: Interest</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(42,462</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Present value of lease liabilities</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">283,885</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Less: current maturities</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(58,504</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Non-current lease liability</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">225,381</td> <td style="line-height: 107%"> </td></tr> </table>

283885

303161

1782

3037147

11038929

1782

9000

24563

27981

P3Y4M6D

0.0800

73508

92603

90495

69741

326347

-42462 0.08

Note 4 - Stock-based Compensation   We did not grant any stock options to employees or non-employees during the three months ended March 31, 2019 or 2018. At March 31, 2019, we had outstanding options to purchase 384,400 shares of our common stock of which options for the purchase of 9,000 shares of our common stock were vested. We recorded $58,559 of stock-based compensation expense for the three months ended March 31, 2019 as general and administrative expense. No expense was recorded during the three months ended March 31, 2018 since we had not stock options outstanding at March 31, 2018.

17947

If the Alberta Securities Commission does not allow us to convert this debt into common stock units, we will be required to repay the principal and related accrued interest of approximately $255,000.

EX-101.SCH 6 pcsa-20190331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Organization and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Senior Convertible Notes link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Net Loss Per Share of Common Stock link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Operating Leases link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Net Loss Per Share of Common Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Operating Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Intangible Assets - Summary of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Stock-based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Senior Convertible Notes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Net Loss Per Share of Common Stock - Schedule of Earnings Per Share Basic and Diluted (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Net Loss Per Share of Common Stock - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Operating Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Operating Leases - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Our Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Operating Leases - Schedule of Maturities of Lease Liabilities for All Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 pcsa-20190331_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 pcsa-20190331_def.xml XBRL DEFINITION FILE EX-101.LAB 9 pcsa-20190331_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-In Capital [Member] Accumulated Deficit [Member] Preferred Stock [Member] Related Party [Axis] Corlyst [Member] Debt Instrument [Axis] Senior Convertible Notes [Member] Subscription Receivable [Member] Stock Option and Purchase Warrants [Member] Legal Entity [Axis] Contract Research Organization [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Ex Transition Period Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Assets Cash and cash equivalents Due from related party Prepaid expenses and other Total Current Assets Property and equipment, net Operating lease right-of-use assets, net Intangible assets, net Security deposit Total Assets LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Senior convertible notes Current maturities of operating lease liability Accrued interest Accounts payable Accrued expenses Total Current Liabilities Non-current Liabilities Noncurrent operating lease liability Net deferred tax liability Total Liabilities Commitments and Contingencies Stockholders' Equity Preferred stock, par value $0.0001, 10,000,000 shares authorized; no shares issued and outstanding Common stock, par value $0.0001, 350,000,000 shares authorized; 38,674,265 issued and outstanding at both March 31, 2019 and December 31, 2018 Additional paid-in capital Stock subscription receivable Accumulated deficit Total Stockholders' Equity Total Liabilities and Stockholders' Equity Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Operating Expenses: Research and development General and administrative Operating Loss Other Income (Expense): Interest expense Interest income Net Operating Loss Before Income Tax Benefit Income Tax Benefit Net Loss Net Loss Per Common Share - Basic and Diluted Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Basic and Diluted Statement [Table] Statement [Line Items] Balance Balance, shares Recognize the fair value of the license acquired from CoNCERT in exchange for 2,090,301 common shares of Processa held by Promet Stock-based compensation Payments made directly by investor for clinical trial costs Net loss Balance Balance, shares Statement of Stockholders' Equity [Abstract] Common stock, shares exchanged Statement of Cash Flows [Abstract] Cash Flows From Operating Activities Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Amortization of right-of-use assets Amortization of debt issuance costs Amortization of intangible asset Deferred income tax benefit Stock-based compensation Payments made directly to our Contract Research Organization by an investor in partial satisfaction of their stock subscription receivable Net changes in operating assets and liabilities: Prepaid expenses Current portion of operating lease liability Accrued interest Accounts payable Due (from) to related parties Accrued expenses Net cash used in operating activities Cash Flows From Investing Activities Purchase of intangible asset Net cash provided by (used in) investing activities Net Decrease in Cash Cash and Cash Equivalents - Beginning of Period Cash and Cash Equivalents - End of Period Non-Cash Investing and Financing Activities: Right-of-use asset obtained in exchange for operating lease liability Reduction in deferred lease liability Operating lease liability Recognize the exclusive license intangible asset acquired from CoNCERT Recognize deferred tax liability for basis difference of Intangible asset Recognize additional paid-in-capital for consideration paid from the transfer of 2,090,301 common shares of Processa released by Promet to CoNCERT for Processa Net Common stock, shares transferred Accounting Policies [Abstract] Organization and Summary of Significant Accounting Policies Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Income Tax Disclosure [Abstract] Income Taxes Share-based Payment Arrangement [Abstract] Stock-based Compensation Debt Disclosure [Abstract] Senior Convertible Notes Earnings Per Share [Abstract] Net Loss Per Share of Common Stock Leases [Abstract] Operating Leases Related Party Transactions [Abstract] Related Party Transactions Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Business Activities and Organization Basis of Presentation Going Concern and Management's Plan Use of Estimates Intangible Assets Impairment of Long-lived Assets and Intangibles Other Than Goodwill Stock-based Compensation Net Loss Per Share Research and Development Recently Adopted Accounting Pronouncements Summary of Intangible Assets Schedule of Earnings Per Share Basic and Diluted Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Our Operating Leases Schedule of Maturities of Lease Liabilities for All Operating Leases Net income loss Net cash used in operating activities Clinical Trial Funding commitment from investor capital Impairment of Long-Lived Assets Right-of-use asset Lease obligations Amortization expense Weighted average amortization period for intangible asset Future amortization expense, year two Future amortization expense,thereafter Purchase price Transaction costs Capitalized cost Business combination of tax basis Gross intangible assets Less: accumulated amortization Total intangible assets, net Deferred tax liability Deferred tax liability, financial reporting basis Deferred tax liability, tax basis Number of option purchase during period Number of option purchase during period for vested Stock-based compensation expense Senior notes outstanding Contingent payment of principal and related accrued interest description Weighted-average number of common shares-basic and diluted Basic and diluted net loss per share Antidilutive securities excluded from computation of earnings per share Operating leases incremental borrowing rate Lease costs Weighted average remaining lease term (years) for our facility and equipment leases Weighted average discount rate for our facility and equipment leases 2019 2020 2021 2022 Total lease payments Less: Interest EX-101.PRE 10 pcsa-20190331_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2019	Apr. 30, 2019
Document And Entity Information
Entity Registrant Name	Processa Pharmaceuticals, Inc.
Entity Central Index Key	0001533743
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		38,674,265
Trading Symbol	PCSA
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2019

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Current Assets
Cash and cash equivalents	$ 1,248,532	$ 1,740,961
Due from related party	47,165	21,583
Prepaid expenses and other	247,200	257,832
Total Current Assets	1,542,897	2,020,376
Property and equipment, net	15,264	17,375
Operating lease right-of-use assets, net	275,251
Intangible assets, net	10,238,950	10,437,782
Security deposit	5,535	5,535
Total Assets	12,077,897	12,481,068
Current Liabilities
Senior convertible notes	230,000	230,000
Current maturities of operating lease liability	58,504
Accrued interest	24,943	20,343
Accounts payable	283,057	292,102
Accrued expenses	128,220	103,259
Total Current Liabilities	724,724	645,704
Non-current Liabilities
Noncurrent operating lease liability	225,381
Net deferred tax liability	2,004,047	2,134,346
Total Liabilities	2,954,152	2,780,050
Commitments and Contingencies
Stockholders' Equity
Preferred stock, par value $0.0001, 10,000,000 shares authorized; no shares issued and outstanding
Common stock, par value $0.0001, 350,000,000 shares authorized; 38,674,265 issued and outstanding at both March 31, 2019 and December 31, 2018	3,867	3,867
Additional paid-in capital	19,179,844	19,121,285
Stock subscription receivable	(1,685,000)	(1,800,000)
Accumulated deficit	(8,374,966)	(7,624,134)
Total Stockholders' Equity	9,123,745	9,701,018
Total Liabilities and Stockholders' Equity	$ 12,077,897	$ 12,481,068

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	350,000,000	350,000,000
Common stock, shares issued	38,674,265	38,674,265
Common stock, shares outstanding	38,674,265	38,674,265

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Operating Expenses:
Research and development	$ 484,750	$ 821,388
General and administrative	397,766	470,228
Operating Loss	(882,516)	(1,291,616)
Other Income (Expense):
Interest expense	(4,600)	(87,740)
Interest income	5,985	1,024
Net Operating Loss Before Income Tax Benefit	(881,131)	(1,378,332)
Income Tax Benefit	130,299	281,534
Net Loss	$ (750,832)	$ (1,096,798)
Net Loss Per Common Share - Basic and Diluted	$ (0.02)	$ (0.03)
Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Basic and Diluted	38,674,265	35,272,626

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Subscription Receivable [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2017	$ 3,527	$ 4,228,723		$ (3,859,086)	$ 373,164
Balance, shares at Dec. 31, 2017	35,272,626
Recognize the fair value of the license acquired from CoNCERT in exchange for 2,090,301 common shares of Processa held by Promet		8,000,000			8,000,000
Net loss				(1,096,798)	(1,096,798)
Balance at Mar. 31, 2018	$ 3,527	12,228,723		(4,955,884)	7,276,366
Balance, shares at Mar. 31, 2018	35,272,626
Balance at Dec. 31, 2018	$ 3,867	19,121,285	$ (1,800,000)	(7,624,134)	9,701,018
Balance, shares at Dec. 31, 2018	38,674,265
Stock-based compensation		58,559			58,559
Payments made directly by investor for clinical trial costs			115,000		115,000
Net loss				(750,832)	(750,832)
Balance at Mar. 31, 2019	$ 3,867	$ 19,179,844	$ (1,685,000)	$ (8,374,966)	$ 9,123,745
Balance, shares at Mar. 31, 2019	38,674,265

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) (Parenthetical)	3 Months Ended
	Mar. 31, 2018 shares
Statement of Stockholders' Equity [Abstract]
Common stock, shares exchanged	2,090,301

XML 17 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash Flows From Operating Activities
Net loss	$ (750,832)	$ (1,096,798)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	2,111	2,112
Amortization of right-of-use assets	17,947
Amortization of debt issuance costs		36,140
Amortization of intangible asset	198,832	25,435
Deferred income tax benefit	(130,299)	(281,534)
Stock-based compensation	58,559
Payments made directly to our Contract Research Organization by an investor in partial satisfaction of their stock subscription receivable	115,000
Net changes in operating assets and liabilities:
Prepaid expenses	10,632	1,257
Current portion of operating lease liability	(19,276)
Accrued interest	4,600	51,600
Accounts payable	(9,045)	54,194
Due (from) to related parties	(25,582)	36,025
Accrued expenses	34,924	102,561
Net cash used in operating activities	(492,429)	(1,069,008)
Cash Flows From Investing Activities
Purchase of intangible asset		(1,782)
Net cash provided by (used in) investing activities		(1,782)
Net Decrease in Cash	(492,429)	(1,070,790)
Cash and Cash Equivalents - Beginning of Period	1,740,961	2,847,429
Cash and Cash Equivalents - End of Period	1,248,532	1,776,639
Non-Cash Investing and Financing Activities:
Right-of-use asset obtained in exchange for operating lease liability	(293,198)
Reduction in deferred lease liability	(9,963)
Operating lease liability	303,161
Recognize the exclusive license intangible asset acquired from CoNCERT		(11,037,147)
Recognize deferred tax liability for basis difference of Intangible asset		3,037,147
Recognize additional paid-in-capital for consideration paid from the transfer of 2,090,301 common shares of Processa released by Promet to CoNCERT for Processa		8,000,000
Net

XML 18 R8.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)	3 Months Ended
	Mar. 31, 2018 shares
Statement of Cash Flows [Abstract]
Common stock, shares transferred	2,090,301

XML 19 R9.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Organization and Summary of Significant Accounting Policies

Note 1 – Organization and Summary of Significant Accounting Policies

Business Activities and Organization

Basis of Presentation

Certain amounts have been reclassified in our March 31, 2018 statement of operations to confirm to the current year presentation.

Going Concern and Management’s Plans

Use of Estimates

Intangible Assets

Impairment of Long-Lived Assets and Intangibles Other Than Goodwill

Stock-based Compensation

Net Loss Per Share

Research and Development

Research and development costs are expensed as incurred and consisted of direct and overhead-related expenses.

Recently Adopted Accounting Pronouncements

XML 20 R10.htm IDEA: XBRL DOCUMENT

Intangible Assets

3 Months Ended

Mar. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Note 2 – Intangible Assets

Intangible assets at March 31, 2019 and December 31, 2018 consisted of the following:

	March 31, 2019			December 31, 2018
Gross intangible assets	$	11,059,429		$	11,059,429
Less: accumulated amortization		(820,479	)		(621,647	)
Total intangible assets, net	$	10,238,950		$	10,437,782

XML 21 R11.htm IDEA: XBRL DOCUMENT

Income Taxes

3 Months Ended

Mar. 31, 2019

Income Tax Disclosure [Abstract]

Income Taxes

Note 3 – Income Taxes

XML 22 R12.htm IDEA: XBRL DOCUMENT

Stock-based Compensation

3 Months Ended

Mar. 31, 2019

Share-based Payment Arrangement [Abstract]

Stock-based Compensation

Note 4 - Stock-based Compensation

XML 23 R13.htm IDEA: XBRL DOCUMENT

Senior Convertible Notes

3 Months Ended

Mar. 31, 2019

Debt Disclosure [Abstract]

Senior Convertible Notes

Note 5 – Senior Convertible Notes

XML 24 R14.htm IDEA: XBRL DOCUMENT

Net Loss Per Share of Common Stock

3 Months Ended

Mar. 31, 2019

Earnings Per Share [Abstract]

Net Loss Per Share of Common Stock

Note 6 – Net Loss per Share of Common Stock

The computation of net loss per share for the three months ended March 31, 2019 and 2018 was as follows:

	For the three months ended March 31,
	2019			2018
Basic and diluted net loss per share:
Net loss	$	(750,832	)	$	(1,096,798	)
Weighted-average number of common shares-basic and diluted		38,674,265			35,272,626

Basic and diluted net loss per share	$	(0.02	)	$	(0.03	)

The following potentially dilutive securities were excluded from the computation of diluted net income per share as their effect would have been anti-dilutive for the periods presented.

	2019		2018
Stock options and purchase warrants		3,917,763		-
Senior convertible notes		124,789		1,305,577

XML 25 R15.htm IDEA: XBRL DOCUMENT

Operating Leases

3 Months Ended

Mar. 31, 2019

Leases [Abstract]

Operating Leases

Note 7 - Operating Leases

Weighted average remaining lease term (years) for our facility and equipment leases			3.35
Weighted average discount rate for our facility and equipment leases			8.00	%

Maturities of our lease liabilities for all operating leases were as follows as of March 31, 2019:

2019	$	73,508
2020		92,603
2021		90,495
2022		69,741
Total lease payments		326,347
Less: Interest		(42,462	)
Present value of lease liabilities		283,885
Less: current maturities		(58,504	)
Non-current lease liability	$	225,381

XML 26 R16.htm IDEA: XBRL DOCUMENT

Related Party Transactions

3 Months Ended

Mar. 31, 2019

Related Party Transactions

Note 8 – Related Party Transactions

XML 27 R17.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Mar. 31, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 9 – Commitments and Contingencies

Purchase Obligations

XML 28 R18.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Business Activities and Organization	Business Activities and Organization Processa Pharmaceuticals, Inc. is an emerging clinical stage biopharmaceutical company focused on the development of drug products that are intended to provide treatment for and improve the survival and/or quality of life of patients who have a high unmet medical need condition or who have no alternative treatment. Within this group of pharmaceutical products, we currently are developing one product for multiple indications (i.e., the use of a drug to treat a particular disease) and searching for additional products for our portfolio. Our lead product, PCS-499 is an oral tablet that is an analog of an active metabolite of an already approved FDA drug. The advantage of PCS-499 is that it potentially may work in many conditions because it has multiple pharmacological targets it affects that are important in the treatment of these conditions. Based on its pharmacological activity, we have identified multiple unmet medical need conditions where the use of PCS-499 may result in clinical efficacy. The lead indication currently under development for PCS-499 is Necrobiosis Lipoidica (NL). On June 22, 2018, the FDA granted orphan-drug designation to PCS-499 for the treatment of NL. On September 28, 2018, the FDA cleared our IND for PCS-499 in NL such that we could move forward with the Phase 2a safety-dose tolerability trial. We dosed our first NL patient in this Phase 2a clinical trial on January 29, 2019. As of May 1, 2019, we have enrolled nine patients in the trial with one of these patients discontinuing in the trial because of the inconvenience associated with a clinical trial. No adverse effects were noted in this patient. All eight of the other patients are receiving 1.8 gm of PCS-499 daily with no dose limiting side effects. One of these patients has been dosed for three months while two others will soon reach three months of treatment on PCS-499. As expected, we have not seen any significant change in the NL lesion in the one patient who has been treated for three months. Our expectation is that changes in the NL lesion will take at least six months to see any major effect. We anticipate all 12 patients planned for this trial will be enrolled on or before June 2019. In addition, we expect to request a meeting with the FDA before the end of 2019 to further discuss the development of PCS-499, including the next clinical trial. We continue to evaluate other unmet need conditions for PCS-499, as well as other potential assets and are developing strategies, including the regulatory pathway and commercialization plans for product(s) for these unmet medical conditions.
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions of the Securities and Exchange Commission (“SEC”) on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the Company’s financial position and of the results of operations and cash flows for the periods presented. These consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the SEC (as amended). The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year. Certain amounts have been reclassified in our March 31, 2018 statement of operations to confirm to the current year presentation.
Going Concern and Management's Plan	Going Concern and Management’s Plans Our condensed consolidated financial statements have been prepared using U.S. GAAP and are based on the assumption that we will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. We face certain risks and uncertainties that are present in many emerging growth companies regarding product development and commercialization, limited working capital, recurring losses and negative cash flow from operations, future profitability, ability to obtain future capital, protection of patents, technologies and property rights, competition, rapid technological change, navigating the domestic and major foreign markets’ regulatory and clinical environment, recruiting and retaining key personnel, dependence on third party manufacturing organizations, third party collaboration and licensing agreements, lack of sales and marketing activities. We currently have no customers or pharmaceutical products to sell or distribute. These risks and other factors raise substantial doubt about our ability to continue as a going concern. We have relied exclusively on private placements with a small group of accredited investors to finance our business and operations. We do not have any prospective arrangements or credit facilities as a source of future funds. We have not had any revenue since our inception. We are looking at ways to add a revenue stream to offset some of our expenses but do not currently have any revenue under contract or any immediate sales prospects. During the three months ended March 31, 2019, we had an accumulated deficit of $8.4 million, incurred a net loss for the three months of $750,832 and used $492,429 in net cash from operating activities from continuing operations. At March 31, 2019, we had cash and cash equivalents totaling $1.2 million and a Clinical Trial Funding commitment from an investor (PoC Capital) of $1.7 million. During the three months ended March 31, 2019, PoC Capital paid $115,000 of costs on our behalf related to our Phase 2a trial for NL directly to our CRO. Subsequent to March 31, 2019, PoC Capital has paid an additional $216,965 directly to our CRO. Based on our current plan and our available resources (including the Clinical Trial Funding commitment from PoC Capital), we will need to raise additional capital before the end of the second quarter of 2019 in order to fund our future operations. While we believe our current resources are adequate to complete our current Phase 2a trial for NL, we do not currently have resources to conduct other future trials without raising additional capital. As noted above, the timing and extent of our spending will depend on the costs associated with, and the results of our Phase 2a trial for NL. Our anticipated spending and our cash flow needs could change significantly as the trial progresses. There may be costs we incur during our trial that we do not currently anticipate in order to complete the trial, requiring us to need additional capital sooner than currently expected. Additional funding may not be available to us on acceptable terms, or at all. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or future clinical trials, or research and development programs. We may seek to raise any necessary additional capital through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. To the extent that we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Uncertainty concerning our ability to continue as a going concern may hinder our ability to obtain future financing. Continued operations and our ability to continue as a going concern are dependent on our ability to obtain additional funding in the future and thereafter, and no assurances can be given that such funding will be available at all, in a sufficient amount, or on reasonable terms. Without additional funds from debt or equity financing, sales of assets, sales or out-licenses of intellectual property or technologies, or other transactions providing funds, we will rapidly exhaust our resources and be unable to continue operations. Absent additional funding, we believe that our cash and cash equivalents will not be sufficient to fund our operations for a period of one year or more after the date that these consolidated financial statements are available to be issued based on the timing and amount of our projected net loss from continuing operations and cash to be used in operating activities during that period of time. As a result, substantial doubt exists about our ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are available to be issued. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be different should we be unable to continue as a going concern based on the outcome of these uncertainties described above.
Use of Estimates	Use of Estimates In preparing our condensed consolidated financial statements and related disclosures in conformity with GAAP and pursuant to the rules and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the consolidated financial statements and accompanying notes. Estimates are used for, but not limited to: stock-based compensation, determining the fair value of acquired assets and assumed liabilities, intangible assets, and income taxes. These estimates and assumptions are continuously evaluated and are based on management’s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable, actual results could differ materially from those estimates and could impact future results of operations and cash flows.
Intangible Assets	Intangible Assets Intangible assets acquired individually or with a group of other assets from others (other than in a business combination) are recognized at cost, including transaction costs, and allocated to the individual assets acquired based on relative fair values and no goodwill is recognized. Cost is measured based on cash consideration paid. If consideration given is in the form of non-cash assets, liabilities incurred, or equity interests issued, measurement of cost is based on either the fair value of the consideration given or the fair value of the assets (or net assets) acquired, whichever is more clearly evident and more reliably measurable. Costs of internally developing, maintaining or restoring intangible assets that are not specifically identifiable, have indeterminate lives or are inherent in a continuing business are expensed as incurred. Intangible assets purchased from others for use in research and development activities and that have alternative future uses (in research and development projects or otherwise) are capitalized in accordance with ASC Topic 350, Intangibles – Goodwill and Other. Those that have no alternative future uses (in research and development projects or otherwise) and therefore no separate economic value are considered research and development costs and are expensed as incurred. Amortization of intangibles used in research and development activities is a research and development cost. Intangibles with a finite useful life are amortized using the straight-line method unless the pattern in which the economic benefits of the intangible assets are consumed or used up are reliably determinable. The useful life is the best estimate of the period over which the asset is expected to contribute directly or indirectly to our future cash flows. The useful life is based on the duration of the expected use of the asset by us and the legal, regulatory or contractual provisions that constrain the useful life and future cash flows of the asset, including regulatory acceptance and approval, obsolescence, demand, competition and other economic factors. We evaluate the remaining useful life of intangible assets each reporting period to determine whether any revision to the remaining useful life is required. If the remaining useful life is changed, the remaining carrying amount of the intangible asset will be amortized prospectively over the revised remaining useful life. If an income approach is used to measure the fair value of an intangible asset, we consider the period of expected cash flows used to measure the fair value of the intangible asset, adjusted as appropriate for company-specific factors discussed above, to determine the useful life for amortization purposes. If no regulatory, contractual, competitive, economic or other factors limit the useful life of the intangible to us, the useful life is considered indefinite. Intangibles with an indefinite useful life are not amortized until its useful life is determined to be no longer indefinite. If the useful life is determined to be finite, the intangible is tested for impairment and the carrying amount is amortized over the remaining useful life in accordance with intangibles subject to amortization. Indefinite-lived intangibles are tested for impairment annually and more frequently if events or circumstances indicate that it is more-likely-than-not that the asset is impaired.
Impairment of Long-lived Assets and Intangibles Other Than Goodwill	Impairment of Long-Lived Assets and Intangibles Other Than Goodwill We account for the impairment of long-lived assets in accordance with ASC 360, Property, Plant and Equipment and ASC 350, Intangibles – Goodwill and Other, which require that long-lived assets and certain identifiable intangibles be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to its expected future undiscounted net cash flows generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amounts of the assets exceed the fair value of the assets based on the present value of the expected future cash flows associated with the use of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. Based on management’s evaluation, there was no impairment loss recorded during the three months ended March 31, 2019.
Stock-based Compensation	Stock-based Compensation Stock-based compensation expense is based on the grant-date fair value estimated in accordance with the provisions of ASC 718, Compensation-Stock Compensation. We expense stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. We estimate the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. Stock-based compensation costs are recorded as general and administrative or research and development costs in the statements of operations based upon the underlying individual’s role.
Net Loss Per Share	Net Loss Per Share Basic loss per share is computed by dividing our net loss available to common shareholders by the weighted average number of shares of common stock outstanding during the year. Diluted loss per share is computed by dividing our net loss available to common shareholders by the diluted weighted average number of shares of common stock during the period. Since we experienced a net loss for both periods presented, basic and diluted net loss per share are the same. As such, diluted loss per share for the three months ended March 31, 2019 and 2018 excludes the impact of potentially dilutive common shares related to the conversion of our Senior Notes and outstanding stock options and warrants since those shares would have an anti-dilutive effect on loss per share.
Research and Development	Research and Development Research and development costs are expensed as incurred and consisted of direct and overhead-related expenses.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements On January 1, 2019, we adopted Accounting Standards Codification (ASC) 842, Leases. ASC 842 was issued to increase transparency and comparability among entities by recognizing right-of-use assets and lease liabilities on the balance sheet and disclosing key information about our lease agreements. We elected practical expedients upon transition that allows us to not reassess the lease classification of our leases, whether initial direct costs qualify for capitalization for our leases or whether any expired contracts are or contain leases. Additionally, we elected the optional transition method that allows for a cumulative effect adjustment in the period of adoption and we did not restate prior periods. The adoption of the new guidance on leasing resulted in the recognition of a right-of-use asset of $293,198 and lease obligations of $303,161. The difference between the right-of-use asset and the lease obligations is due to deferred rent liability related to our facility operating lease at December 31, 2018. The adoption of the new guidance did not have a material impact on the condensed consolidated statement of operations. For further details regarding the adoption of this standard, see Note 7, “Operating Leases.”

XML 29 R19.htm IDEA: XBRL DOCUMENT

Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of Intangible Assets

Intangible assets at March 31, 2019 and December 31, 2018 consisted of the following:

	March 31, 2019			December 31, 2018
Gross intangible assets	$	11,059,429		$	11,059,429
Less: accumulated amortization		(820,479	)		(621,647	)
Total intangible assets, net	$	10,238,950		$	10,437,782

XML 30 R20.htm IDEA: XBRL DOCUMENT

Net Loss Per Share of Common Stock (Tables)

3 Months Ended

Mar. 31, 2019

Earnings Per Share [Abstract]

Schedule of Earnings Per Share Basic and Diluted

The computation of net loss per share for the three months ended March 31, 2019 and 2018 was as follows:

	For the three months ended March 31,
	2019			2018
Basic and diluted net loss per share:
Net loss	$	(750,832	)	$	(1,096,798	)
Weighted-average number of common shares-basic and diluted		38,674,265			35,272,626

Basic and diluted net loss per share	$	(0.02	)	$	(0.03	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following potentially dilutive securities were excluded from the computation of diluted net income per share as their effect would have been anti-dilutive for the periods presented.

	2019		2018
Stock options and purchase warrants		3,917,763		-
Senior convertible notes		124,789		1,305,577

XML 31 R21.htm IDEA: XBRL DOCUMENT

Operating Leases (Tables)

3 Months Ended

Mar. 31, 2019

Leases [Abstract]

Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Our Operating Leases

The weighted average remaining lease terms and discount rate for our operating leases were as follows at March 31, 2019:

Weighted average remaining lease term (years) for our facility and equipment leases			3.35
Weighted average discount rate for our facility and equipment leases			8.00	%

Schedule of Maturities of Lease Liabilities for All Operating Leases

Maturities of our lease liabilities for all operating leases were as follows as of March 31, 2019:

2019	$	73,508
2020		92,603
2021		90,495
2022		69,741
Total lease payments		326,347
Less: Interest		(42,462	)
Present value of lease liabilities		283,885
Less: current maturities		(58,504	)
Non-current lease liability	$	225,381

XML 32 R22.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Jan. 02, 2019	Dec. 31, 2018	Dec. 31, 2017
Accumulated deficit	$ (8,374,966)			$ (7,624,134)
Net income loss	(750,832)	$ (1,096,798)
Net cash used in operating activities	(492,429)	(1,069,008)
Cash and cash equivalents	1,248,532	$ 1,776,639		1,740,961	$ 2,847,429
Clinical Trial Funding commitment from investor capital	1,700,000
Payments made directly by investor for clinical trial costs	115,000
Impairment of Long-Lived Assets
Right-of-use asset	275,251		$ 293,198
Lease obligations	283,885		$ 303,161
Contract Research Organization [Member]
Payments made directly by investor for clinical trial costs	$ 216,965

XML 33 R23.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended
Intangible Assets (Details Narrative) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 198,832	$ 25,435
Weighted average amortization period for intangible asset	2 years
Future amortization expense, year two	$ 795,000
Future amortization expense,thereafter	788,000
Purchase price	8,000,000
Transaction costs	1,782
Capitalized cost	3,037,147
Business combination of tax basis	$ 1,782

XML 34 R24.htm IDEA: XBRL DOCUMENT

Intangible Assets - Summary of Intangible Assets (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Gross intangible assets	$ 11,059,429	$ 11,059,429
Less: accumulated amortization	(820,479)	(621,647)
Total intangible assets, net	$ 10,238,950	$ 10,437,782

XML 35 R25.htm IDEA: XBRL DOCUMENT

Income Taxes (Details Narrative)	Mar. 31, 2019 USD ($)
Income Tax Disclosure [Abstract]
Deferred tax liability	$ 3,037,147
Deferred tax liability, financial reporting basis	11,038,929
Deferred tax liability, tax basis	$ 1,782

XML 36 R26.htm IDEA: XBRL DOCUMENT

Stock-based Compensation (Details Narrative) - USD ($)	3 Months Ended
Stock-based Compensation (Details Narrative) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Share-based Payment Arrangement [Abstract]
Number of option purchase during period	384,400
Number of option purchase during period for vested	9,000
Stock-based compensation expense	$ 58,559

XML 37 R27.htm IDEA: XBRL DOCUMENT

Senior Convertible Notes (Details Narrative) - USD ($)	3 Months Ended
Senior Convertible Notes (Details Narrative) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Debt Disclosure [Abstract]
Senior notes outstanding	$ 230,000	$ 230,000
Contingent payment of principal and related accrued interest description	If the Alberta Securities Commission does not allow us to convert this debt into common stock units, we will be required to repay the principal and related accrued interest of approximately $255,000.

XML 38 R28.htm IDEA: XBRL DOCUMENT

Net Loss Per Share of Common Stock - Schedule of Earnings Per Share Basic and Diluted (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Earnings Per Share [Abstract]
Net loss	$ (750,832)	$ (1,096,798)
Weighted-average number of common shares-basic and diluted	38,674,265	35,272,626
Basic and diluted net loss per share	$ (0.02)	$ (0.03)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 39 R29.htm IDEA: XBRL DOCUMENT

Net Loss Per Share of Common Stock - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Stock Option and Purchase Warrants [Member]
Antidilutive securities excluded from computation of earnings per share	3,917,763
Senior Convertible Notes [Member]
Antidilutive securities excluded from computation of earnings per share	124,789	1,305,577

XML 40 R30.htm IDEA: XBRL DOCUMENT

Operating Leases (Details Narrative) - USD ($)	3 Months Ended
Operating Leases (Details Narrative) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Leases [Abstract]
Operating leases incremental borrowing rate	8.00%
Lease costs	$ 24,563	$ 27,981

XML 41 R31.htm IDEA: XBRL DOCUMENT

Operating Leases - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Our Operating Leases (Details)	Mar. 31, 2019
Leases [Abstract]
Weighted average remaining lease term (years) for our facility and equipment leases	3 years 4 months 6 days
Weighted average discount rate for our facility and equipment leases	8.00%

XML 42 R32.htm IDEA: XBRL DOCUMENT

Operating Leases - Schedule of Maturities of Lease Liabilities for All Operating Leases (Details) - USD ($)	Mar. 31, 2019	Jan. 02, 2019
Leases [Abstract]
2019	$ 73,508
2020	92,603
2021	90,495
2022	69,741
Total lease payments	326,347
Less: Interest	(42,462)
Present value of lease liabilities	283,885	$ 303,161
Less: current maturities	(58,504)
Non-current lease liability	$ 225,381

XML 43 R33.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Amount due from related parties	$ 47,165	$ 21,583
Corlyst [Member]
Amount due from related parties	$ 47,165	$ 21,583

XML 44 R34.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative)	Mar. 31, 2019 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Purchase obligations	$ 23,000

EXCEL 45 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

<)@$^ M>!+PD248T]9X+#*B?U;X3^YQ" M=00U/[ 9C-M$S1IX.AXG/UQIMY$"=$#+@/77(IN$4"V)$*E^6C9 Y_I$%/[XL%[DM-G06+W(& X^?J63 MN#I+8R=QYC*PV0*JY&KG#FS*VHGU'I :IA48XHVJ'KNO5SS+0,V>X+/ Q$=2 M?<\Q6)MYSEV&3;R[AZ3DL@VJTH\AF80& 4:GK.&VO0[7$C#^_%"2U%2/:78J"VXI'5_$K$"T,=F%<879JA M6EJVR*C.@>^88KE,)QHCOJP<.3])*+)68FLG>V6FE V52+!QI+S7#5OKS:.B M(%O/.7A]5.^""9;AO%PQDAV0JP H.NX'Q#2=:3AR5JCBT', 'RU]%40!=5G M(F8=L/B9B6BEP.>>A2-8CW:V;])W^% <+);8!/2ZH/RPJ1F$.QL9M1&8:@&I MN?5R/?YUMXF=''[_62](?W#>-$?]LMSCJ-#G)X]\88_ 4JT-E1APR$KO;-L] M,L5?P\Y )"%!--MYFD5R0UIS33Y=E/F^R=&B8CVQ#2HRI:7C8/BO*85V:2C:TCI/"%AV1Q=-B#WSR8V$G$=U@IZ!Q MB*X^3#S%YH5B_7L?4T=&AG>$QD7G:2/@P,HZAWN=$TCLGJZF^%4NY[ /B=(J(PF(8L0_M(=HC6X4#VTJD2'>H I;JD2+I914P@68KW4/$'DSJJ5L M/*WV:F;$5\3DEFFD %H]Y8ILO!\ML#SV22P DJ1Y#$^]26[ MFP\'IU_J*!X9O)C2M#&U/R*I?!WG]'##?\]<@/[&*":'Y#ZX=W-^*5;4F8C/ M/;(X*H"F;O+8!6(/06 X?O84MZ;,J:-^L_TH[K'A"5B.D[BP%4% M>@\>A!IL.+$O9#U0H3W&0GCW&@E+3%._\+=J A50G7HI1PKI-1:]%;\(E3PB M\;J*T;G&\J1D0S/1_EZ@#0>T&^QZ90.[V]ZQ3ZT>V2EDUJZQ"WK[,S;IBX-! M*=BR'IQI8[4X?ET$IZ?7JBC@!LR]D1F48(=8/_,Z'5VS'^AB M8[3F(S#8P>3JTA0W!@?3,YAQ]A7"C&H5K(LB<6+['B8VB9_!N(> %(AKNDO& MIFST>_#IGYXH6ET?]1W=G)">WN&;3-2":%.+ZX6.QQ=: &3'P<45ES"B@..\ M568>9- ;%*-B7 ZYL\+E96,%#@KX(1V6?P8N2=@&KG;$/3H6E.*P@TM;_FDB M6%B<@1[WP80N'A'JPK1&R@+X!R?A,1#'!*BJ_127+?<$=5 @\5;[Q"&34F 2 M!P.M25KJR09[\?%$7J" ]5J6,!K%T'5A.'GU3]*Q/T)-IUA2VHIZ+)G7@^[@ M??;JQ>GQ:'(\FIZ-SB9>8T00UD,J:[A78KEHWN9UV: MAPM:\3\X8MA8"JR7H:M"$6!RCOC,F-E[NRA;(WC= 19PTXL>29"+,'@K,6>X(:Z/ JU+ MCR")"D[@'C\Y"F?&&OB2GS67CBK+Q%/-@7\, S\!RS :4ALM4"J:T[1RY5SF MOIG2?N8Q-W8NG:%;5OH M,SA5HV'7[!5/FJ/WF%IQ'\3/*"_'V4B7&\KF M?4LW,#8NMGTQXO'D\C0\=>V>Q6!N.DH+B0:;^?9-I-?DZ\IO&MVW"O8J"!XH M?D#Q3)O:/SB[#,_.KLC=V>;8/D,3VW?*JMNO-I#UJ*F"K_XM4,^XADMQ$P3A ME,=IN!2M!MDT.3"3.S^2(;[*C=?]_7U?]_=76/NTNU0]LU*UNT' CE&'B%3; M+@S8MI&3'DQ/CLU3AB&H&XE^;^-T*)"N MTQF66/@/OKTWWFN,NXDTLST,^RBQSG#8H9BWTO1M ^526Q_\5V )WGB(1Z+4 MX2-[*/'R;8!P,]1QKDL.3*)MS67CYO"*?!%NRICQFX+6*5S!&27MC6&!(=MU M]"1!''JX;Q]5BVG=:OY/QDS31IN>D977(=">\ YV!_.Z_+9GO(ZH@M*?,4BM M_3_40"1\;DG8@K V"P8M$"3BU!/'\$(X@1_"L4.' DJM=FZ.KEVT:/-VJK5= M\'7;F>>W8OF6_1$2$XM8-(51:$F7/)QRX*/DSD7%&ATD!5\1CT-] MB#T!R.DO7P9O=E@BH"4H . :D _?W7AQ=0E. MONF+/NH&2!MT-9IU]O1^LN+D+)Q>3,/SZ?E.L"$0Q^-C 0?^=0+_^N1'0?H9 MSY7E!]NID"-W#@3Q:KRH*^FSQ/0!\L./,VYPY/-+JUE%X)I5>!=SUZ'6CEI3 M)^'5Y"*\.#]1HV#HYVC49'H*KN65FH0GQV?AV<5%Y^=TVI&R]O<2%_P:97 ! M5GA[>30KN3LIE31CH3,^&\#> >R'1%[I;\ C[=MOY"3@1/[4:F7"M-]!BFIL M-/X,E!074G4HZ7*LBL+9: "8[HDK+LG!J"M6Z[@Z\F!6)VD\PH+A>8IMP3!0 MR4'*4*H9&H!@WC7B\D[^V1D!Q>5H^!US6N8&!WQ^^W-*@SC@"%$#7:DTTA4- M0\*>/SO4X_MQJ!;)%TS$FX[-3NH7W#4&/3=3'BFO!CC8!DD9O*27I.7>/ MU,?]"4#=Q:8\GHL'A5!\L)4'-FT)%EC*P6#3S!'I40JF38]-M'C!T:,GV 6U M\OE\&UK7A0L=0JIV+G\)^[?VZQM-;TOFK\,0##; MVR('*Y!H>J-=D?]>PTVD'AB2&*#*]#$SG(3/VIUH;"0R:+=*@8.@PP=RXPQ$ M"X7=IA?AU>7D-X=860^VC:C E8+P2?@)E>G*1,&DPE13>,\@S'CIL.>T8#=V M_M)J)VNY]6VJ#BFB>F1WDF8&K9\\,]N>C$_.N@OWP[QYI?)]#P\.;V0=(#]D9?#TVEX>@[:.+AM4WCG)&IZ>1)>7I[) M&O/N[Z0=8LSA^!16\W]\K-79&@XSG9Z%)T">W:[1[$;=4F\1+Z3647'#([=Y M[)?6W=FPQK6?6<;4?/'N":N2W[V[009)5C/LIU,&- ;JF M&IJ5BQS(RIIGY@(#+SXGX5NWJ#QR>4X S@BC,6:4:IZN32-SNHJ&Q B&?PV- MF>S@]"*<@*W*HG$2G@$A-^7'X2STSPTRC&9O1I=2$_YC8>D4&#O2 MYDC):\DO^\D[Z#<=Y+?=Y+?=Y+?=Y(WT95])_E])_E])_E])_E])_G_ M1YWD.SY#M[%\ZC66)_1N:2R_PY)_Q[WJG;43[MJ*\6^\=?WV5F<[-$/;][K_ MF^]U'VQI_?2_W>L^,+WN+?O^D;WN@]Y.9;]7K_MN XS=^@C_AA;Y09\S*@&D MY[;([X*U:\?\KY^Y[[7_^_?:5X>?4"QU>PEX#0FV->CO;S^V;ZC?TU#_^4U" MAR]HOM0Q/N#"G$>WZN06)9=>&]['O=:(AX MT[RI[H7OQ).?EON^C+^A+^-.O&C;D5T+T7VTT1'N!O?)-E=[91J5?30!!BSQ MW-8-\E.?:=MJIA;\?^W@MNEFFLW=^#+>>5D5W >?G6ZY@'[6VG>.^UT[Q_VF M!DFOQ*)ZC_( )[))>IO)^GVLNJW2Y(&-]2@:E_&7 MG\CBZK1'ZS$MGW,/?3\UU![3D1/-("J'@^5]?<,N:R\TY1_N:7_\1FKY>D ) MN=JH>LR?,\E5!+9GW39^=ZR.UR06P ME[OA2@=,\2Y!;K*_.ZC98'AO^LV=/FILC_\)PSQ&W@XZ;_N M(G&^WN'KZT6SS=/[SL_OG%^$Q#>KT!I/> HND8 MMIQ";8 <1-8@ P_!T77&GL/I']HF]W#3\/94="PZ?H77V'LKH,U+_]W]0W?] M6^VEW^ZPM;S:;\! MT_3)^DTBXYIU;,>M_EG_>ETWK=OB>-!7>T;#[N?:_4@&MA^T43_R/*ZKB8L4 MVT4/28G-79EWL %O>SK]NC$ORK+Z_G\ 4$L#!!0 ( !AIKDX5*>ID.0( M -T) - >&PO97?2 ?O&;]#\B/Z!>6NJ@GZ(T+J38GRD+F-J$ ]H0 MEN ;PNA:49M5$$[9UL-S"V22286T62*C+;)(\^C#D??LZO4\G JI7&U?P?_7 M??>#P.!9@92Q4> <>R"-:Z(U*'%K'-?9@=^$4&^OMK516"JRC>8+/"6XQA19 M2Y6#&LM$>(#2F$%AY2A:5K;5L@YL4&O)C9%34DI!G(8AHS<,;0:,W=NM_:G8 MX^X*Y/O8)0DQLBH&TXRZ-Z=5"YWD73;/O4-[=10MJNE&ZK>M&8UPOMTZ<*>@ MH)WSNV*L;]A)7;/M&T9+P<&/Y:<%HR,+IC$9ZJ!**OIH^.Q.R0P "J,-*$VS M7>2+(O4*.CWLIJXX5O/\!#4_]3R7($ 1MBO:;/W_>9;_L>++5W\NV1TJAX*? M4*.]ITY Y.(41"[_LLB@/]!W;HV].V-$T;JE3%/1RZUHGH/78R_M!'^T[P6V M=W1/5X>AUV1MWEI[_"8WAX*T3-_9(;I@@B?[O14>+<=>JY$BP9/] 7+:\BM7 M<'K0I5\!4$L#!!0 ( !AIKDZKN8S[40, &,7 / >&PO=V]R:V)O M;VLN>&ULQ9A;;]L@%(#_"O)3]] E)I=>U%3:VETB56E45WV=B'V2H&*(@/3V MZW=PEA4W[=%>6)X2 X;/Q\!WS-FCL?GG8XKEU +]]FL M0&/-W-A:>+RTBXY;61"56P+X6G5XMSOLU$+J[/QLV]?4=N(+XZ'TTF@L# 5W M$A[=:WVX9 (;/,"MF(VR;L;$VIOO4GFPE\+##VO6*ZD7HRS/V%Q:YXLP=M.R MEEK6\@6JYLHMS>-/8^6+T5ZHHK1&J>:N4-'&K_)8QF/I2JRP MXRH/X.D@+XRN0#NH&/YS1LD*.2KV52BA2V 1)"<@^1XA?_$(LD= ]O8"600< MO#6"[!.0_3U"MB(Y(" '^X3L19!# G*X3\A^!'E$0![M$W(001X3D,=I(:_M M0FCYTE0T>V6QKFMAGYF9LT(N(L@3 O(D+>08S:0784SVQ3DT1[Q]=ZG]NYL: MK#0UL%OQ!"TFTBF)I5)X4]X?SL1FXM78D]M1'J63/+%/"M#2V+ F'D(J$5[J M!).=5OPHD^2)53+!?J^,"[;H6/TD>>V!\WH1"GWE183+ENK<#IUR2R+4+*'7ER>=2U]*&1:W8\G(DA MCJ!+V0XCY8X\L3S(?;F5*^24/?+$^MC9F=D!?BTH<)]B0DH=>6)WD,NY%4A. MF80G-LG;Y?Q>'#FE%9Y8*_2$C/-"3GZL)+;+.Q/R$KR0RK&)L#;&I"3#$TMF M%_,P#FB,24F&)Y9,G-^T RG"T4.,23F')W;.1RG/'^08DQ(/3RR>CS*?=S I M]?#$ZJ%WS-9*I]3#$ZN'QHR_ 3GE'Y[8/[L;>VL9Q<%\K=0%EEWK*R.:8]C0Q_9\^_PW M4$L#!!0 ( !AIKDXSW*/_@P$ &L5 : >&PO7W)E;',O=V]R:V)O M;VLN>&UL+G)E;'/%V$UNPC 0AN&KH!P 9\;\5L"*#=NV%[""22+R)]M5X?9- MLVF0P-,%^M@$1:"9=\,CRYMW6YE0MHTORLY/+G75^&U2A-"]*>6SPM;&3]O. M-OTWI];5)O2O+E>=R$:RVXQG3@[';>(.1THFG\;E-FP3=:G4 M=^O.OK V>#5\T+1?T/_DVMG_K&]/IS*S^S;[JFT3[E3\+4C4_2".!S$\2,># M-#QH%@^:P8/F\: Y/&@1#UK @Y;QH"4\:!4/6L&#UO&@-3R(4D'&%)\D88W7 MF@2N">\U"6 37FP2R":\V22@37BU26";\&Z3 #?AY2:!;L+;30+>A->;!;T9 MKS<+>O,+SMK281NO-PMZ,UYO%O1FO-XLZ,UXO5G0F_%ZLZ WX_5F06_&Z\V" MWHS76PMZ:[S>6M!;X_76@M[Z!7NN1WKXPSAX_@BN;W#^[ MY&;XPYH1W#Y<*_O\C&'JP_TCI4._Q:KA^?3_TS#U-T+=W*WN?@!02P,$% M @ &&FN3IH"R0:6 0 ^!4 !, !;0V]N=&5N=%]4>7!E&ULS9C? M;L(@%(=?Q?1VL0C=W)^H-]MN-Y/M!5A[:HDM$$"G;S]:=N73A138Q,=O4[,>$]'(<85M3/T 7.6?E$*\% M]97J KLG/ZG@X3;DQM'0NAAU0?5L+R+-8]2S=N(YMTCMU2FH.*IX3'VY#_MI MW+)[[SOP[Z!G77/:J9^/0X!P9" Q ./D(!03$J M1U$J1W$J1Y$J1[$J1]$J1_$J1Q$K1S&K0#&K0#&K0#&K0#&K0#&K0#&K0#&K M0#&K0#&K0#%KAF+6#,6L&8I9,Q2S9AFC53Z+Y(/8Y:'^JS[X3O[ E!+ M 0(4 Q0 ( !=IKDX?(\\#P !," + " 0 !? MD !D;V-0&UL4$L! A0#% @ %VFN3@^$ M$"3N *P( !$ ( !F0$ &1O8U!R;W!S+V-O&UL M4$L! A0#% @ %VFN3IE&PO=V]R:W-H965T&UL M4$L! A0#% @ %VFN3J;=I<(/! NQ( !@ ( !J L M 'AL+W=OT/ !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ %VFN M3G8VMV28 P *! !@ ( !:!4 'AL+W=O'4<$ 1% & @ $I&P >&PO=V]R:W-H M965T&UL4$L! A0#% @ %VFN3O7TJJ; 0 V , !@ M ( !IA\ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ %VFN3A'U MA.*S 0 T@, !D ( !7"< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ %VFN3KCO:GFT 0 T@, !D M ( !'"T 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ %VFN3HWV2FPS @ ; < !D ( ! MWS( 'AL+W=O*E,O+&PO=V]R:W-H965T&UL4$L! A0#% M @ %VFN3HS",8[" 0 -P0 !D ( !,#D 'AL+W=O&UL4$L! A0#% @ %VFN3B/'H SN M 0 _@0 !D ( !UD 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ %VFN3HXD807A 0 M00 !D M ( !,4< 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ %VFN3NIO1*GJ 0 RP0 !D ( !T$T M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M%VFN3AR1QJC" 0 800 !D ( !7E0 'AL+W=OID.0( -T) - M " 5F" !X;"]S='EL97,N>&UL4$L! A0#% @ &&FN M3JNYC/M1 P 8Q< \ ( !O80 'AL+W=O7!E&UL4$L%!@ K "L GPL +V+ $! end XML 46 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 47 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.1 html 42 143 1 false 9 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://processapharmaceuticals.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://processapharmaceuticals.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://processapharmaceuticals.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://processapharmaceuticals.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) Sheet http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquity Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) (Parenthetical) Sheet http://processapharmaceuticals.com/role/StatementOfChangesInStockholdersEquityParenthetical Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://processapharmaceuticals.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 00000008 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) Sheet http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) Statements 8 false false R9.htm 00000009 - Disclosure - Organization and Summary of Significant Accounting Policies Sheet http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies Organization and Summary of Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Intangible Assets Sheet http://processapharmaceuticals.com/role/IntangibleAssets Intangible Assets Notes 10 false false R11.htm 00000011 - Disclosure - Income Taxes Sheet http://processapharmaceuticals.com/role/IncomeTaxes Income Taxes Notes 11 false false R12.htm 00000012 - Disclosure - Stock-based Compensation Sheet http://processapharmaceuticals.com/role/Stock-basedCompensation Stock-based Compensation Notes 12 false false R13.htm 00000013 - Disclosure - Senior Convertible Notes Notes http://processapharmaceuticals.com/role/SeniorConvertibleNotes Senior Convertible Notes Notes 13 false false R14.htm 00000014 - Disclosure - Net Loss Per Share of Common Stock Sheet http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock Net Loss Per Share of Common Stock Notes 14 false false R15.htm 00000015 - Disclosure - Operating Leases Sheet http://processapharmaceuticals.com/role/OperatingLeases Operating Leases Notes 15 false false R16.htm 00000016 - Disclosure - Related Party Transactions Sheet http://processapharmaceuticals.com/role/RelatedPartyTransactions Related Party Transactions Notes 16 false false R17.htm 00000017 - Disclosure - Commitments and Contingencies Sheet http://processapharmaceuticals.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 00000018 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) Sheet http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies Organization and Summary of Significant Accounting Policies (Policies) Policies http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies 18 false false R19.htm 00000019 - Disclosure - Intangible Assets (Tables) Sheet http://processapharmaceuticals.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://processapharmaceuticals.com/role/IntangibleAssets 19 false false R20.htm 00000020 - Disclosure - Net Loss Per Share of Common Stock (Tables) Sheet http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables Net Loss Per Share of Common Stock (Tables) Tables http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock 20 false false R21.htm 00000021 - Disclosure - Operating Leases (Tables) Sheet http://processapharmaceuticals.com/role/OperatingLeasesTables Operating Leases (Tables) Tables http://processapharmaceuticals.com/role/OperatingLeases 21 false false R22.htm 00000022 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative) Sheet http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative Organization and Summary of Significant Accounting Policies (Details Narrative) Details http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies 22 false false R23.htm 00000023 - Disclosure - Intangible Assets (Details Narrative) Sheet http://processapharmaceuticals.com/role/IntangibleAssetsDetailsNarrative Intangible Assets (Details Narrative) Details http://processapharmaceuticals.com/role/IntangibleAssetsTables 23 false false R24.htm 00000024 - Disclosure - Intangible Assets - Summary of Intangible Assets (Details) Sheet http://processapharmaceuticals.com/role/IntangibleAssets-SummaryOfIntangibleAssetsDetails Intangible Assets - Summary of Intangible Assets (Details) Details 24 false false R25.htm 00000025 - Disclosure - Income Taxes (Details Narrative) Sheet http://processapharmaceuticals.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://processapharmaceuticals.com/role/IncomeTaxes 25 false false R26.htm 00000026 - Disclosure - Stock-based Compensation (Details Narrative) Sheet http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative Stock-based Compensation (Details Narrative) Details http://processapharmaceuticals.com/role/Stock-basedCompensation 26 false false R27.htm 00000027 - Disclosure - Senior Convertible Notes (Details Narrative) Notes http://processapharmaceuticals.com/role/SeniorConvertibleNotesDetailsNarrative Senior Convertible Notes (Details Narrative) Details http://processapharmaceuticals.com/role/SeniorConvertibleNotes 27 false false R28.htm 00000028 - Disclosure - Net Loss Per Share of Common Stock - Schedule of Earnings Per Share Basic and Diluted (Details) Sheet http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock-ScheduleOfEarningsPerShareBasicAndDilutedDetails Net Loss Per Share of Common Stock - Schedule of Earnings Per Share Basic and Diluted (Details) Details 28 false false R29.htm 00000029 - Disclosure - Net Loss Per Share of Common Stock - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock-ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Net Loss Per Share of Common Stock - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 29 false false R30.htm 00000030 - Disclosure - Operating Leases (Details Narrative) Sheet http://processapharmaceuticals.com/role/OperatingLeasesDetailsNarrative Operating Leases (Details Narrative) Details http://processapharmaceuticals.com/role/OperatingLeasesTables 30 false false R31.htm 00000031 - Disclosure - Operating Leases - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Our Operating Leases (Details) Sheet http://processapharmaceuticals.com/role/OperatingLeases-ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingLeasesDetails Operating Leases - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Our Operating Leases (Details) Details 31 false false R32.htm 00000032 - Disclosure - Operating Leases - Schedule of Maturities of Lease Liabilities for All Operating Leases (Details) Sheet http://processapharmaceuticals.com/role/OperatingLeases-ScheduleOfMaturitiesOfLeaseLiabilitiesForAllOperatingLeasesDetails Operating Leases - Schedule of Maturities of Lease Liabilities for All Operating Leases (Details) Details 32 false false R33.htm 00000033 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://processapharmaceuticals.com/role/RelatedPartyTransactions 33 false false R34.htm 00000034 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://processapharmaceuticals.com/role/CommitmentsAndContingencies 34 false false All Reports Book All Reports pcsa-20190331.xml pcsa-20190331.xsd pcsa-20190331_cal.xml pcsa-20190331_def.xml pcsa-20190331_lab.xml pcsa-20190331_pre.xml http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/us-gaap/2019-01-31 true true ZIP 50 0001493152-19-007021-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-19-007021-xbrl.zip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

&930 ?Q?8NJO0(1CZTGB^'X,HHU6'_ M-X'Q'2[<>*4?[Y'I\5#$=*B;PV0 X#Q'!,QF^?-XC/K',$>:+8;FP-X5%X(_ M 44G7[Y]-O;=$Q&R$.AP3%8O8%=GH?=$T5%TJ,<:G_IR\W&1P)QGN0YU[+"9$;.8:.\^^,X7+]4SU C9\ IC&_?J9PXGJ2>EKU^E#4=*0,HR56Y/O M;=C,E E*G*UR2SJ. SV[T>25Q%]$K!SU%?>E(MC=/M9WI]PD=CM+Y19T^4/W M9C@>).^IPQ2;M.)YMLHMZ9M#.>Q?PJIG9R:(84E:\CQ;Y99TN?#6Z3&0;JP> MY1Q32(:@/'+%L7#[TZ"BPD5J42C'6KE%>IHAYEMX43U(9N>A(H;*T>OZ9PIO MLJERA/G%L]129>>IW(9PUC"[-CGFT';+??$ IPK]7]*6DKR5V]2%H[)+,>LQ MESY2UX>9/35^+0R5HQ\(R!%%X)#O&$K\2;FD&:4XJ[>'=\.[%7=>:A7.)U6/ MV"/N;+N0?J9J#DA3T.T\E=M@JOL#7SAS.&)^UD_EZ9L$R:G)RE*Y!=UA/S5J M8PV5HWO@[&/T-SF,(X-]6,K%SW)5;L=/L.P3-X#53T_X1<2#0CU^XL6HX\3* M4?](L'KRQ2IS&LDC5(YV(/@B??!.M1T(1MB$"[PTASAY=Y>>J*TL!V)!E !Y MT#.TRC%'B,Q[?.%G[O,3.I>C4!%],KASY+='/OWBI M4U&JL7*4YN/LZ;U&O*ERA/WI%,XRIOR>JJ;D$"I'&[R,VQ$$WX-"1?3=7@+I M.238NY':LY"R0T(7$U_(X*OXZ5K+_@HJM[ZTE7\(:_0? UGJIISD*Z!5COG* M/+R?+CQF6BO'.>!2Z=M#:_W7($U/Z>-F(;UR['J($N%0[%UA]B6S$R\F'QCR MS&Z\F%PY\F"RSUL #@=C%RL\XV*=S8@X!,">RH(9$$ M"V<>?V@OO6"4X*S>GO 6PH]YQ]\B8N6H;7]UMP,ZM=\C(\KQXO JLFEW&P,. MT$+9;"<3+UO!JTMP^3]02P,$% @ &&FN3BK;^5T!#0 ,IP !4 !P M8W-A+3(P,3DP,S,Q7V-A;"YX;6S57=U3XS@2?[^J^Q^TV;JZV8>0!(:9@1UN M*Q"8HHJ!+&'V/EZFA*T0U3A65K8AN;]^6_X(=FS9,HDM91X82-2M[OZU6JWO MS[\MYPYZ)MRCS#WK# [Z'417 M9<_XA?$?WH'%U-A-6, MLN8UOI@,T6%_<-(_.AJ@0?]W]/L C:YN#Y934&2$ M?2@COO['X:A_##\&[Q\&QZ?'@]/CD_\I5NAC/_#6%?:7G_K]PS[\B\@_.]3] M<2I^/&*/((#']4Z7'CWKI-1\.3I@_*D'9(/>?[[>3*P9F>,N=05,%NDD5()+ M$=W@Y.2D%WZ;%,V57#YR)ZGCJ)>(L^8,W]*2\BE)/'KJA>+=, O[H9=55H.D M)<1?W:185WS4'1QVCP8'2\_N),8/+ 5SXOI#U[YT?>JO!'A05,@.^H3,9YQ,SSH+R\/=Q%>$ M!#^KT/JK!30BCXHVT$&]W0A]CAUA[\F,$-^KDK*PC'#[A/QKMV)SZP?,^;8$%4O_PS M_90%5^*B49%:OK,%R\:=Z@)[LRN'O=3RJ1Q1>V*^S?"5'!I1X(X_89?^/VQ] M$($GP7R.^>IN.J%/+IU"80C,EL4"B,SNTY@YU**D$H>MF#:BYK4+?>L3?73( MT/,4PKVL?$/"P:_D 2^K+5M0M"&_AJ;?%0F#+3)/XGI*?7D%63.B$I".BW1,'0J<-L=)?/7 ,OF8I91Y5=(T(*_"B?ACG(2*"WPDCP:A1 M(9HJD)K3-33:16CI*AXP_%J[P\A2M1Y/U(16Y]!&;%&3N93(G'8P(CZFCG>+ MN9#VF332'F25M-(NZFJH2M^*\-VU@25BU=5&F6'3&61]6"I)V\PPZXI?DTV+ M&6AM36IQ:;U'Z8H)4SMPX--+S%V(0NMRY]BC%@2M$74"2*P46U CE>DTRQ!B MLRVD I@FQ HX]2%&7RXM)[")?<797'AHX(<.FE=LMV;;K3!M=/^U>TPU\C9$ M3]G]WX0^S< OA]"*\1-PGV/J)@4?")][H>]Z85=^#^.0*\;O EZL3$T3-"U& MRZ;\BOW8;>^FX9<-K,I4 M CFMP G#X0W\G:$@2Y^X$#83/D*5W2Z.P<>"93_Z-T!=E%"E?\6NC2(6*,.C M+4V*%\$RHA^"O.LI;?@=<+$A*2.V^,V#<8LMG!#%G%#$"KW[YN+ IO#-+\F* M9**-PZR,!HY8$F4\ZQVQ N&ZYQ1[C^'B9^!UGS!>](37](CC>\DGH1]U^X-X M#?3G^./O4;Y^$7 Q^9Y4X.!'XH35?H_+;13KZ1-8K!<(WX?_Q/K,,W;"UN!? M@..OH#6$R^5R113)-Q5,^=>06XAQF_"SSB"I!W,KXU7Y!>FX1,\30R;!I@O( MSQ/Z*>0F9?:.;HDH:%Y"B@U["?C*47B..HX"(C"P5H2&(5?IA.94::H=: M45/1VSBPQIPL,+4OEV*P2<#I[OP9X8JQ0XE8#;HCK=#5L()Q"&:7]&0!WI3 M)P%@/TP]Y@PR9G\U=G"4 $%P7HC4 (:Q9:VDC,J,R"9M%]4*&X?2YI0ER!K- M%$#/^84Q^X4ZCAPM-6HS@IH$M3H&, Z][)CT7HAT-_WF1:K(8:L@4\/KO1Z\ ME%0V#JAX'FXU(@OFT1)H<@75P#C6 X9$+>/,GYK,J4?DJ)CE'I@02*/>IJ1F1*0$+[ 2]34M\RUZJ\GY.%9;&4/=;VC;5%@".V-,[6OW B^HCTOF3:4$NJ.[ M,EH5*AL'46JK7-72>*ZD[LBM#(I,2>/0&/,X1U !I+"P[M&>,B8EJAH'2\I_ MPJV@WB1X]"Q.%YE#4J5-II!.]W#O+0VHQ #&X99*[<0!DAK)4#6E[OQ!53?Y M:+$>;!K'4W7TJ[IV0*;FY]ZFEC?PMXY-A,4'W3,["H^VW5&(WF5J^:6]_9(5 M=UQDU'ROIN8K2\2FZ)6I(5LHUZ/'Z%B1.*F@,%Y.%]8Z"O,(-!FQD7!$GHG# MPHT;\1:GL@%8*9GNV%D"26[PI:!_063IZEXSJP MY>42T "?H2[FJVO /9PH;:'#MKI.;H04I2L6B=1T>>Y_&:.AY:P*T$;2+ [MI'>F(+#BQ:.84 M9M%2?+J4 5WF=M 4*6T<,L,YXWY\%<[=] I2-=<"Y2Z8YZ=/K9<=X%'FH'M5 M9VM$ZQK+<+1E]RY689RGT[TVM&-DRR^D- C/9.-/[8%*):'N!:0=1%\ETQ@' M:7+O3O&EG@43:I+R:@!^,!? ;N$8D^O_:S9[:+9TTJ*!4P_*C MN5BJ&L>\V=&\Y!N;_$O/UJI1J\'[:9_@E1MI#QKNQGFH.O#F2-6P/=DG;"7F MV0-@1P%Y8-D+,.J 6TBN.(/0WR>$2^RT!RCG#\K5;,$Y:D6,#9XFJF.E'4*< MOTA,/%_T'2)'.&?Z%=MD1#FQ?&=UOKIVGZ''8!R2 ^%SV)F ;MXTNCGM;OHP M(Y1'&\526\3NB47HLR1,B\H:JDO1)4R6$%!8I)VMNL5/Z\6T;FPTV94]2H>&&H+CIA8I#F$'L,'# MZ$ZNM+,;?-IA9P>]?_Q;BQU_Q1-T&65S/7NN]T/O(OH6%:CQ'%U:F<-<5UX= MY31H5_YP74:A7'>_&?1TB+_3!^HRZN8RA:U:7EPG6E>JL0FJZ9]+-0H:HTE: MJ;]UEU$SEXSDU>RFD99;0>?^]2OJP@#O!A"P"VZ-ED^N5-%IG#TJ$>T++]VZ M7DVI>Y9(#:Z-R1!5@Q@WF5TB>.HFI?1,_9NPE?+2/1&V:[0KC&;R^3.5=STS MX3DWTDK/,>CM@.H^\IG1*S<0D\U#:-:QWO.?&15SHS397(5>%9MY\3-CB=P@ M3F$H .:*ZQ9?);6G"$(!PCPT%B&5B)AFO!V_^YDQ;F[06-NX:>G0JW@HD0^) MB(Y2$DH0T6!_U>=&TQ8[RHU,\P,YG0VR[?=#,[:I'N1F?2<1"<4RH;5047D4 MBA4WTT@P)"1#4XB$()O<]D98?.NW1S/&S0^IRXW[6KOX*[)G2H#0AB!"F0TU MWGP&)B=$LBDH6=4?E=TNJ,Y!YP5O*D)&C0+2;'$8T /G^R_!?$O%)3QU#^WJ MPKYY.=S6YC1N^*=J$:'$PPO;OCVL&>D>^+7A"WG#[;<#0,4["(DI5KH/4[?I M!&GC[;4;7+%@V_XAPTGWN>L6G2!M.H-W0]5^^#V32>86)^3KV'H',V]Y#SZC M:6Y]HG2M6ZYL#+;X(2:9X)._ %!+ P04 " 8::Y.[$*L%I , R[.3RHL*)B$)&8K0 J0O^?HT(%(F18(7220Q&_O!EB5T MXW0?H &BF]3G7U[F#GHB7%#FGK5Z>]T6(J[%;.I.SUI?1^W^Z&(X;"'A8=?& M#G/)6<_(?CY_)=V&UU1XMBG:,"L]M"=L)_1#9Z34_1/XA*./<9_ M1K]AQY?OL"OJ$(XNV'SA$(_ !\N.3]'AWO['1]1N%]#[&W%MQK_>#U=Z9YZW M..UTGI^?]USVA)\9_R[V+%9,W8CYW"(K77<7HS[:[_9.N@<'/=3K_HI^[:'! MURP0,&6 /VLB/_[H_Z![!K][A0^_H]*AW>G3R[X(=>MCSQ:K#[LMQM[O? MA9^E^&>'NM]/Y:]'+ @">EQQ^B+H62MBYO/!'N/3#HCU.O_ZE&3ZUO95 M/%19_EAM"G- M4!T!+>BI4)9<,PM[:D#F(D+:%O*_=MBL+=]J]_;;![V]%V&W0IZ4LSESR#V9 M(/D7QM6JUP5G%A$"+V:8S[%%?(]:V)%#:]Z1;3M K3\GKM=W[4O7H]ZKY!F: M2NQ@CU(^XV1RUEI8 K?#8241_%1$UGM=P'P35$Z7%NKL!O0Y=J2_1S-"/)&' M,K5Q];#N, ?7S(AJ5 ICJF0E@.4\)I)!<3NY7L[S/FV!" +W_W8?@5!EY(2X.&E!H[6ZBL?%!=8#&[D=/,N%3M\:08Z.(: MZH@MQ3!G"IDS#P;$P]01-YA+M$^DDOF@ZZ26>5'6PJ+RM8!OKQRL@576FL(* MJ]Y!EJ;9J^PZ\>XFY"U%HU>X<"VI! MT!I0QX>-5<$95$EG3;JE#['9EJB IA&Q?$X]B-&7+Y;CV\2^XFPN1ZCOJ0&: M-&RW;MLMF#J6_](K9C'Q.J!'_/Z-T.D,QF4?9C&>@O8YIF[8\('PN5!C5ZBE M_!ZN0ZX8O_5YNC$E75 UC)I=^05[P;"]G:@/KRE^I(YZ!^#V'6?77MNVQUHO M<\O.E[)ZZKX,+FO/!JJR3,+<"JU*:QS%HLFTA0D_F6([4A!GH();_B-IVQ2 M"G44%G04==M*"W6]#C3M!&TZJ0JJQ[WJK&TS&3C*@4Y*UX!8]=2>D_DCX27A MQD6KQXH=IQQ")5 ]+I=Y_;+00IE:QR298-_Q-AZ4H7@<,[P-*Z2,B-?P;PPW M>?&("[NF$+E4N-O<.+PM57:7/SW41J%4]"5V;;14@6(Z:C(D/04>0[X/<%<) M+7@-4=D&MQ-;OA+,H;9<@E"@"2U5H0]?7>S;%#[Y>S/&I*?;8I8=;&L9^A#K MI3Y+"#T@<.LF.&.+.]A/#4BJD@VP>)1A3-?M*<8+SIR!]0ACB?"=]2>J-WM!?4\ M/P5OCU>0P=MD""]7C#OXD3BJ[W'0.*UMQP#HZFRW .R@W3KDMQ'7YR'X8#DH MN.8NUZ!3"_:6,$8O'=4;K&-D*E^$R"9P,9WKS\!W+-."J(,!2 LQ#D/KK-7K MOF%Q& S/LY;'_123FV!I.>SE:0)SU6;\A189:^EB.^4P=?>7$>0IOE.B4E>(>2QDNEP5L0 '3G[W1^>G7$OQ89=$13NEK>- MA=LRJ(S4D7C0+(F1(]@OP66DCL!$T_'.N8M?SVIXR9XE+!^SF<'N#G01SHE= MB(RTUA5,IIT3HL6M):595OJVK9R'G3M,[:%[@1?4PTX>/9EBX[3 ;1A/^09H M5Z5-"4N>D\H;.<8C_U%8G"XDFGMB$?HDMSE: J1,EL@X+>":XOQ"X+4K2;,S MY5Z>7+O$#O-Q>5,DO?WXT&!Z\I'KN#ELEAO]H4+:9*AI?V__ABF85[8)KU[M:;92_S!548 M3UPY2[1+D/&$J@&:J+FZ)Q U!/7(B/ G:I$[PBFS8?5ETR5!ZD;/[<;!-CW_ M(8;/U@[0+JZ[W7#>X5=ER!=LDP'EQ/**&>,L24EF5II_J[-F M!_3RW:0<6($TY\=J$V)&)$&3=X;&7/!IDQRHU(F4TF9SH/DWD<9L/=Z=K8U1 MN]W-IC%WG,AJ"RIDCLWG!/Z)ZE;E%X%VZ8:(?O36 7KKH2;[M;>J1DWK===- M>Q-#H5QM@)/WL,:P]I)8I00*1&J;4]GWLL8@[Z]#CDBCN'A=\+-O<(VA/TB@ M5\(H(HT"\9K0%[K?-6;#X;H-H ))'0B4(*5%!2^E!P6*Z@I1FKMB8P8<)8)/ M*(5"L9K@YMX@&\/]<1UW((Z4/(HKJ,F"(K?,QHSXM&Y$1(,*_&LZ3%[;,M>X MWO$.USA8\X-7]2WW.3?:QFQ-K.>)10]]6,K7A[_$/;=16_83"WA^?*O?N.R; M&M\3:;869:Y:TH)H56BD:&%@VE0J\BHE?;R$I"VW R: MQ%O47/^7X3>F0:C-CVU3&U:Q7XVLW"OM^VI*\S2)!;D1YW ]<4\$@7YFT84T MLYXE7[#VDB+=&&:E46L'OUGE++";\>>^NCP<@%\MZND7W7S9\9'A:82")NC( M:[:H=:/$CNF,)-%6L1KOQ/GRF/V.LR<*US/GKU]A+S9T5]=(?0NV_>J^]$QF M"NKX$6@K8XHV&C9;)0X6R-,H^",S8T_84>=38!GGKV!$3GE$(7'CF2QNA79# ML>/]A!-)ME_YJM[J[?!//B@ES,P'%1BZ[459/>92M;DY.L[^4,4E1O.VJ4$Z MYIHM+AG.%YCR96'#-7.GU_2)V,&Y+SL' \5"'E+<3O1AL[ *08FDKQ%7^V9LS*1$5 TLIV-.VB=T*=IN<_C3-F M9*)J(%HKTRB+99_,&3,K452@JZ=IUL1RC^R,69BH.-#5W#1J834/Z8PY(E&0 M4""Q#=X*^I8?A;U'!!0 E5<-(#0PEYMY4F?,MXD"B-*^C:)#;_!0B _)51=% M$&H(>7._ >G>Q'[@/5/]GJG> 4L#\N@-70$XU /?,A^$D];6T"1V!F(S3\_C M2.6W#>8]5T4OTG2R';O 8H.XO M&HBY)K]2/'[)&D)" 2:T K5LCQ2LX'!@"0Q)9&C". )L>M>;X/"MOZ,@YMMD M77JV;]]ZE_\MW1D!H%P($$QP8>GO.X@Y)G%$KK^KZ;T>__V4X__IE$,WL.)KI!6TU30X.;'K#6^\T[_QOU9FKEE%N2 M&5T\L)S;.].LS%-2<^3+)2*#L&+^J#H6&LNED9&R.KY-_D:.@4]D0B&R[:5$ M7/B[*S))E_G&CNQ393[9C["29]."7P@?\ER4WCG M?U!+ P04 " 8::Y.>"6FE^XT #SL ( %0 '!C'IZ>O2%$&:10D64K_\BK-7OW[ MO_WW_T;8__WY?^SODY.8)M$7Y"L MX2_929S0G!QFRU5"2\I^$!_^0GYX^_&/<[*_[V#W[S2-LOS;U6EC]ZXL5U_> MO7MX>'B;9O?!0Y;_5KP-,S=SU]DZ#VECZ_+P>D8^OO_P^?VG3Q_(A_=_(W_[ M0(Y.SM\^+EA!CH*2R<#/_^OCT?L?V?]\^.'FPX]??OSPYE=#:>Q MS'Z-#?(M)$7\I>#PSK(P*#G+K)\A6@GXK_U:;!_^M/_AX_ZG#V\?B^A57?F\ M!O,LH5=T07@QOY1/*\;<(@;BO:K^=I?3A1I,DN?O0/]=2F]9BT?PH<_PH0]_ MA _]2_7GLV!.DU<$)!D=M>7ZW+%5*;WS#?:2YG$6':?C4/>U)X+/^DY>/J, M;7WO1;C)RB 9!;ZMZ1WV.1U7XQL]_S7-IA4ZKJ9;FCN!7ONEX3^.,9 M^[<.1/I8LOF21C5(,&$8@?D7^,10V6ZL9V'';@*C>98KR\Y-+H)BSNVNB_W; M(%B]@UGS'4W*HO[+/OQE__V':OC^E^K/WV&"I$N:EL?_7,?E$W@+S.](RV+V M&!?U!WEI__+*4>==OS2@/=WFR],QS,&:YFEUV46_O:5+N>33UJ8;0Y)0FAXHT/6 MYXJ0(UR0_"I$D1!E%D4Q>*Y!&K_8G#*AQCP.U8-+5AW_'+51D/)P9#[ M1*W$")?;DA._"HM@O]YIY<2#O5?F+^;)4U$J1RJ5@ _BZ($!,>1?)V]X+239 MZ^8RR$:>(SHO3].BS->PX#2,,"I!GR.)'FA[Q)"E)B>(%5J?*"!(-I*['0.N M:1IG^6&6WM.\C.<)/<]*JO:!'>2]C1 NL)L!PR0\.3U<$?99(E1(2X=PI:V- M+SK"K.=%F,](8M>%@E7K EJO ETH6@2I R9[32 M)K7Z5KV8HG9C"AJ^O%_>G[&;T-DN.TC)5K(J6$ M#^H8H %;%#]/3A ]ICXGN!018KM>EJ1ESI9-5[2@K#KN+O+;((U_YQ$-IK6* M7F*JZ;GC=B#2E&0RT7)1SD&H!46C55JH3IUL-42WN2>4K N**W,4!/2XA* M4PS :C%?,Y8)9#UMJ60F9XP%F'1"+CBQD>5!@A/RXI#"@)B7&1J876KTA!!Q0XU,0XY*F'!IPL0GH4<]E-TPNXIR=7_V1085J)H#[=]0 M-+T"D':^ )E)F[D)^(209T-A>G*^&UX)L\^ CA J*JB0:3DAA)D;$?$X]$GH M,6-((D!SD@2WBH+U?O=%!R6LF@:='U$TOPJ1%%I0RQ 0FJ2Q#]=Y#B#C(@R2 M?[#ED7XXT(OZHH -;,T&G1P*8EC 2:M7(4Z$/ &%:8<'X;'P6SZ'#,-MENL] MR)Z47_]1";'K/79$4+!#CTOC.5;7K2K9"1EQO0R2Y&!=Q"DM5#NC2BF_C%!" M[#*B(X*($2I<&D9P45++3C>U"#C'2YK?QNGMSWGV4-Y!F'B0Z@<,C;1?FA@A M=^FB%$5$&Q,^#7UJ%2)T2*4T)84>>4 3C^H5#K*^O I1S^31@NTQ1Y+#1!L= M.!UG'LE&H5K$3+G!M;F/<'T7L.JY6)?\=C.CM7Z_QJCD>>O+H0"]?3"#!B)B M.<#4[9"U[H[L$:%,6MJ3T(V1'KY]_;2<9ZI"]W[W12(EK)HOG1]14$.%J,^" M2H8(H4FWS<1*3 QR)^QO*F?7(.M[^TP+M[^%)@FB((<-G78KK5HP5SMJ7 4! M;6#][D::EN0TE)&@J@G3B"&D2Q^;C2Q\=V5K5-GB->F+Q4FG3;H3"?%04M"PL- M^T)>+\4J 79NP78DT)!("4LZ/+B^/KZYQD2%:JO:B1&2K']B:.#*_.@)(J.) M&IWN&$'HX&#-85#:* ^#/']BSC[/GJ4INZ.NUR0.0XK3 M2>S@HHB&=4/02BQD2CRN.X1_H1MU'(0\6M,3UJ2M"Y,QK?N7IC;,*E[OJ3F M[]Q8,\BC(9L#2,FG7U,"-4/RZD+K"BZTXB#894Y701P=/ZYH6E#6BR[*.YIW MQG%-13AI>K['[UJ4WK5^FQH:\KEC55SZ!TU"A6K!Q[P,M''PT(5Q$W++RJ+I M^%*VTO39JTVWF0E&"$:7[#+/5I0-EY<,+P^&9U/T"M:DYU0_,IE4_ Y)=O#= ML4@OCV@0LH*41Q^APD<=6LOOD926.%AVL8*LP.FZI.%0PK3)J.+'AI.#@#;I^9&%1\1 MKVFXSN/RZ8BN8'=7MY?:4JRZ:L68@8"FYP>GLX/3L].;T^)K,SH_(]+LZ/CJ^@_D^&_? M3F_^@8ZJ;N<\)H6)Z.APXJ.7QDBY86<_+44E$K0KS.D ]KU MA_I2:#BCA:;)[A6VLGNEH(6#,-TE:LWG)S-Y;$K3;1WH"J#?.^AKH"&8$TS= MP+0,2G#%V;@$H2]9;T\AJ8WAX"!;5U)6>^5E\ 1IS,S*5$&]FGG(UWI'U=LM-\&CLH]I*L:NYO=KK\ LZ3!Y\@MQ7^0(0*#E)U'\DS7>922D[W**'VHI9"# UQ M]-CT+Q(6(IG**LC)/2B0__G^[?OW[S_LD0_O]]B_P/^30J1:"=;E79;'O]/H M3R3-ZK_&10%[6_QZPW9SL6QGWJQRS1AO$DIB$[W\K+\?V)-!PSD-,,VSSWJV M??K12+=//^W]\5]_V/OXQQ\U?"-!2>99>4>^!O"\PR=F$CC!Q8YHR-]WJ/_Z M$PYR:EXVUNTYZZ01O#&MW,57BZ(AKAF?X45IN-6U'Z,U33Z^>1D,3!/7FAY+RBFGJ)ZK8T MQ;5[IL6GWD3#NRJU!6S;=P\U:IA"["T;LTH=7'QS1&O=PN5K +QL[*[:+X/\ M(N=IP"*^GKJD.?<7G);\>N7I=E)L!=)OKN@TT?GT-I+33P+323=IDP4N[4[[C,Z V:H6IZ=8%;J.:D$9-LPY$ M5XJ)#3N\]-)GAG?6FIIHFMSPCBJH*6?/#J_C'>;3B(%NGI/F1-MU0QP\!S4T M9'3'ZGC8@8Z$CDZ=46/2/6*S.V<0QT@R1T>N2RZD7IQ4+*,+IY6>E%QZYTTC MBI=41K=-22A,/MN IWS<5":EE<550_V(SP"03BQ#YZ&=IF&VI$T6?DL$G%;: M[]5>(^3NW5ZE*!I:F?')R;U FFR>3,#V.$)S-Z+*'FM[)\$@/\F-%1ULY4V5 MOC :4MD0ZM,9U@I?<-#IBA848IMF:71$[VF2\92>%4CMF:]1Q^_YN@/\[M&Z M00$-O5Q0]BE6Z_"#J6BCA8-GUS1)(+4B35E'2%BY9M$R3F/H-&5\3\V$F':*#G)#"I#5S*'FED5,!.HPR:J 9IYQ@2A0#)5(Y M_:\KI3=(?+,Z+9%YB+80FC5\!0YG[E4G6P%"T'N&29P\@2# M:Y3:HNK$_5+&#+K+';4LFD'' E!+HYA+8V%1/0_#BTCB$NF:S;K5])NEQ0%= M9#D5S(^::.$UR9+1P#70E<%337VX%GR>3O%<^6Y'$6L9K+2Y.;;<#9;X6#@/UGB&3;S37J<.)0 M0Z?XPFF#"EV)XAA46+&DCB?$P999]%]KL=%7H+:9 M,WM^>'QU0^*4T,?PCAEDNEE./NZ]__Q^[]/[#R2LXFBK -H%N614Y=:Y)U]'C ?'_Q[5BE\[_@*'JTNXI)>T_R>U=4E'SFJ6@4! M4SZWW7\66\_;1B4.[;#/^>:+ZN=;**@RL],^MPE=NC'ZW&Z["HN =\;WGZJN M>'EX/?M^&3SQ(GX-(GK$AINP3)X.GL21:):?9/DALQ&'07*3QT%RF!72^[/C MS?CH*L\M)%!_K(W)J?Q,X-)UVLH263)3)*ILP6F6/;;JEP+ M\D6LYIKMH(O%B SI3KJ3[..Y%$>YM6=21#.P#D&KWP!DJRM5VC!T%\T.UD6< MLC7@+!0>*?,C!=(ZG*:Z 'R1PS]A^[MS7&.^G+TMXSY9OMT*:7>#[5A&TT^V M6ARG*[_UM@:V8[F+Q6%0W)TDV8/MBH!99:+!7 M>,X9+\F@HZ0#2.&*#$N%: MZ,9IYL@#NLL\NX\C&AT\P<'V:=I$-,[",KX7^2[-%!QCR',LV,B"]E9M ZV@ M(?%HZ-(8NF$S!-FVHE\W)G"0N[.1!KM@:1BSZ:*]PKW)MD/_W7QJLBW=+5>6 M=AMW2]]!T\EV6#CY^8?F4Q"(E-,TEC34@*'-@>U_6RQOX;C M8JZ)8PSIENXD3@,V)J:W_&R!AWP68;9.)=8-5_V==2=G)PC =N8 M&M%YR3/'P3:N_41H*J:>IB4K13Q/U*.BJ])TK-050,_%O@92!FI@VG@7-VIB M?,1!NOI9ZF%7 *U:4SP;/N!*H$4%#?'<<,H>7)5I6MP*Y\^&SS%=$JRO&W5# M54Q'J\UO22:;A]*0[$W*Q;[,*;RZ:\NN95.;EJSJ0I@IVM5!F%?#!:_BO180JA-T M/7N/0./MR.@.U\QW3\M+6#W"A-/TIC/XO7XQL/_\XW.->?-:GEW@QC,9;6GR MH7,K\*5#6*%-5D(=O('-4)J A6841?*FI%P#=4 /\Y9X& ]UG_U5JM,.I?K" MF(=360_;\G$ 9L4SS?F:;TT(!:Q,9#CYIG)5(.>*D/2FY:"F&&8"]I3PLT\- M6$$]+L463T^8%T)':PJ1 OPI<[X$I;K-?T?=:2EH*(Z9A@K%R6?N,6BE[=DU M):^AUMZ(* WQ9OU*Z& E935NMQZL'M([)=7)1T5-8:P#8T_O18R-:LRZF7E; M"Q[?T:C/#G+$&GWZO*A3=#D,A^%6;A;9PM=04U?L+V\AD-IH" &5'0KJ0&F# M%33>P&CHMD#JQ@*Z0.KZ/.,FFXG<(([Q*@YZ7I^I=BU&YZ%JFQ*V+5!7P-(> M*,-R!QM':,-7W'O>L[LNUC'U>6/IBW /]+BU[L&J,@%GIZ\K7^%-=82*T5F M8L_2"/X!=QOO@P0ZK,C6TG?J-94WS(37YV5'%*[SW.P ?5R$'H%<1>E:!!Q> ML#51O@=U:6:LS^;Y$^M5VD1-3HHXTT$.@ZYTZ. F_]+RP#D *:W<0H9N'F" M-([F_\]V19AB91CP(:W*/NS6GAZ=),8 !G0SBZ91$T7/$\?:UI_N^EY=I*'% MZGA(KLIX%ID#$4OS2);N<[YN%I5 X<9&:XF)),2&7T6Z6'RKKB)=S,L@3L$? M/*[2,YQDN5MTQ%8L>GV'^/E%[[Q2/-XO) M&S1V"%PIV(_3_5"8$CFJV\:XA!@W8;!E"_JT8,0&4KL\KY!3[B^TGE@03Y*) M!QO@:[7HCKK$>98>ZG8I-AL,[XFSY)[J7ZVOUDIQ]$T]5\E%+:S&KG,H SI^OU\'$N2O=^CU4- M#5?=L?89*I$2"_VJC&;. ZA1P_-],AOTWC4RG3@B>MDPRK3BJ>68"NY!3BJ7 M?70SJ4S,,\MXII?'S#3["%93#8L_N,%^L>@^MLGO\O+,M)OG..O;%Y;Q[;E& MO:;SHZH3]YE0V >ZF4E9) MXF&;"9Z<.'E>8G9GK^^RO+RA^1* VL9+G;#?O,DFP-V\R2I)-#0RPI/&(IK& M&4_J>D_SDB^]S[,2B_-Z'.1PZ0@NH?%AUC(:Z<5]$LD&NDTEG2P:,ED ]NE4 MB\.=(L(5T U,_1+9QB:#_)2L,HY06F&TO+*-4W"S%-X?:Q$+GJ84A_?K@0:QBAA]6DBA-"-.6>T*"CM!M9;%Y$V);^L<2E MET4F#42L['%3V;R#E7V.: .*U#G MSI&3YN0\'057(BB_N\LO,&["SGC6GL7W-!)03],P64>0QE!9 M=#=&[^1+7L.]=U=5G2CQ[7\&S8B^N[))W:WY$LP.\(7]!#Y17_SJ7@DI.[J.#JH^B7XB_JR)ZLL5D96,G"(JAK2ADB-L.0W&&UT4;N1:H/- M8)MMQA?A987=]@-BW&82J]:4(4H.([Q%!F/:.' Z:?H]E74N2O?;JB$;P)"8L,M=EE4IX MZ+6377QHFGZS[8I2=ZEM?05A;]MRT4P=L?TILOD6J3]69TEO/J?NO3LZ%M]4 MR2\4'D*AT>R>YL$MO:++($[K^'VX^UCPT:C@?N)54/*75M9Y/\[?-$MY^:*W M@W<_5=>6YM]G^"\ MQZ*ZDM-DW_\:E# F/3DYF*,L37VMRK&HMKM6%C.3=Z'G8S=UC4HQ%BGG16]H MO63#>\ L20;U@)WN$I4B6N/V'3*1. R2FSP.DI-U M&O&0NCI^'?Q?\1! EE>O7JAFZQ%&O#EGHPO8^%N#+4S.S6?!EFXS5'8(-T0J M2_SM$6%*K%OBRABIGC3!X>^T(D'Z\1\WV0$5P2$TNEC8(TEL^A/%"+D52Q/Y M8U:>G,=C$3M$Z9RUHG0FFBR[?EGO/5-5PQD5\#TNX@;7_@HKCI%DV /#*!X/ M'O P\*2/_KH\5S#H)5^Q)LGF27P;6"]$[[ !9LLL+YL'[_I'6*IV,&O@Z^.. M>*5W6UIJA(IH"QS=O'X"\X0Y/27ELT2_5+T=*3:B+=;)6;R@NCIZEDF_#PH] MO_#=)X?&VT,S]&RA$'WZ-YN+0;6Y&+3[ QOJXBSBVRC]%U5Q]!%#3;0[=A5% M]0\:Y#5=QV=QAE"$T_> [Z?@0WB%03 -[Y(FIDO(A M>XEDGRU*FD/93YC"5BJR9Q$O\95%'T__CKD7V@E491C2%>"R" W "(Z^4.<1 M.,R6\SAMW@YK'JV]V3SM^$%3@<-,>+VI/Z)PJC="7?31\'D$Z#Z!+QF>.UAO MK?(X1.+%'\COFD(^>4A/()RYX[2,.WFW>+IY2R4-MC8%?4<6V?+:K8LI=*0> MA[_/[Y88"4$.!\6K3?OX=\K3%$&2+"B%_**VBX+7%%-6X)UT4EII-'2S0I1. M5#8*G%$[3@G5&MLO%C?!(T^VHCHQLBAX3_9D!"YE=E)*3TX29XC:G$WA1@E. M+\K@DT4V8CVG,X2$F9:"NJZ\U5;\L/>S8&]*;^'[IG.&T260CX:* MX@L)-CJ=E3=Z=NO=.YL2$M9JW#RSAM>QM,R8;S:2BWJ?[P:LRL/I'DFQ[.HK MG)0K&F:W*?BIIQ%D@EC$0:O;B;74+(U:P9_LM_621D=4[!DP'Z?UH_L>Q-8_ M//%&THXJTK+]M.6OHO%HO!55?A=."',G/*F#$'!T7W5!V%@5I"&$H6[>"=7U MPT$6_#Y".+AHW9<)G=714'PX9C>N[I&%L,$FHYRNP/-);S&M)]4%AW>BJQ]$ M+/R@:E-H3T]?;9'LU)54D=-6A]>5LLBV/-19LUI=\N!)>K=V]A#D$?]K49^7 M1"=9SO^LJR7HYISEL*F8K$7E4'^5% MZQSF!1&)A*C7S>UU,N_7B4AG5_R=%FRU+XI\L1 59:K^K7_*>^_;465)/7#+ MW\'5"W=3N)$]D<<$WG.S.#KE+.'&::0>L:HP&%U@I:.RUPC8007JQ+HZ::(A M]R"XIFR?84O+)91[EZ,>?V^;/[%]N&:.9*K<:I2E\(75&S!J'AE/099DZ[(H M WY!#\< 7>MZN?2FV>0RFJPO%A$(:_9!D87 MM)-L8+ 5- /*:.CRZUFU,ED);9@75[4^3[F15T\?!F&8K_F=:6&21+0(\WAE M.\O9(1%Z=P$ZT__%IGOVLGJIR##.$K[![)GET%V>V*\O3Z2-\Q2*)\L+[FK! M_%1E.8OL6T9(X9K)G)@J; M+2%%D,X9VXYMKX[R-JNCXT=OPS":67&;I9$N4;;SR16;?'*TDT\N[.:3HW4^ MN:UU+TWT82\!UVD:YGS1'"0'69YG#^P7R)>E"I=S5O46D3BP,$ULHJ/>Y'0= M ;;/QDVVIX2K0S:B6I_,:P.$R2 9T'DI(5!7Y]!N?O>;MJP'JYN,K/IQ/:;B9Z3(_N!=2GQ+";@,-)4<"MU[2SIL,D'R$(VS) MN22OX;9J\8;OS+)2D$40\E-+[M/2?ZYC_BA$-2:^@![0SJ3)O)"0:IW6X6;0 M] !#(9U[@,+&R^@!>N#6'A#5F4[S.M/I"Z&\,1%FM4=5B*$A@KV)$U;0((&; MN]II;[Q!-$E0G0KNG O5: U-UWAV$?J=!!CW@DA^M+8DY!AL!1V=Y2(.YO#& MQ,LBKH1;9NO']R^0K>S#NE/D$7;0,K9=S-&?GAYO#UA=;F% MBA%FL+*V7 *RGY\691]9GW@I.ASJ(GKWME U.H;:&+KHCI8 MWU52\2Y&362'47*BG7U5;(9!;/(ARXY-??^U%D*1^7A48EIT)^ VH%+:)(8# MMDGN@V3-G]40/3/97)O U3B&B#JSAJ^F KH0ZCG56?>_JHDD\KZD" ME:#/M9,>:)M6LM3D7=L*39NF9AF-,H+N&2JW@*I_A*(3)5Y;,; MA+TM?:R F]6/5O)[E(7>",&^M>;Q1(J>Y013&E0:>=(HD%^%BG'L?R9+UCQQ M#%^ F1FB$/3*#BW0#C,D*7RLT$%4,6+-Z5#=)]@U&VYSRF/D##SHB_AC@!K< MINV[OR-K=24XJ;UKJ5TW-%RPNS*VLW.S[@:68E-<<4 7N_U MT,;9NBAI$&WBO,_*R-#@)G%_K6\'O:&"7A89+ZQ )9)4&J3U+CO3<:+,SIIF MBVEP<36/ ]3!Z7#?[NJ!U*L+?1]N_>CO0=,^H,U#I?4ON)J[#TNZ\'EUT?2S MG;5BD 91'*2;+1[#XLP@[*^5;8 WK:Z31,8""TPY2;J0;^W*[7QQ=AB4P6V6 M/\&IOHD>LI1'7N@@M@C1%\'&! T^F0)"D/S@J^$O4FIO]Y:0]V:7 $JMWDC@ M;/0^/&V;?_#5YM?TGJ;V5N^(>6]W!4BIY5LR.-M>!JAM_7_UU?H\Z-#>^ATQ M[ZVO "FU?DL&9^O+ +6M_\E;ZS]D#FV_$?+?\GV ML51G-/0?%+CI.:/%^Z%V##%KH.,.\Z )395FGQGX(X2 MK@S_T:A/NJ-SR/X0AT%RD\=!JGHB2VW*H!60M M.Q*^U,Z5'5*"(;(0EGC^'V%*1 G$E3$2"FL[VUW(S@^/KVXN[P)&OI"N2\ & M"10,PXI-Q=^0X@9^0T&S/#+".8&54Y!Q+=)3VR-,<>?3%.,PS2%!^T&0_F9> MD.I$/7+'"+;%&:4<-JZ80,H!S4@-S$-O@:0#!'>>*"S-+JB07) HRSAH^ASBJ$B<982,$A:%GF2![!)A%'"K)*NV6E=["Q/GK3A2IU? ML;6?#$UN$RZSZ\'DN,[AP2/N]>.$6L[;$&""V;2X2@A7PQL0]MN_$24BK=:. M>7!"X1GX1$^ GH"WEE<":YJ\\RNNME9!ZS=R);/SQF5K9H,/T/G97\/*H#;- MNOD-6:-*P*0F!8E=-^A?:5 ^K/-'X[:#0LA;XVH!-DTL2>!J:!V\?G/7R>"'K+$"%D4)S6T.'4<(6V-77/E+ [A>8XK2.M6 MW&3L;Q"#<1ZG%/Y?SQHW/6_\&5*,ADDN2K@X-0"Q=%69:Y*6C8-;Z1R@][0R2R.BTA.6!67ITFC1;@: MJ?1V'JUYL5@P[EM6GPHA?UE#= W"4/Z$K@HH8,G9?7F6MJ%D4Q8 R2RR".3M,JEN DRP_9[!5'/)](]\[[* .X6G,D M>NG&_.;-K: Q1%;,TGZ MQ@T7V!O>&821<>! 42ZSE#[]/4C6'+^)"#I9CVPPPVU10BV(C1=& ME#(YBG+_*\B31F'G!,GC>W@'(0E"/CK=Y$%:!*%ET\)%RQ]IG(NPH8]5!1F1 M7/$JDO/_1"IMTJB3MO[N&98M:5EO]YHXI9+SR"(]S!9O9"%L3-$BE!-P@NB[ M9B/>"P]L[3]1NQO;&V\[.[2OGV:]N6/+H!6/$RZ86V-K98VXYT8W@NYQ0"F+ MD1(FH!J&M%5\.*6C8C(QQ5X.C[%\8;&48V,F$<=%7M$PNTWCWZML*T=T0?.< M1@RE,OVVJPZV=G,%++=<2Q/VOJ)*ER>8:=(&&W>Y=MUTE#\;7,3WM-IW/655 MD=[&\X3.BH*6L_"?ZSCO/B@^R@#.1AV(7M?"5+R/#'98NXK]Z[BQ1 (P10)A M:I+FOJ9IS+=J[VE> J;SK*2Z@=4DC*L9'9#VFTRHD)8.X4J[GJ#54,]-WKM5 MQ=OD[ C>PJ!SG&Z_&UA7'NV1\]TO$*[!&S 0I_VS/Y+(H#:$V/R&K/$E8%)# M<\]K2C>+Q\G42:=_"?(\T#O%!EEL%6\#*C<$A LUR;=KG9WWM?6\\@U,/4X6 M\M?O= WI.A+(*."!IY$@/5\O_*N)NZ0ZWD1YC&/66 N((WO S;^ZRM?*XRN M'6Q(%4W2J)"-SJ[[)%M\':[+8I9&_SN;%[/0X$1I1;WU3PO8AB@:.5P<,8.4 M7D%AZUP0YX$]H$"8QJ[)\2T-EAESR7ZGT1&=EZ=%L89+IH>9*3.^@Y(WPC@7 MH*&.50,7B5SA]NG4TB.@2&I- JJ[YM7?:5'22$2J&5-H: 2]\<<(M.&,4@H7 M3TP0^]P0LE4T>2=QQJZBR-KHC'DS-(*3\$&?,T,IA9LZHJ%""+AB>KBG*]ZU9[Y0(*,_,I+ MHM#SBNA.LB#=\"Q.Q8-QC%]%ZZM5ML X)P7?MRC:*Z6\^?0D;#Q-PQPNWQQ1 M\<_3M'HJ[Q*\*Z@QA\=TGV<)%ZN>6XP^A,,%IS[IZF]2FGI?FM&KB:V16N?,Q7Z4$S-H>X&)I,3',/6@\RP]#(H[,1TQ4+,T.HDAQ17\.V/0/2_*.97?@G?6Q-5<0V$K7U-F M!JKI%-H1MHH6M0T2-$;V2$K+25JU?B9H4R!6S(O\-DBKV([++(G#IQOZ6!ZP M!>1O4N,.-8"KC4>BUSZVM+'#V[IMB?PJ;!$P1KBU23;X?\YX#F$FE,-5QJ]! M&MSR>*OK2U8F6W,/TL;5UF.@]QOZ*"[")"O6.7__.@A#>&49^O)*M"TLS'+* MO2#VQX<[FH*CS*1C1@CN)Y=!ROWI*%O/2Q+,LW4)+C>#P0;V/S I,<1##@K6 MDLS,&F)LF/)M)C(V<_S\0P$!_RM+^:D$FROBC*?N+N,E):]O:0I9L9A/'Y G M&N0BP3/D^)X'"=]7+.XH+4D4E/3-6U(5C'XAKX,W8(Q]&1PZ]CUQIU$0&AZD M8(N&6T9R!B:/V:S$@()5B ,JBOHFI*ZD(+GEHNZ1U_,WW/ J*PH>K$ 7"[:< M*020\$Y="*87OF'+GYH%#!"];Z[15/G0B_@VC1=LF0T5QO_&ZDA3*?"O0?I$ MENRG6S%OPWHIR^%3T9L-O(C5M2AO;;;RE9E!)DI[J%:LN0KR.D[#9,VS=NC*+V/(0R!U_?V M>+/'ZWG363E#?PS4C>"FK=*QKX.*.,UXY)ZU0)+5FSTO< M[4%?_4K@7VV)[S2"WM]S5 *5WG+\*]Y,=R:(VC<<_SH@OYV?_9?ZA7?+YDLM MAJL-C!AMVRYQ)8Y@$ZS@FZ^\J,E!EN?9 _L%IB-+JVCU,#>3#;2EW0K6<(T^ MF=<&Q/PY25O.1(!'==F&IRG,%NM"W,:0=S7-XKA:S@EKO\':2GRA 6K[V6*? M*8K%AO<#S76Q?QL$J^\"=W50TFX9I<#WC]^3>>*M-3JXJU8PXY)JGDOMD4IN MTDK6URZZ:K74YT35V#I(,!!6ED)4O09P4J;6C>C4_-4<22E^QEG5+G4\4=6* MQU1$6 /D>R[:P0W*VC9K(&H 1Z":YV6XWA[/]T/W2$=UHJ;BB*I\W/#>1OR*(JEV'3 [4$G*D$IRLKJ&];X+'"L8!3>DB5OJH&E%4=6]&J B6 M [+#7:%*@[RN=*;BOG Z+M8E'+3!>:)RNNX+??^$I@WTV*3)FDOND9;LE)5^ M$!0T8GX<\$!*J&R61-0%+ "5;; _!WE2ITJ>P>UF<0Z\1\Y9[4&4U.2C5"]* M]C*GD,39.$68=1 UFC-4;;3OZUH50@E(I8VNT>HYCS$-G/%>-.(0/=2-9X#K MV("-O6P]1P^9I&EITQ%SWL MS:>#Z]Z"8(%,O]56WP2ZR:J$8+TT8P2H)(0_N- MQ2V80\2";91"NNA61Q=\*ZJAF]1V84*N+?/0RLUNI7C(K;$^X7%87/*Y"#H' M#WJ^I6G(AJ?-C01E3.\X"XBH,!*XZOBL,B-&AK8ATKK6\>MTH;-UD7_.LN@A M3A)6WKZK8KB>,UP;42N/ -UOX=H$;U[)2V,CO[BA,_TM+/-&6O/&')NBX,;# M/;SBD5:UX+YA:#2#J.&?@W[@5B.BIC^!.R9LSKJG$MW9PG"]7"I M6GZX%40-_PSP_787IO:Y+57/;]DC;8/X&E^S7VG6>!F-:MJCM#7@=%N39Y1! MH!I7L]X>.%HK5V"NNHC:;S!D*NKQX 'K2 0 5 <&-S M82TR,#$Y,#,S,5]P&UL[5U?<]PVDG^_JOL./&]=7>Y!UA_'B>U-;FLD M62G5V1JM)">W]^*"2,R(&PZA TE)DT]_ $B.."0!-#C$ *,X#[$MH4%T_] - MH-'H_NEO3XLD>, TBTGZ\ZO#UP>O IR&)(K3^<^OOESO3:Y/SL]?!5F.T@@E M),4_OTK)J[_]U[_^2\#^^^G?]O:"LQ@GT8?@E(1[Y^F,_#6X0 O\(?@%IYBB MG-"_!K^BI. _(6=Q@FEP0A;W"7;Q^FC%&3E'.VO!?__O1Z<%;]K_#[V\.WWYX>_CA[?O_!7XP M1WF1K3YX\/3NX.#H@/U7DO^4Q.GO'_C_;E&& P9/FGUXRN*?7S78?'SSFM#Y M/B,[W/^?SY^NPSN\0'MQRF$*\:N:BO?21W?X_OW[??';NFFGY=,M3>IOO-FO MA[/JF?TV5K1OC"2+/V1B>)](B'(QR[2?":0M^+_VZF9[_$=[AT=[;PY?/V71 MJUKX0H*4)/@*SP+^)YLLJZ_>4Q+B+$/W=X@N4(B+/ Y1PN?+8I^WW6=X%0N< MYI,T^ICF<;[DX+&F?.R,']'Y'<6SGU_=AQG:J^<*'\%?(+3Y\IXI419S'7@5 M[(\SZ&.4<'E?WV&<9[I1]C:V/ZQ+1)EH[K!H9#3&7DHK ^;*B3F"V70VO>?V MBR&G%:B:RNY I[.3.Y3.<7:>7N9T?DF2.(RQ%H>-.K7"YGG*UM9Y?)O@298!S+VLO:7!L;_B M&_2DEVQ/4TOSFJG^'M\P1'SGB=,,M)9KR.P,%:;W-[3EA6HSFK/<%BM.ZX0VFBTS,W4PLY5?L'')&Z+2@_':Z!-^BTBH3J#\&O>K:JR3VRRG;-;4'27H%B>B^Z^<%D:Z/V2P7-(9$[6X MV,QP^'I.'O8C'.\S!M[QOW!.WNT='%;7FG]A/_I:#N(*SV/^[33G5\D]0V=- M^UNV1]J<(1,:!H1&F#+(ZCX1#=?F1?R^73N1]4E#.XQD[5J#D'QA1Y=27MP:B\-8G%'2\.UQ]10#A M"1O+G%#EVMMJ"(3A!Y]@4'#L$('K!4J2XR*+4W9.4"'0:@A$X$?_$.CEV"$" M'Q>8SMGY\!=*'O,[[OI"J5(7) 1 1-[YAXA2 BZ1>1+.B)@S46X=E+#TM 9B M\MY#3*2\NSRL/?N3A2LXFQ:Y"&5GDT=Y\_Q7%FNO[*-@+5C'1[.\GA'TNS7#$_Y:1 M)([X+490]124707??4E1$<7L-_\YR!M>,2#PFZ'L5H!89'MSA.[Y['N_CY,\ MJW\B_.:-:5C]^&LCB/XL3MGX8J8FI%S?%<[SBAQ&/5BQ-F>OC&?1,])NY\J1 M;B37=>62<#*>F1L+CUTMX3X8)*SZ@09_NL&O(=D?_*G, TK$ MQ61^@BA=LMV+>+DH1P=([LPM#P*"#&'))Q!/"\PC8QHWY3&NN95CIZ9RYLH? M !F$?S^0NJ3X'L71QR<>\8?9-)OF=YBN\2H'#$3L["I@ &X&TO #/B!0PR 9 M_UY@ "0ZX;.QSS#[9?2IY%HZ0C&\G.0H$2T=:QVYQS1?7B:H/*LPNW[/=U87 M6*EN*BIGMPPF&Q (XWYHUGJ VA6/ IS.OF1E++H<(PV9LXL($Y! K/N!4ON- M )M&96@N=] 3$CW&29]#KR*'43N[JC#!S$00?D!7!5,O3_$]/T,JCO/MAL[N M*4P D;#GA^S7WV++]@LN+QO,3[4O96_0")7F[]4HN.C@Z*E+73L3%2,$GX@1K;IV(FT/P2+?F#1P:^??1_TRZ7BA_**-D;/0_;>*/8 M)(4":>W6'X8$:+O8%8D?")Y69N,&/?5RJ[A/UE)"\;/F_QB"'U0@?L#7&"+( M7L)!V0&7QDM9!@&9\WI"<51$4)"WX0\9 C(XEZ!K_1OB0![!97RT#??($.!V MQ5%\6=L),6!-U%MO8RA2UEPDQM@H>/8#E,8+%ET<8J\S!3]]O$*YXN*L51G01O$H;%HA Q ML.S0$H>J* \(+3@$V!ODX1+Q0V?E]3<@NT0X0M8<(B/L!U_*H4VW41X>0 +' M>1N.DPW/Z$K9C#H'?'HSV%\89>T!X9M-'Q &WZU]Y=N#PBT=%IG4IU2,.1+[ M]CH7+?3\**??W0>(9A+R8S%>'W.Y$O9.JL+0H&AZ1ML7:G,3)XEC*WC.IT,%\&0<2N MWS-N@*2!<+Q#$[[\*8ENS^$!D MU0+P1=UJDU_6D^3!Q 5;"IX/7L=X1BANE)C]^,389B)G)URZ/&<&2#P 8)1, MH(E81?1(6_RH:R? P,EB'0:?YAMCH!+,,=L8SE3!65("U[F1S)9@#=^[;^\O M< [9+K>:N60ZDE=)["R0Q=H"#\L*.MXL 7Q>(6T^FL MK"?][#H&@SFT/W?5* 9AO)G8/'; 3VS1OB 0CF5>($TDHIWLD\Q!)!^ MLEW$II^3QOV.RPWG^MA.R0+%J6*;V=_<,U14,ZZ]S^QGJ.'$\B,LXS/FFR-0 M+$;=U/4%XQ XI!S[L=%?#X'48=+?VO6EX1!85'S[@8SD):P.(@V9ZZO#(5B! M)+$I:/=AA@04!V\J('C5M:_-]ZQ7.,3Q U\?I2!P&C6)ZZL](P#T[/BD,>TG MJ3I5D;5W?=,W1$?4O/N!SY:>X-I?_CNG,/LO;^]%*4TV IJ[]^D:1-0.#Z.U MOUW0P@B(E-UA%"?1/XOR!CF[(9(U5MPVJC8;X"Z\V7CH4#<6BQ_&%3)L,:%O M488COJ;@-$/EHLY,5!;G^!K3ASC$9=5>MM23>2IZT20$LO]E;_9,8\R=,4"P MM-F]1$LQ]L\HPJ+(^79:0)H6>$GK ^^!7!#8U1??N9?>9E7H4?%QE3D"R;A.7^C,VZ<3*^PQ$I_[%QZSX-;(%/51N]\M\0)>4/,1L$APOOS! SM/5LZ9)F,BVBDJ[7DM7/)9>?"W7+\CWM9&T2I4?E@<)C'* MJX.>XO+/AHRJ U0TCUP'\Y?*6_1-)G+UM]+OBGFQDM2,EBRO&S0'W0>6'/[#9\'&W+NMZ;7EXQL MZ1-7B]C([O=10Y&VF9YO;(V72\GEAM/6G)B$I3.DXM9D0G1(H;/!9BZ_L6># M1#XO<2J<%ICOFD1=.['[5=6%!I)#IX0UOZ.%*:&0DZ^6G\UB6K 9"BGC#J.& M FO-KVA'UR52VGUUA]^$CA'1 9\?UMR08X8(&$INU_.823@N?2/C1 $I^X+. M'8NU@<>* P+(S(\UHW:'W1 1F\CS8T)OH "DX#B0+5L#"#S$E%GW+H)MFX$Q MU!\^2;8=568^2-^H4"KX]CX0QDF0\[MT?2B3WEE%BQL /%MZ]@]>FHJM(9>->54KR2E>/>[@A;8[C-VP M^7;,QOR[7!J6/^O8 .GG1[MP\C90\&^S(HT.:!J-PX.VT7@F"RHZ=_KS"R'1 M8YSPBO-M;I['K+<.AMVXK9LM&1Y [4'$CI5W$*+=:MM0(?FHE:O:O_T*>=A5 M2$X1E"1.(WO+@9MHGI+(AP+&A@JFHG*L60!\9-6,=TJ!Q!/8O4YF[WYE.FHK M4X,Z6"-WF(YA-3YVHEK+52["_$7ND.=LYG40H%[W-NW7988*Z-"/FT,':/#& M'3M6\G'F2CN5Q3C2]M!4X#06SF!V\L_Y?N&"Y+)E]TW'4@CBH$$=E.0N$[?< MYB:KKZR]TTPDA.8WF"[XV **VOO6@^52'12B:AX]D]M+G#.TQ74%=2%4:B+ M*_8KS_=MY6%=!+R/@'42B%Z$1UOT4Z[!#M6H72)>KTAR"I<56%N# FB3@L2Q M0NDP:5=?U?'NGU:MAW)(5J&W'1=N31549.[F6SD O;*TVSE4D4\,$8Q;D@?H MB8[.L;+T(]%2$1CO_NE)XW7S\H8BMA<5D6@2A?FAK3 5>2#H@[4.'$:D2GC2 M*Y.>TFDET/[!&3E5C#IQK'A0'#M50XWEY)]>\LU;7":XX@\%B+@.P:GT.O+P MQ[9J-GH0MY'K?3A\%R+GS.2T9=B-X_+PVI$"5->T'\?:.PCGGCKSYJ+[%K*0 M*4,7#M^-&+H0?%?_S65PE!=1#)*0Q>=XG-6CXC1J2EQ\?JFR +P?\VYV)G)@ M&'O2I=M%-%L9V]!B>:E'MH[9 M*[+L=B' UB)AA+0<._$)$5/@TQY2;T,TK1 M7 3575\F"*A^AGVXKH=BIGR#!.2'YGW)\'3V,@TB=EY$%?FPP24G*_AJ6#^X,%W?SGIS7-C%% M=ZBP_+NY:.\J;O@+,XDCLO.&JO,<(OBNI'?I7/S3O8NX#N]P5"2X6UJ-C;UF M0^ "B2D;TMD+>#>Q@1#]4VI5D)I"P8\Z[YWTH6H^:/P+B5E[GH+MX7&W;"A* M9"9%SM-PF.JR88>[%>^VH=S\V'X],S%AFXJ(#YB=\JYQ6%!QO2*2YC"#<,:$ MQ4^&15[E9AD0Z6CC6ZZO.@;/F;'%[=]JT YS4RP G?=U[1!+'\S]5F,M)7=4 MS_/G-\S3_^%H\L D-<=7>('BM!8V#VQOUC:^0KG(!EC0/E!TEUJV/^IUY.8V M!.#3@M 7HKI*OO49Y=Q0+:$[@4&=N3;I@R-Y@6+RT%(/"1XZQ3F*D^P"42Z" M!]QOV3N//3<*(JJ^&:P^^J>/)AHY:]2-NNA;NYU.53L3W@\W6IN-9B%:'U!@ MZHU%ZC8 $HVV?J#1/Y=D"#2&WRSZ,AB%K(8AP^'K.7G8CW#,$7C'_\(%_ZXA M>/8CMM[-4?*1S9Y\.7F*^R3.6G4:[8*H^\;=6#NW)^)R *>$[Y7ZY;O>PK%P M^^36D>SZB)]WJ&-N]GDD,[=B]9U.<^G\C'DR-LF&'4+H++*I([SN?AO.N!][ MYBMWAERA=> \A]*"\8QJ%5H$;=>K FW$EP M0V.4G!5I)"*_ZV=6W#M=IHPFM$KP+=N)F/?C.FI7C]- QJP"5F< ^HPB?!I3 M'.;)\GA9CX&G7V\.6*0/DD VJ"?7,; PT#80DA^6LA&YVX[7O2''N SFQ=%T M)K>6!EVX#F(%6TQCL?B!YKKWN%7.28Z@ALQUR"D8-1#[N[]=-:YJMFG%,FO! MJ .1A91N\2P:$7:WT4E/UQ.7Z-6-Q9\N1'&R(#1?E1."ES#7T;V P$.8:';? M_-9EO<[8SB['8F?09K9UJ<^6H%F1?(IGBC/G9KVZ]B"-,G]&D*L?VS %!TTE MJ=Y0_ ,C>O-(Y%-C8'>NO4QCS(F-)+F+DV$RRS'E?)PU-@F;3HE6IZ[]5MN? M&+U2]6-ZU/E'3LCB-DY17;UD5==.9!(KE\E#^7PPZ\6U0VR,"3!$;GXAWJB3 MQ1U#/%E)N0"6EYF-%'(RYUI+%,8=NO:QC3D/!DK3CRE1>73C/W!4WU3S4?:7 MDUPY]>4TKOUL8P"KEXDEQW>/99G.;M"32"DD<7%K:%Q[T#;" \#?KGAA]E:! MJ!+_3+];II/XO.N6V6M&G4+\-= Q>/'$JG:\#\' M!37W_L-.3[*^7H*'9;@,S;UV[TL+G.(Y[].]UT[!NW*;I:-[X5Z6_NV6F>GV>7,B^JAE_/SO,*AV2>\H/!><1S2,UBU+!C MY:F/J4-]2\A?;V19L1 AHV+6,BX;OS3RJHS^[9VK)[@]0/S8>/2/D9E,E(8\ M!)(I?%HF+57,)*-.7&\US.?$ !GY#"YGO?I%*0M38'LZ<+U/& M4J6S\._U+ M:HC"%OQ.R1E935'/%O]O=4:!R3L;1NEXV2E\.7E$-!(_S2X+&M[Q7YT1*GXL M%]+X7W)= =%&)5);>/BQI#R+0\W=;9N[,C5J]BO.F&0O"OXH;3HK6=;,N-&_ MYGH'8F_:60+&CZDW243G..K7L.HR7!&#!*1WO9>Q,CW,A.?A;J>W##)LL],I MXB4KB^S;9N<%E$H6DA;"/2DHG_P*8]_3UO4&P:A$LI37W8\*Y:]$ZNK/JX)A M>65[IK-+&K.C\#U*IO0\S3$#297O:T!?SI=LDXDP7%C^V5U5BM(]<$9'Y?US MIVX:()LIL^'5M_FOZJ\W",0 1+ZD:@A>7%*_D RH5O, >))Y4I<,P*'X6W'B M:WOV:9%G.1+/:ULZ*,=I:'^NC;(AHIN);??7<(V-AMN@H1/!VHG)<"( !?&R M"IX"%_(-T^PJ%_I.70+CA;XYNN!Y>$$]OH!/C: Q0LGNX-M>X%LJQ"&6XULB MQ!>;"'$<=\UYRN9/(7RK_CR/ZAMOHR8(G:%9<98W3_:[DR1Q5FO[Y6%O5#D"76F\Z M-:"Z)4"\NLSRH1I(2]#G:4C%_$/),:&4/++?\!H4$CL*IO:^/H>A'/PPJ6*L M_/);,W?*)JYW$\"B&"V6O+=->V.7=E$YC-[HRQRMNX?J(075F(+5H,KV@1A6 M=2M4#BS@(PMFA 9L;'(;^J>QG#9RN&EGBB+U@WE/7EO?P5SY9(F5HV]J/-N MA=L*N#Q70+IG_JF83VX=/9VMI"_G3"$(G26)BZ;MEC]26_OGK_%^E M<6\,0!AT-H1O!GT;5<[J$,32<$7\4O6,88D2GI-(Q=[P/G?!R&\N,S_,/8B/ MTT*?Z0Z%=_H M^#8%M%OP;@ZK^\1ZH\*Y<91/7]Z'\9V4BG#JKB?/.%[:6NX[4Q\D(!#:^4%W M"ZGHK:6L&W!L5:6AW]$(2 F#VI):/9"\1'0M(RKP0K53G:+J+A#]!OGO'L;\.$%_BXFO'=C>@/ M)GX, M&].+3$;S!BKL7VU$V(^^WO!3!T_1'L4/<52@1*(5K*VDJ1\8J)5"/OJ&T]^U MY'^+\SMA8OF*=1??WY"/HIR&5#WZN-)UXA@M.1!ZP'2LV= A<^M68!X!WE@J M8T"R&375K@3&0WA_63Z>YYKA/+QTE5TEC*%Q\YUJ%XT>163H6I^>>7I4W!LD MBC+LQJ%RUV^LIK=)/$?JN@=];1TK\B"\6CHN%X%1N&#U&_X_GC>._>3_ 5!+ M 0(4 Q0 ( !AIKDX!9,B[=V$ $W, @ 1 " 0 !P M8W-A+3(P,3DP,S,Q+GAM;%!+ 0(4 Q0 ( !AIKDYX$EV-40T *A] 1 M " :9A !P8W-A+3(P,3DP,S,Q+GAS9%!+ 0(4 Q0 ( M !AIKDXJV_E= 0T #*< 5 " 29O !P8W-A+3(P,3DP M,S,Q7V-A;"YX;6Q02P$"% ,4 " 8::Y.[$*L%I , &UL4$L! A0#% @ M&&FN3G@EII?N- \[ " !4 ( !'8D '!CNKQX 'K2 0 5 M " 3Z^ !P8W-A+3(P,3DP,S,Q7W!R92YX;6Q02P4& 8 !@"* ) 0 (-T end